SG173768A1 - Pyrazole derivatives used as ccr4 receptor antagonists - Google Patents
Pyrazole derivatives used as ccr4 receptor antagonists Download PDFInfo
- Publication number
- SG173768A1 SG173768A1 SG2011059813A SG2011059813A SG173768A1 SG 173768 A1 SG173768 A1 SG 173768A1 SG 2011059813 A SG2011059813 A SG 2011059813A SG 2011059813 A SG2011059813 A SG 2011059813A SG 173768 A1 SG173768 A1 SG 173768A1
- Authority
- SG
- Singapore
- Prior art keywords
- chloro
- indazol
- mmol
- methyloxy
- methyl
- Prior art date
Links
- 108010017317 CCR4 Receptors Proteins 0.000 title claims abstract description 16
- 102000004498 CCR4 Receptors Human genes 0.000 title claims abstract description 15
- 229940044551 receptor antagonist Drugs 0.000 title claims abstract description 15
- 239000002464 receptor antagonist Substances 0.000 title claims abstract description 15
- 150000003217 pyrazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 288
- 238000002360 preparation method Methods 0.000 claims abstract description 111
- 238000000034 method Methods 0.000 claims abstract description 70
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 38
- 230000008569 process Effects 0.000 claims abstract description 14
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 7
- -1 5-Chloro-2-thienyl Chemical group 0.000 claims description 205
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 143
- 150000003839 salts Chemical class 0.000 claims description 90
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 90
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 72
- 229910052736 halogen Inorganic materials 0.000 claims description 28
- 150000002367 halogens Chemical class 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 197
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 541
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 303
- 239000000243 solution Substances 0.000 description 299
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 266
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 259
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 175
- 239000000203 mixture Substances 0.000 description 169
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 143
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 138
- 239000011541 reaction mixture Substances 0.000 description 131
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 127
- 239000007787 solid Substances 0.000 description 120
- 239000002904 solvent Substances 0.000 description 110
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 108
- 235000019439 ethyl acetate Nutrition 0.000 description 94
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 93
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 85
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 82
- 238000006243 chemical reaction Methods 0.000 description 81
- 235000002639 sodium chloride Nutrition 0.000 description 79
- 229910052757 nitrogen Inorganic materials 0.000 description 76
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 71
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 71
- 229940093499 ethyl acetate Drugs 0.000 description 71
- 235000019253 formic acid Nutrition 0.000 description 69
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 68
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 63
- 239000000377 silicon dioxide Substances 0.000 description 63
- 239000000047 product Substances 0.000 description 60
- 230000002209 hydrophobic effect Effects 0.000 description 59
- 239000003921 oil Substances 0.000 description 55
- 235000019198 oils Nutrition 0.000 description 53
- 239000000460 chlorine Substances 0.000 description 52
- 238000004587 chromatography analysis Methods 0.000 description 51
- 239000012044 organic layer Substances 0.000 description 50
- 230000002829 reductive effect Effects 0.000 description 50
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 48
- 239000012267 brine Substances 0.000 description 47
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 46
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 44
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 43
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 42
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 40
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 37
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 37
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 36
- 239000010410 layer Substances 0.000 description 36
- 239000000725 suspension Substances 0.000 description 36
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 35
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 34
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 32
- 239000003607 modifier Substances 0.000 description 29
- 239000000843 powder Substances 0.000 description 28
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 26
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 25
- BUTPBERGMJVRBM-UHFFFAOYSA-N methanol;methylsulfinylmethane Chemical compound OC.CS(C)=O BUTPBERGMJVRBM-UHFFFAOYSA-N 0.000 description 24
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 23
- 229920006395 saturated elastomer Polymers 0.000 description 23
- 239000007858 starting material Substances 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 20
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 20
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 20
- 235000017557 sodium bicarbonate Nutrition 0.000 description 20
- 238000003756 stirring Methods 0.000 description 19
- 239000002253 acid Substances 0.000 description 18
- WACQKHWOTAEEFS-UHFFFAOYSA-N cyclohexane;ethyl acetate Chemical compound CCOC(C)=O.C1CCCCC1 WACQKHWOTAEEFS-UHFFFAOYSA-N 0.000 description 18
- 239000012074 organic phase Substances 0.000 description 18
- 238000001914 filtration Methods 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 17
- SORSTNOXGOXWAO-UHFFFAOYSA-N 5-chlorothiophene-2-sulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)S1 SORSTNOXGOXWAO-UHFFFAOYSA-N 0.000 description 16
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 16
- 239000007821 HATU Substances 0.000 description 16
- 229910000027 potassium carbonate Inorganic materials 0.000 description 16
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 16
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 15
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 15
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 15
- 229910021529 ammonia Inorganic materials 0.000 description 15
- 239000002585 base Substances 0.000 description 15
- 239000012043 crude product Substances 0.000 description 15
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 15
- 239000008101 lactose Substances 0.000 description 15
- 229960001375 lactose Drugs 0.000 description 15
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 14
- 239000001099 ammonium carbonate Substances 0.000 description 14
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 14
- 230000001143 conditioned effect Effects 0.000 description 13
- 239000012530 fluid Substances 0.000 description 13
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 13
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 12
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- 238000005342 ion exchange Methods 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- 235000012501 ammonium carbonate Nutrition 0.000 description 10
- 239000005557 antagonist Substances 0.000 description 10
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 10
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 10
- 239000012280 lithium aluminium hydride Substances 0.000 description 10
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 9
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 9
- 235000011114 ammonium hydroxide Nutrition 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- 239000006260 foam Substances 0.000 description 9
- FUJAAQPTGDOYAZ-UHFFFAOYSA-N n-[1-[[3-(aminomethyl)phenyl]methyl]-4-methoxyindazol-3-yl]-5-chlorothiophene-2-sulfonamide;hydrochloride Chemical compound Cl.N1=C(NS(=O)(=O)C=2SC(Cl)=CC=2)C=2C(OC)=CC=CC=2N1CC1=CC=CC(CN)=C1 FUJAAQPTGDOYAZ-UHFFFAOYSA-N 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 9
- 238000012856 packing Methods 0.000 description 9
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 8
- JZAMRGWQDJMEJD-UHFFFAOYSA-N 4-methoxy-1h-indazol-3-amine Chemical compound COC1=CC=CC2=C1C(N)=NN2 JZAMRGWQDJMEJD-UHFFFAOYSA-N 0.000 description 8
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 8
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 239000003246 corticosteroid Substances 0.000 description 8
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- MSXYCPYATZLBMW-UHFFFAOYSA-N 5-chloro-n-(5-chlorothiophen-2-yl)sulfonyl-n-(4-methoxy-1h-indazol-3-yl)thiophene-2-sulfonamide Chemical compound C1=2C(OC)=CC=CC=2NN=C1N(S(=O)(=O)C=1SC(Cl)=CC=1)S(=O)(=O)C1=CC=C(Cl)S1 MSXYCPYATZLBMW-UHFFFAOYSA-N 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 7
- 229910052796 boron Inorganic materials 0.000 description 7
- 239000012458 free base Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000003999 initiator Substances 0.000 description 7
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000012453 solvate Substances 0.000 description 7
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- XZPVPNZTYPUODG-UHFFFAOYSA-M sodium;chloride;dihydrate Chemical compound O.O.[Na+].[Cl-] XZPVPNZTYPUODG-UHFFFAOYSA-M 0.000 description 6
- MHCGJOLEGDCKQA-UHFFFAOYSA-N 2,4-difluoro-6-methoxybenzonitrile Chemical compound COC1=CC(F)=CC(F)=C1C#N MHCGJOLEGDCKQA-UHFFFAOYSA-N 0.000 description 5
- XBPPLECAZBTMMK-UHFFFAOYSA-N 2-chloro-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CCl XBPPLECAZBTMMK-UHFFFAOYSA-N 0.000 description 5
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- RBTCRFLJLUNCLL-UHFFFAOYSA-N (1-chloro-2-methyl-1-oxopropan-2-yl) acetate Chemical compound CC(=O)OC(C)(C)C(Cl)=O RBTCRFLJLUNCLL-UHFFFAOYSA-N 0.000 description 4
- GQIRIWDEZSKOCN-UHFFFAOYSA-N 1-chloro-n,n,2-trimethylprop-1-en-1-amine Chemical compound CN(C)C(Cl)=C(C)C GQIRIWDEZSKOCN-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- FVKFHMNJTHKMRX-UHFFFAOYSA-N 3,4,6,7,8,9-hexahydro-2H-pyrimido[1,2-a]pyrimidine Chemical compound C1CCN2CCCNC2=N1 FVKFHMNJTHKMRX-UHFFFAOYSA-N 0.000 description 4
- WRXVOTDGLNPNND-UHFFFAOYSA-N 3-(chloromethyl)benzonitrile Chemical compound ClCC1=CC=CC(C#N)=C1 WRXVOTDGLNPNND-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 229940124225 Adrenoreceptor agonist Drugs 0.000 description 4
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 239000012317 TBTU Substances 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- RFGAKHZYGOSPPE-UHFFFAOYSA-N n-[1-[[3-(aminomethyl)phenyl]methyl]-4-methoxyindazol-3-yl]-5-chlorothiophene-2-sulfonamide Chemical compound N1=C(NS(=O)(=O)C=2SC(Cl)=CC=2)C=2C(OC)=CC=CC=2N1CC1=CC=CC(CN)=C1 RFGAKHZYGOSPPE-UHFFFAOYSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 229960004017 salmeterol Drugs 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 4
- XFCBVBCCLMYSGC-UHFFFAOYSA-N 2-(7-fluoro-4-methoxy-1h-indazol-3-yl)isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1=NNC2=C1C(OC)=CC=C2F XFCBVBCCLMYSGC-UHFFFAOYSA-N 0.000 description 3
- BAWMMJAUVBLLEE-UHFFFAOYSA-N 2-[2-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 BAWMMJAUVBLLEE-UHFFFAOYSA-N 0.000 description 3
- OOYATKQQGVPYQR-UHFFFAOYSA-N 3-(chloromethyl)benzamide Chemical compound NC(=O)C1=CC=CC(CCl)=C1 OOYATKQQGVPYQR-UHFFFAOYSA-N 0.000 description 3
- SEIIPIGWARWFBZ-UHFFFAOYSA-N 5-chloro-n-(5-chlorothiophen-2-yl)sulfonyl-n-[1-[(3-cyanophenyl)methyl]-6-fluoro-4-methoxyindazol-3-yl]thiophene-2-sulfonamide Chemical compound N1=C(N(S(=O)(=O)C=2SC(Cl)=CC=2)S(=O)(=O)C=2SC(Cl)=CC=2)C=2C(OC)=CC(F)=CC=2N1CC1=CC=CC(C#N)=C1 SEIIPIGWARWFBZ-UHFFFAOYSA-N 0.000 description 3
- QGGRRHYGHGJEKP-UHFFFAOYSA-N 5-methylthiophene-2-sulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)S1 QGGRRHYGHGJEKP-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000017925 CHRM3 Human genes 0.000 description 3
- 101150060249 CHRM3 gene Proteins 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 241000400611 Eucalyptus deanei Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004296 chiral HPLC Methods 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229950003420 efletirizine Drugs 0.000 description 3
- 150000004675 formic acid derivatives Chemical class 0.000 description 3
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 3
- 229960002848 formoterol Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- BVWTXUYLKBHMOX-UHFFFAOYSA-N methyl vanillate Chemical compound COC(=O)C1=CC=C(O)C(OC)=C1 BVWTXUYLKBHMOX-UHFFFAOYSA-N 0.000 description 3
- MSRUAKWQSMEGMR-UHFFFAOYSA-N n-[1-[[4-(aminomethyl)phenyl]methyl]-4-methoxyindazol-3-yl]-5-chlorothiophene-2-sulfonamide;formic acid Chemical compound OC=O.N1=C(NS(=O)(=O)C=2SC(Cl)=CC=2)C=2C(OC)=CC=CC=2N1CC1=CC=C(CN)C=C1 MSRUAKWQSMEGMR-UHFFFAOYSA-N 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- XNAANNODSRXAGD-UHFFFAOYSA-N tert-butyl 3-amino-4-methoxyindazole-1-carboxylate Chemical compound COC1=CC=CC2=C1C(N)=NN2C(=O)OC(C)(C)C XNAANNODSRXAGD-UHFFFAOYSA-N 0.000 description 3
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- ZTYCZUDIIGEYMK-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-4-methoxyindazol-3-amine Chemical compound C1=C(OC)C(OC)=CC=C1CN1C2=CC=CC(OC)=C2C(N)=N1 ZTYCZUDIIGEYMK-UHFFFAOYSA-N 0.000 description 2
- BLWLZXJCBNYJAP-UHFFFAOYSA-N 2,4-difluoro-6-methoxybenzaldehyde Chemical compound COC1=CC(F)=CC(F)=C1C=O BLWLZXJCBNYJAP-UHFFFAOYSA-N 0.000 description 2
- CMGFDVIQHBAJHT-UHFFFAOYSA-N 2,6-difluoro-4-methoxybenzonitrile Chemical compound COC1=CC(F)=C(C#N)C(F)=C1 CMGFDVIQHBAJHT-UHFFFAOYSA-N 0.000 description 2
- QXERNBBXHXHXHI-UHFFFAOYSA-N 2-(4-methoxy-1h-indazol-3-yl)isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1=NNC2=C1C(OC)=CC=C2 QXERNBBXHXHXHI-UHFFFAOYSA-N 0.000 description 2
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 2
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 description 2
- JGLUUECGMAVKGG-UHFFFAOYSA-N 3,6-difluoro-2-methoxybenzonitrile Chemical compound COC1=C(F)C=CC(F)=C1C#N JGLUUECGMAVKGG-UHFFFAOYSA-N 0.000 description 2
- CVKOOKPNCVYHNY-UHFFFAOYSA-N 3-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=CC(C#N)=C1 CVKOOKPNCVYHNY-UHFFFAOYSA-N 0.000 description 2
- VKZQCTHCVNLLCL-UHFFFAOYSA-N 3-(hydroxymethyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(CO)=C1 VKZQCTHCVNLLCL-UHFFFAOYSA-N 0.000 description 2
- RQBNPRDCSJBTSK-UHFFFAOYSA-N 3-[(3-amino-4-chloroindazol-1-yl)methyl]benzonitrile Chemical compound C12=CC=CC(Cl)=C2C(N)=NN1CC1=CC=CC(C#N)=C1 RQBNPRDCSJBTSK-UHFFFAOYSA-N 0.000 description 2
- KVXRKRURRSOVSJ-UHFFFAOYSA-N 3-amino-1h-indazole-4-carbonitrile Chemical compound C1=CC(C#N)=C2C(N)=NNC2=C1 KVXRKRURRSOVSJ-UHFFFAOYSA-N 0.000 description 2
- QPLXQNVPEHUPTR-UHFFFAOYSA-N 4-chloro-1H-indazol-3-amine Chemical compound C1=CC(Cl)=C2C(N)=NNC2=C1 QPLXQNVPEHUPTR-UHFFFAOYSA-N 0.000 description 2
- HTMNYSASBRVPKD-UHFFFAOYSA-N 4-fluoro-1h-indazol-3-amine Chemical compound C1=CC(F)=C2C(N)=NNC2=C1 HTMNYSASBRVPKD-UHFFFAOYSA-N 0.000 description 2
- WGYBIEOLAFYDEC-UHFFFAOYSA-N 5-bromothiophene-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(Br)S1 WGYBIEOLAFYDEC-UHFFFAOYSA-N 0.000 description 2
- KQWWFYVWCPEIKM-UHFFFAOYSA-N 5-chloro-n-(4-methoxy-1h-indazol-3-yl)thiophene-2-sulfonamide Chemical compound C1=2C(OC)=CC=CC=2NN=C1NS(=O)(=O)C1=CC=C(Cl)S1 KQWWFYVWCPEIKM-UHFFFAOYSA-N 0.000 description 2
- RGRVASGIDMJXOC-UHFFFAOYSA-N 5-chloro-n-(5-chlorothiophen-2-yl)sulfonyl-n-[1-[[3-[2-(dimethylamino)ethoxy]phenyl]methyl]-4-methoxyindazol-3-yl]thiophene-2-sulfonamide Chemical compound N1=C(N(S(=O)(=O)C=2SC(Cl)=CC=2)S(=O)(=O)C=2SC(Cl)=CC=2)C=2C(OC)=CC=CC=2N1CC1=CC=CC(OCCN(C)C)=C1 RGRVASGIDMJXOC-UHFFFAOYSA-N 0.000 description 2
- VHDPEICLYKCFHI-UHFFFAOYSA-N 5-chloro-n-[1-[(3-cyanophenyl)methyl]-4-methoxyindazol-3-yl]thiophene-2-sulfonamide Chemical compound N1=C(NS(=O)(=O)C=2SC(Cl)=CC=2)C=2C(OC)=CC=CC=2N1CC1=CC=CC(C#N)=C1 VHDPEICLYKCFHI-UHFFFAOYSA-N 0.000 description 2
- NPQNOQUDMOHPQV-UHFFFAOYSA-N 5-chloro-n-[1-[(3-cyanophenyl)methyl]-6-fluoro-4-methoxyindazol-3-yl]thiophene-2-sulfonamide Chemical compound N1=C(NS(=O)(=O)C=2SC(Cl)=CC=2)C=2C(OC)=CC(F)=CC=2N1CC1=CC=CC(C#N)=C1 NPQNOQUDMOHPQV-UHFFFAOYSA-N 0.000 description 2
- WZEQHLPOVNIIBJ-UHFFFAOYSA-N 5-chloro-n-[1-[(3-cyanophenyl)methyl]-7-fluoro-4-methoxyindazol-3-yl]thiophene-2-sulfonamide Chemical compound N1=C(NS(=O)(=O)C=2SC(Cl)=CC=2)C=2C(OC)=CC=C(F)C=2N1CC1=CC=CC(C#N)=C1 WZEQHLPOVNIIBJ-UHFFFAOYSA-N 0.000 description 2
- BGIANJWWCGMDFJ-UHFFFAOYSA-N 5-chloro-n-[4-chloro-1-[(3-cyanophenyl)methyl]indazol-3-yl]thiophene-2-sulfonamide Chemical compound S1C(Cl)=CC=C1S(=O)(=O)NC(C1=C(Cl)C=CC=C11)=NN1CC1=CC=CC(C#N)=C1 BGIANJWWCGMDFJ-UHFFFAOYSA-N 0.000 description 2
- LNSXSZVFDHGGAG-UHFFFAOYSA-N 5-fluoro-4-methoxy-1h-indazol-3-amine Chemical compound COC1=C(F)C=CC2=C1C(N)=NN2 LNSXSZVFDHGGAG-UHFFFAOYSA-N 0.000 description 2
- QVFSZQBFFBLSJP-UHFFFAOYSA-N 6-fluoro-4-methoxy-1h-indazol-3-amine Chemical compound COC1=CC(F)=CC2=C1C(N)=NN2 QVFSZQBFFBLSJP-UHFFFAOYSA-N 0.000 description 2
- VVHDNIJNRVTTNO-UHFFFAOYSA-N 7-fluoro-4-methoxy-1h-indazol-3-amine Chemical compound COC1=CC=C(F)C2=C1C(N)=NN2 VVHDNIJNRVTTNO-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 102100022278 Arachidonate 5-lipoxygenase-activating protein Human genes 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 125000006847 BOC protecting group Chemical group 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- NOTFZGFABLVTIG-UHFFFAOYSA-N Cyclohexylethyl acetate Chemical compound CC(=O)OCCC1CCCCC1 NOTFZGFABLVTIG-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 2
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000755875 Homo sapiens Arachidonate 5-lipoxygenase-activating protein Proteins 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- JZWXFQOIQLKHJM-UHFFFAOYSA-N N-[1-[[3-(aminomethyl)phenyl]methyl]-4-hydroxyindazol-3-yl]-5-chlorothiophene-2-sulfonamide formic acid Chemical compound OC=O.NCc1cccc(Cn2nc(NS(=O)(=O)c3ccc(Cl)s3)c3c(O)cccc23)c1 JZWXFQOIQLKHJM-UHFFFAOYSA-N 0.000 description 2
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 2
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Chemical group 0.000 description 2
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000004479 aerosol dispenser Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 125000006242 amine protecting group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 229960005475 antiinfective agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229960001803 cetirizine Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- UMYZHWLYICNGRQ-UHFFFAOYSA-N ethanol;heptane Chemical compound CCO.CCCCCCC UMYZHWLYICNGRQ-UHFFFAOYSA-N 0.000 description 2
- 229960003592 fexofenadine Drugs 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229960000289 fluticasone propionate Drugs 0.000 description 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960001508 levocetirizine Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 239000002032 methanolic fraction Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- YUHSMQQNPRLEEJ-UHFFFAOYSA-N methyl 3-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=CC(CBr)=C1 YUHSMQQNPRLEEJ-UHFFFAOYSA-N 0.000 description 2
- YKUCHDXIBAQWSF-UHFFFAOYSA-N methyl 3-hydroxybenzoate Chemical compound COC(=O)C1=CC=CC(O)=C1 YKUCHDXIBAQWSF-UHFFFAOYSA-N 0.000 description 2
- VESZOGFONIDODI-UHFFFAOYSA-N methyl 4-[2-(dimethylamino)-2-oxoethoxy]-3-methoxybenzoate Chemical compound COC(=O)C1=CC=C(OCC(=O)N(C)C)C(OC)=C1 VESZOGFONIDODI-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229960001639 penicillamine Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000009491 slugging Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- DKSSHIYZYCEVPM-UHFFFAOYSA-N tert-butyl 3-amino-4-cyanoindazole-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OC(C)(C)C)N=C(N)C2=C1C#N DKSSHIYZYCEVPM-UHFFFAOYSA-N 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229960002282 vilanterol trifenatate Drugs 0.000 description 2
- KLOLZALDXGTNQE-JIDHJSLPSA-N vilanterol trifenate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)O)C1=CC=CC=C1.C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1 KLOLZALDXGTNQE-JIDHJSLPSA-N 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- VLHQXRIIQSTJCQ-ZCFIWIBFSA-N (2r)-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoic acid Chemical compound OC(=O)[C@@H](C)N(C)C(=O)OC(C)(C)C VLHQXRIIQSTJCQ-ZCFIWIBFSA-N 0.000 description 1
- VOMNVECKPIKEGA-UNTBIKODSA-N (3R)-N-[[3-[[3-[(5-chlorothiophen-2-yl)sulfonylamino]-4-hydroxyindazol-1-yl]methyl]phenyl]methyl]morpholine-3-carboxamide formic acid Chemical compound OC=O.Oc1cccc2n(Cc3cccc(CNC(=O)[C@H]4COCCN4)c3)nc(NS(=O)(=O)c3ccc(Cl)s3)c12 VOMNVECKPIKEGA-UNTBIKODSA-N 0.000 description 1
- KVXXEKIGMOEPSA-SSDOTTSWSA-N (3r)-4-[(2-methylpropan-2-yl)oxycarbonyl]morpholine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCOC[C@@H]1C(O)=O KVXXEKIGMOEPSA-SSDOTTSWSA-N 0.000 description 1
- JZYRBUCTYZYXAQ-VEIFNGETSA-N (3r)-n-[[4-[[4-methoxy-3-[(5-methylthiophen-2-yl)sulfonylamino]indazol-1-yl]methyl]phenyl]methyl]morpholine-3-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1=C(NS(=O)(=O)C=2SC(C)=CC=2)C=2C(OC)=CC=CC=2N1CC(C=C1)=CC=C1CNC(=O)[C@H]1COCCN1 JZYRBUCTYZYXAQ-VEIFNGETSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- OTGQPYSISUUHAF-UHFFFAOYSA-N 1,3-difluoro-5-methoxybenzene Chemical compound COC1=CC(F)=CC(F)=C1 OTGQPYSISUUHAF-UHFFFAOYSA-N 0.000 description 1
- NDZYPHLNJZSQJY-QNWVGRARSA-N 1-(5-acetyl-4-methyl-1,3-thiazol-2-yl)-3-[(1r,2s)-2-[[(3s)-3-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]cyclohexyl]urea Chemical compound CC1=C(C(=O)C)SC(NC(=O)N[C@H]2[C@@H](CCCC2)CN2C[C@H](CC=3C=CC(F)=CC=3)CCC2)=N1 NDZYPHLNJZSQJY-QNWVGRARSA-N 0.000 description 1
- SFOVDSLXFUGAIV-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-n-piperidin-4-ylbenzimidazol-2-amine Chemical compound C1=CC(F)=CC=C1CN1C2=CC=CC=C2N=C1NC1CCNCC1 SFOVDSLXFUGAIV-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
- IVGOASIEVSAFSO-UHFFFAOYSA-N 1-[[3-[[3-[(5-chlorothiophen-2-yl)sulfonylamino]-4-methoxyindazol-1-yl]methyl]phenyl]methyl]-3-propan-2-ylurea Chemical compound N1=C(NS(=O)(=O)C=2SC(Cl)=CC=2)C=2C(OC)=CC=CC=2N1CC1=CC=CC(CNC(=O)NC(C)C)=C1 IVGOASIEVSAFSO-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CPPPQWJPPSCELE-UHFFFAOYSA-N 1-tert-butyl-3-[[3-[[3-[(5-chlorothiophen-2-yl)sulfonylamino]-4-methoxyindazol-1-yl]methyl]phenyl]methyl]urea Chemical compound N1=C(NS(=O)(=O)C=2SC(Cl)=CC=2)C=2C(OC)=CC=CC=2N1CC1=CC=CC(CNC(=O)NC(C)(C)C)=C1 CPPPQWJPPSCELE-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YWTXHALVWAISPR-UHFFFAOYSA-N 2,3,6-trifluorobenzonitrile Chemical compound FC1=CC=C(F)C(C#N)=C1F YWTXHALVWAISPR-UHFFFAOYSA-N 0.000 description 1
- AOINHYTZCDVZGW-UHFFFAOYSA-N 2,3-difluoro-6-methoxybenzonitrile Chemical compound COC1=CC=C(F)C(F)=C1C#N AOINHYTZCDVZGW-UHFFFAOYSA-N 0.000 description 1
- HTKFGTCCOJIUIK-UHFFFAOYSA-N 2,4,6-trifluorobenzonitrile Chemical compound FC1=CC(F)=C(C#N)C(F)=C1 HTKFGTCCOJIUIK-UHFFFAOYSA-N 0.000 description 1
- BNBRIFIJRKJGEI-UHFFFAOYSA-N 2,6-difluorobenzonitrile Chemical compound FC1=CC=CC(F)=C1C#N BNBRIFIJRKJGEI-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- XPTAYRHLHAFUOS-UHFFFAOYSA-N 2-chloro-6-fluorobenzonitrile Chemical compound FC1=CC=CC(Cl)=C1C#N XPTAYRHLHAFUOS-UHFFFAOYSA-N 0.000 description 1
- YPMSIWYNTPSPMV-UHFFFAOYSA-N 2-fluoro-6-methoxybenzonitrile Chemical compound COC1=CC=CC(F)=C1C#N YPMSIWYNTPSPMV-UHFFFAOYSA-N 0.000 description 1
- MGOLNIXAPIAKFM-UHFFFAOYSA-N 2-isocyanato-2-methylpropane Chemical compound CC(C)(C)N=C=O MGOLNIXAPIAKFM-UHFFFAOYSA-N 0.000 description 1
- GSLTVFIVJMCNBH-UHFFFAOYSA-N 2-isocyanatopropane Chemical compound CC(C)N=C=O GSLTVFIVJMCNBH-UHFFFAOYSA-N 0.000 description 1
- MFNXWZGIFWJHMI-UHFFFAOYSA-N 2-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C)(C)C(O)=O MFNXWZGIFWJHMI-UHFFFAOYSA-N 0.000 description 1
- KPDLITGXUYMJEC-UHFFFAOYSA-N 2-methyl-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoic acid Chemical compound OC(=O)C(C)(C)N(C)C(=O)OC(C)(C)C KPDLITGXUYMJEC-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- PCOFIIVWHXIDGT-UHFFFAOYSA-N 3-(hydroxymethyl)benzonitrile Chemical compound OCC1=CC=CC(C#N)=C1 PCOFIIVWHXIDGT-UHFFFAOYSA-N 0.000 description 1
- PWCGYIQCGGKFRV-UHFFFAOYSA-N 3-[(3-amino-4-fluoroindazol-1-yl)methyl]benzonitrile Chemical compound C12=CC=CC(F)=C2C(N)=NN1CC1=CC=CC(C#N)=C1 PWCGYIQCGGKFRV-UHFFFAOYSA-N 0.000 description 1
- VNIOQSAWKLOGLY-UHFFFAOYSA-N 3-[(5-methylfuran-2-yl)methyl]-n-piperidin-4-ylimidazo[4,5-b]pyridin-2-amine Chemical compound O1C(C)=CC=C1CN1C2=NC=CC=C2N=C1NC1CCNCC1 VNIOQSAWKLOGLY-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- KVCWOQYRJKBZFI-UHFFFAOYSA-N 3-[[4-methoxy-3-(thiophen-2-ylsulfonylamino)indazol-1-yl]methyl]benzamide Chemical compound N1=C(NS(=O)(=O)C=2SC=CC=2)C=2C(OC)=CC=CC=2N1CC1=CC=CC(C(N)=O)=C1 KVCWOQYRJKBZFI-UHFFFAOYSA-N 0.000 description 1
- SAPTYURANIHAPE-UHFFFAOYSA-N 3-fluorobenzene-1,2-dicarbonitrile Chemical compound FC1=CC=CC(C#N)=C1C#N SAPTYURANIHAPE-UHFFFAOYSA-N 0.000 description 1
- NAETXYOXMDYNLE-UHFFFAOYSA-N 3-sulfamoylbenzoic acid Chemical compound NS(=O)(=O)C1=CC=CC(C(O)=O)=C1 NAETXYOXMDYNLE-UHFFFAOYSA-N 0.000 description 1
- KLWYYWVSFYRPLM-UHFFFAOYSA-N 4-(bromomethyl)-2-fluoro-1-methoxybenzene Chemical compound COC1=CC=C(CBr)C=C1F KLWYYWVSFYRPLM-UHFFFAOYSA-N 0.000 description 1
- QNJHTLTUBNXLFS-UHFFFAOYSA-N 4-(bromomethyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(CBr)C=C1 QNJHTLTUBNXLFS-UHFFFAOYSA-N 0.000 description 1
- WWHJLVMBXXXUFO-UHFFFAOYSA-N 4-(chloromethyl)-1,2-dimethoxybenzene Chemical compound COC1=CC=C(CCl)C=C1OC WWHJLVMBXXXUFO-UHFFFAOYSA-N 0.000 description 1
- KZBDMXFIDCWCOU-UHFFFAOYSA-N 4-(chloromethyl)-n,n-diethylbenzamide Chemical compound CCN(CC)C(=O)C1=CC=C(CCl)C=C1 KZBDMXFIDCWCOU-UHFFFAOYSA-N 0.000 description 1
- OVILZFVTUVWJTO-UHFFFAOYSA-N 4-(chloromethyl)benzamide Chemical compound NC(=O)C1=CC=C(CCl)C=C1 OVILZFVTUVWJTO-UHFFFAOYSA-N 0.000 description 1
- LOQLDQJTSMKBJU-UHFFFAOYSA-N 4-(chloromethyl)benzonitrile Chemical compound ClCC1=CC=C(C#N)C=C1 LOQLDQJTSMKBJU-UHFFFAOYSA-N 0.000 description 1
- NTVCMEJZWNSEFW-ICSRJNTNSA-N 4-(diaminomethylideneamino)-n-[[(2s)-1-[(2s)-3-hydroxy-2-(naphthalen-2-ylsulfonylamino)propanoyl]pyrrolidin-2-yl]methyl]butanamide Chemical compound NC(N)=NCCCC(=O)NC[C@@H]1CCCN1C(=O)[C@H](CO)NS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 NTVCMEJZWNSEFW-ICSRJNTNSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- NFUYTVFVCSMTQK-UHFFFAOYSA-N 4-methylmorpholine-3-carboxylic acid;hydrochloride Chemical compound Cl.CN1CCOCC1C(O)=O NFUYTVFVCSMTQK-UHFFFAOYSA-N 0.000 description 1
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- KNSRMVZXDODQBW-UHFFFAOYSA-N 5-chloro-n-(4-methoxy-1h-indazol-3-yl)-n-(2-trimethylsilylethoxymethyl)thiophene-2-sulfonamide Chemical compound C1=2C(OC)=CC=CC=2NN=C1N(COCC[Si](C)(C)C)S(=O)(=O)C1=CC=C(Cl)S1 KNSRMVZXDODQBW-UHFFFAOYSA-N 0.000 description 1
- DTBSHPAFVIGDQX-UHFFFAOYSA-N 5-chloro-n-(5-chlorothiophen-2-yl)sulfonyl-n-(4-cyano-1h-indazol-3-yl)thiophene-2-sulfonamide Chemical compound S1C(Cl)=CC=C1S(=O)(=O)N(S(=O)(=O)C=1SC(Cl)=CC=1)C1=NNC2=CC=CC(C#N)=C12 DTBSHPAFVIGDQX-UHFFFAOYSA-N 0.000 description 1
- ISKBORQVQLUFKK-UHFFFAOYSA-N 5-chloro-n-(5-chlorothiophen-2-yl)sulfonyl-n-[1-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-4-methoxyindazol-3-yl]thiophene-2-sulfonamide Chemical compound N1=C(N(S(=O)(=O)C=2SC(Cl)=CC=2)S(=O)(=O)C=2SC(Cl)=CC=2)C=2C(OC)=CC=CC=2N1CC1=CC=C(OCCN(C)C)C=C1 ISKBORQVQLUFKK-UHFFFAOYSA-N 0.000 description 1
- IEPJCVIILRAHPT-UHFFFAOYSA-N 5-chloro-n-[1-[(3-cyanophenyl)methyl]-4-fluoroindazol-3-yl]thiophene-2-sulfonamide Chemical compound N1=C(NS(=O)(=O)C=2SC(Cl)=CC=2)C=2C(F)=CC=CC=2N1CC1=CC=CC(C#N)=C1 IEPJCVIILRAHPT-UHFFFAOYSA-N 0.000 description 1
- VCXFNZZFYDHRJO-UHFFFAOYSA-N 5-chloro-n-[1-[[3-(dimethylsulfamoyl)phenyl]methyl]-4-methoxyindazol-3-yl]thiophene-2-sulfonamide Chemical compound N1=C(NS(=O)(=O)C=2SC(Cl)=CC=2)C=2C(OC)=CC=CC=2N1CC1=CC=CC(S(=O)(=O)N(C)C)=C1 VCXFNZZFYDHRJO-UHFFFAOYSA-N 0.000 description 1
- NYFATVYZAKZPDW-UHFFFAOYSA-N 5-chloro-n-[1-[[3-(methanesulfonamidomethyl)phenyl]methyl]-4-methoxyindazol-3-yl]thiophene-2-sulfonamide Chemical compound N1=C(NS(=O)(=O)C=2SC(Cl)=CC=2)C=2C(OC)=CC=CC=2N1CC1=CC=CC(CNS(C)(=O)=O)=C1 NYFATVYZAKZPDW-UHFFFAOYSA-N 0.000 description 1
- RWLOVJCNWXQEPW-UHFFFAOYSA-N 5-chloro-n-[1-[[3-[2-(dimethylamino)ethoxy]phenyl]methyl]-4-methoxyindazol-3-yl]thiophene-2-sulfonamide Chemical compound N1=C(NS(=O)(=O)C=2SC(Cl)=CC=2)C=2C(OC)=CC=CC=2N1CC1=CC=CC(OCCN(C)C)=C1 RWLOVJCNWXQEPW-UHFFFAOYSA-N 0.000 description 1
- JJZQTQIQTDTXAP-UHFFFAOYSA-N 5-chloro-n-[1-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-4-methoxyindazol-3-yl]thiophene-2-sulfonamide Chemical compound N1=C(NS(=O)(=O)C=2SC(Cl)=CC=2)C=2C(OC)=CC=CC=2N1CC1=CC=C(OCCN(C)C)C=C1 JJZQTQIQTDTXAP-UHFFFAOYSA-N 0.000 description 1
- PUATYFVTKCFLQQ-UHFFFAOYSA-N 5-chloro-n-[4-methoxy-1-[(2-methoxyphenyl)methyl]indazol-3-yl]thiophene-2-sulfonamide Chemical compound COC1=CC=CC=C1CN1C2=CC=CC(OC)=C2C(NS(=O)(=O)C=2SC(Cl)=CC=2)=N1 PUATYFVTKCFLQQ-UHFFFAOYSA-N 0.000 description 1
- IHQDGJWGWADRQO-UHFFFAOYSA-N 5-chloro-n-[4-methoxy-1-[(3-sulfamoylphenyl)methyl]indazol-3-yl]thiophene-2-sulfonamide Chemical compound N1=C(NS(=O)(=O)C=2SC(Cl)=CC=2)C=2C(OC)=CC=CC=2N1CC1=CC=CC(S(N)(=O)=O)=C1 IHQDGJWGWADRQO-UHFFFAOYSA-N 0.000 description 1
- KRFLBASXPLOGJA-UHFFFAOYSA-N 5-chloro-n-[4-methoxy-1-[(4-methoxyphenyl)methyl]indazol-3-yl]thiophene-2-sulfonamide Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=CC(OC)=C2C(NS(=O)(=O)C=2SC(Cl)=CC=2)=N1 KRFLBASXPLOGJA-UHFFFAOYSA-N 0.000 description 1
- VHEQUPLBALCVDY-UHFFFAOYSA-N 5-chloro-n-[4-methoxy-1-[(4-sulfamoylphenyl)methyl]indazol-3-yl]thiophene-2-sulfonamide Chemical compound N1=C(NS(=O)(=O)C=2SC(Cl)=CC=2)C=2C(OC)=CC=CC=2N1CC1=CC=C(S(N)(=O)=O)C=C1 VHEQUPLBALCVDY-UHFFFAOYSA-N 0.000 description 1
- LNWIOBGBIHSRFB-UHFFFAOYSA-N 5-chloro-n-[4-methoxy-1-[[3-(methylsulfamoyl)phenyl]methyl]indazol-3-yl]thiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC(CN2C3=CC=CC(OC)=C3C(NS(=O)(=O)C=3SC(Cl)=CC=3)=N2)=C1 LNWIOBGBIHSRFB-UHFFFAOYSA-N 0.000 description 1
- USCSJAIWXWYTEH-UHFFFAOYSA-N 7-[3-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]propoxy]-3,4-dimethylchromen-2-one Chemical compound C1=CC=2C(C)=C(C)C(=O)OC=2C=C1OCCCN(CC1)CCN1CC1=CC=C(Cl)C=C1 USCSJAIWXWYTEH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003487 Aspergilloma Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 229940123025 Beta2 integrin antagonist Drugs 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000018202 CC chemokine receptor 4 Human genes 0.000 description 1
- 108091008927 CC chemokine receptors Proteins 0.000 description 1
- 102000005674 CCR Receptors Human genes 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 description 1
- 101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- RRHONYZEMUNMJX-UHFFFAOYSA-N N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3-methylbutan-2-ylamino)methyl]benzamide Chemical compound C1=C(C(=O)N2CCN(CC2)C(C)=O)C(OC)=CC(C)=C1SC(S1)=CN=C1NC(=O)C1=CC=C(CNC(C)C(C)C)C=C1 RRHONYZEMUNMJX-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 101150012648 Odam gene Proteins 0.000 description 1
- 102100027069 Odontogenic ameloblast-associated protein Human genes 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 239000012826 P38 inhibitor Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 238000001237 Raman spectrum Methods 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- VPMWDFRZSIMDKW-YJYMSZOUSA-N Salmefamol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 VPMWDFRZSIMDKW-YJYMSZOUSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- OGEAASSLWZDQBM-UHFFFAOYSA-N Temelastine Chemical compound C1=NC(C)=CC=C1CC(C(N1)=O)=CN=C1NCCCCC1=NC=C(Br)C=C1C OGEAASSLWZDQBM-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- 229940122598 Tryptase inhibitor Drugs 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ALHZEIINTQJLOT-VKHMYHEASA-N [(2s)-1-chloro-1-oxopropan-2-yl] acetate Chemical compound ClC(=O)[C@H](C)OC(C)=O ALHZEIINTQJLOT-VKHMYHEASA-N 0.000 description 1
- OKHZCHJHDXFGCX-UHFFFAOYSA-N [3-[[3-[(5-chlorothiophen-2-yl)sulfonylamino]-4-methoxyindazol-1-yl]methyl]phenyl]methylurea Chemical compound N1=C(NS(=O)(=O)C=2SC(Cl)=CC=2)C=2C(OC)=CC=CC=2N1CC1=CC=CC(CNC(N)=O)=C1 OKHZCHJHDXFGCX-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 229960003792 acrivastine Drugs 0.000 description 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000021825 aldosterone-producing adrenal cortex adenoma Diseases 0.000 description 1
- 229960003790 alimemazine Drugs 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- DQPBABKTKYNPMH-UHFFFAOYSA-N amino hydrogen sulfate Chemical compound NOS(O)(=O)=O DQPBABKTKYNPMH-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 229940059756 arava Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 229940009100 aurothiomalate Drugs 0.000 description 1
- XJHSMFDIQHVMCY-UHFFFAOYSA-M aurothiomalic acid Chemical compound OC(=O)CC(S[Au])C(O)=O XJHSMFDIQHVMCY-UHFFFAOYSA-M 0.000 description 1
- 229960000383 azatadine Drugs 0.000 description 1
- SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229950010123 carebastine Drugs 0.000 description 1
- XGHOVGYJHWQGCC-UHFFFAOYSA-N carebastine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 XGHOVGYJHWQGCC-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000002559 chemokine receptor antagonist Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- WGXZDYPGLJYBJW-UHFFFAOYSA-N chloroform;propan-2-ol Chemical compound CC(C)O.ClC(Cl)Cl WGXZDYPGLJYBJW-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 229960003564 cyclizine Drugs 0.000 description 1
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
- MFNYBOWJWGPXFM-UHFFFAOYSA-N cyclobutanecarboxamide Chemical compound NC(=O)C1CCC1 MFNYBOWJWGPXFM-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HKDDTBNGYXIRJP-UHFFFAOYSA-N cyclohexane;2-methoxy-2-methylpropane Chemical compound COC(C)(C)C.C1CCCCC1 HKDDTBNGYXIRJP-UHFFFAOYSA-N 0.000 description 1
- LNZMEOLVTKHUAS-UHFFFAOYSA-N cyclohexane;dichloromethane Chemical compound ClCCl.C1CCCCC1 LNZMEOLVTKHUAS-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- BSEXNZMHLUMQKR-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1.NC(=O)C1CC1 BSEXNZMHLUMQKR-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000012649 demethylating agent Substances 0.000 description 1
- 229960001271 desloratadine Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 1
- GRTGGSXWHGKRSB-UHFFFAOYSA-N dichloromethyl methyl ether Chemical compound COC(Cl)Cl GRTGGSXWHGKRSB-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 229960001992 dimetindene Drugs 0.000 description 1
- MVMQESMQSYOVGV-UHFFFAOYSA-N dimetindene Chemical compound CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 MVMQESMQSYOVGV-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960001971 ebastine Drugs 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 208000003401 eosinophilic granuloma Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960003449 epinastine Drugs 0.000 description 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960001469 fluticasone furoate Drugs 0.000 description 1
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- 229940111120 gold preparations Drugs 0.000 description 1
- IRPYFWIZKIOHQN-XTZHGVARSA-N gold;[(2r,3r,4s,5r,6s)-3,4,5-triacetyloxy-6-sulfanyloxan-2-yl]methyl acetate;triethylphosphane Chemical compound [Au].CC[PH+](CC)CC.CC(=O)OC[C@H]1O[C@@H]([S-])[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O IRPYFWIZKIOHQN-XTZHGVARSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229940073062 imuran Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 150000002473 indoazoles Chemical class 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 201000009085 invasive aspergillosis Diseases 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 229940054136 kineret Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 229960001120 levocabastine Drugs 0.000 description 1
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- WRIRWRKPLXCTFD-UHFFFAOYSA-N malonamide Chemical compound NC(=O)CC(N)=O WRIRWRKPLXCTFD-UHFFFAOYSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- 229960005042 mequitazine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- JHHMSRLTZAUMOJ-UHFFFAOYSA-N methanamine;oxolane Chemical compound NC.C1CCOC1 JHHMSRLTZAUMOJ-UHFFFAOYSA-N 0.000 description 1
- 229960001869 methapyrilene Drugs 0.000 description 1
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
- 229940120152 methyl 3-hydroxybenzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960001144 mizolastine Drugs 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- JUNOWSHJELIDQP-UHFFFAOYSA-N morpholin-4-ium-3-carboxylate Chemical compound OC(=O)C1COCCN1 JUNOWSHJELIDQP-UHFFFAOYSA-N 0.000 description 1
- BDJBQJAZHHLNLK-UHFFFAOYSA-N morpholine-3,4-dicarboxylic acid Chemical compound OC(=O)C1COCCN1C(O)=O BDJBQJAZHHLNLK-UHFFFAOYSA-N 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- IMNDHOCGZLYMRO-UHFFFAOYSA-N n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC=C1 IMNDHOCGZLYMRO-UHFFFAOYSA-N 0.000 description 1
- ZGAILCXJCUFXAU-UHFFFAOYSA-N n-[1-[[3-(aminomethyl)phenyl]methyl]-4-(1-hydroxyethyl)indazol-3-yl]-5-chlorothiophene-2-sulfonamide Chemical compound N1=C(NS(=O)(=O)C=2SC(Cl)=CC=2)C=2C(C(O)C)=CC=CC=2N1CC1=CC=CC(CN)=C1 ZGAILCXJCUFXAU-UHFFFAOYSA-N 0.000 description 1
- JDAGEFWOFRMZET-UHFFFAOYSA-N n-[1-[[3-(aminomethyl)phenyl]methyl]-4-fluoroindazol-3-yl]-5-chlorothiophene-2-sulfonamide Chemical compound NCC1=CC=CC(CN2C3=CC=CC(F)=C3C(NS(=O)(=O)C=3SC(Cl)=CC=3)=N2)=C1 JDAGEFWOFRMZET-UHFFFAOYSA-N 0.000 description 1
- GOMFXGCZLYXZIO-UHFFFAOYSA-N n-[1-[[3-(aminomethyl)phenyl]methyl]-7-fluoro-4-methoxyindazol-3-yl]-5-chlorothiophene-2-sulfonamide Chemical compound N1=C(NS(=O)(=O)C=2SC(Cl)=CC=2)C=2C(OC)=CC=C(F)C=2N1CC1=CC=CC(CN)=C1 GOMFXGCZLYXZIO-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- VAWHHINUFPFBMZ-UHFFFAOYSA-N n-[[3-[[3-[(5-chlorothiophen-2-yl)sulfonylamino]-4-methoxyindazol-1-yl]methyl]phenyl]methyl]formamide Chemical compound N1=C(NS(=O)(=O)C=2SC(Cl)=CC=2)C=2C(OC)=CC=CC=2N1CC1=CC=CC(CNC=O)=C1 VAWHHINUFPFBMZ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 229940063121 neoral Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 229950009470 noberastine Drugs 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229960004114 olopatadine Drugs 0.000 description 1
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- DGOYLVBDCVINQZ-UHFFFAOYSA-N oxane-4-carboxamide Chemical compound NC(=O)C1CCOCC1 DGOYLVBDCVINQZ-UHFFFAOYSA-N 0.000 description 1
- 229960001609 oxitropium bromide Drugs 0.000 description 1
- LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 description 1
- GXHAENUAJYZNOA-UHFFFAOYSA-N oxolane-2-carboxamide Chemical compound NC(=O)C1CCCO1 GXHAENUAJYZNOA-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229950010674 picumast Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229940072689 plaquenil Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229940063638 ridaura Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229950001879 salmefamol Drugs 0.000 description 1
- 229960005018 salmeterol xinafoate Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950005829 temelastine Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- LEUKUHMRKQVARJ-UHFFFAOYSA-N tert-butyl 3-[(5-chlorothiophen-2-yl)sulfonyl-(2-trimethylsilylethoxymethyl)amino]-4-methoxyindazole-1-carboxylate Chemical compound C1=2C(OC)=CC=CC=2N(C(=O)OC(C)(C)C)N=C1N(COCC[Si](C)(C)C)S(=O)(=O)C1=CC=C(Cl)S1 LEUKUHMRKQVARJ-UHFFFAOYSA-N 0.000 description 1
- VAGXEHUOHJPWGG-UHFFFAOYSA-N tert-butyl 3-[(5-chlorothiophen-2-yl)sulfonylamino]-4-methoxyindazole-1-carboxylate Chemical compound C1=2C(OC)=CC=CC=2N(C(=O)OC(C)(C)C)N=C1NS(=O)(=O)C1=CC=C(Cl)S1 VAGXEHUOHJPWGG-UHFFFAOYSA-N 0.000 description 1
- NVPDPBKPOAQKGQ-UHFFFAOYSA-N tert-butyl 3-[bis[(5-chlorothiophen-2-yl)sulfonyl]amino]-4-cyanoindazole-1-carboxylate Chemical compound C12=C(C#N)C=CC=C2N(C(=O)OC(C)(C)C)N=C1N(S(=O)(=O)C=1SC(Cl)=CC=1)S(=O)(=O)C1=CC=C(Cl)S1 NVPDPBKPOAQKGQ-UHFFFAOYSA-N 0.000 description 1
- AVEANRZNJAQPKQ-UHFFFAOYSA-N tert-butyl 3-[bis[(5-chlorothiophen-2-yl)sulfonyl]amino]-4-methoxyindazole-1-carboxylate Chemical compound C1=2C(OC)=CC=CC=2N(C(=O)OC(C)(C)C)N=C1N(S(=O)(=O)C=1SC(Cl)=CC=1)S(=O)(=O)C1=CC=C(Cl)S1 AVEANRZNJAQPKQ-UHFFFAOYSA-N 0.000 description 1
- VIWCZCUJFLMADH-UHFFFAOYSA-N tert-butyl n-[[3-[[3-[(5-chlorothiophen-2-yl)sulfonylamino]-4-cyanoindazol-1-yl]methyl]phenyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC(CN2C3=CC=CC(=C3C(NS(=O)(=O)C=3SC(Cl)=CC=3)=N2)C#N)=C1 VIWCZCUJFLMADH-UHFFFAOYSA-N 0.000 description 1
- UPZGCPLIKDXOMC-UHFFFAOYSA-N tert-butyl n-[[3-[[3-[bis[(5-chlorothiophen-2-yl)sulfonyl]amino]-4-cyanoindazol-1-yl]methyl]phenyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC(CN2C3=CC=CC(=C3C(N(S(=O)(=O)C=3SC(Cl)=CC=3)S(=O)(=O)C=3SC(Cl)=CC=3)=N2)C#N)=C1 UPZGCPLIKDXOMC-UHFFFAOYSA-N 0.000 description 1
- LPOHBDUWAKEMEU-UHFFFAOYSA-N tert-butyl n-[[3-[[4-acetyl-3-[(5-chlorothiophen-2-yl)sulfonylamino]indazol-1-yl]methyl]phenyl]methyl]carbamate Chemical compound N1=C(NS(=O)(=O)C=2SC(Cl)=CC=2)C=2C(C(=O)C)=CC=CC=2N1CC1=CC=CC(CNC(=O)OC(C)(C)C)=C1 LPOHBDUWAKEMEU-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
- 239000002750 tryptase inhibitor Substances 0.000 description 1
- 208000001319 vasomotor rhinitis Diseases 0.000 description 1
- 201000005539 vernal conjunctivitis Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229950000339 xinafoate Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Indazole compounds (I), processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing such compounds and their use in therapy related to CCR4 receptor antagonists.
Description
PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS
The present invention relates to indazole compounds, processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing such compounds and to their use in therapy.
Chemokines are believed to play an important role in immune and inflammatory responses in a number of diseases or conditions The CC-chemokine receptor 4 (hereafter CCR4) was originally cloned from a basophilic cell line (Power et al, J. Biol.
Chem.; 270: 19495: 1995). Small molecule CCR4 receptor antagonists are known in the art, with examples of such being described in Andrews et al (Mol. Pharmacol 73: 855, 2008).
In a first aspect of the present invention, there is provided a compound of formula (I) or a salt thereof, more particularly a compound of formula (I) or a pharmaceutically acceptable salt thereof
R35 0
R° An \!
O Ss nr \ (RY),
R’ (1)
In a second aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents and excipients.
In a third aspect of the present invention, there is provided a compound of formula (1), or a pharmaceutically acceptable salt thereof for use in therapy, in particular in the treatment of a disease or condition for which a CCR4 receptor antagonist is indicated.
In a fourth aspect of the present invention, there is provided a method of treating a disease or condition for which a CCR4 receptor antagonist is indicated in a subject in need thereof which comprises administering a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof.
In a fifth aspect of the present invention, there is provided the use of a compound of formula (1), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease or condition for which a CCR4 receptor antagonist is indicated.
The present invention relates to a compound of formula (1) or a salt thereof
R35 0
R° Aw \! oO Ss nr \ (RY),
R1 0) wherein
R'is selected from the group consisting of (1), (2), (3) (4) and (5) (1) a group of formula (a) . 0
Ho Na (a) in which A is selected from the group consisting of (i), (ii), (iii), (iv), (v), (vi), (vii) and (viii) (i) hydrogen; (ii) C1salkyl optionally substituted by one or more -NR°R®, -OR, -C(O)NR®R®, -C(O)OR®, heterocyclyl, phenyl or heteroaryl groups;
(iii) Ca.scycloalkyl optionally substituted by a -C(O)OR® or -NR°R” group; (iv) heterocyclyl optionally substituted by one or more Cqsalkyl; (Vv) heteroaryl optionally substituted by one or more halogen or C,¢alkyl (vi) -NR°R%; (vii) phenyl substituted by a —(CH,),C(O)OH group in which pis 0, 1, 2 or 3; or (vii) —(CH,);,C(O)OH (2) a group of formula (b) . 0
NY
H Jj 8 0 (b) in which B is Cqsalkyl; (3) —C(O)NR®R"® or -CH,C(O)NRR"; (4) —S(O)NRR"; (5) Ciealkoxy optionally substituted by NR*R®;
R? R® and R®are independently hydrogen or Cqsalkyl;
R? is halogen, C1.salkyl, CFs, hydroxy or Cyealkoxy;
R® is halogen, CFs, hydroxy, Cisalkoxy, CR‘R°OH or CHF»; in which R® and R® are independently hydrogen or methyl;
R%is hydrogen, halogen, Cq.salkyl or CF3;
R®and R® are independently hydrogen, halogen or Cysalkyl; and nis 0 or 1.
In one embodiment the invention relates to a compound of formula (1) or a salt thereof
R35 2 3
R Hs Re on
O s
N N
N
Ra , (RY),
R1 (1) wherein
R'is selected from the group consisting of (1), (2), (3) (4) and (5) (1) a group of formula (a) 0 “TN A
N
H A
(a) in which A is selected from the group consisting of (i), (ii), (iii), (iv), (v) and (vi): (i) hydrogen; (ii) C1.salkyl optionally substituted by one or more -NR?R®, -OR°, -C(O)NR®R®, -C(O)OR?, heterocyclyl, phenyl or heteroaryl groups; (iii) Cs.scycloalkyl optionally substituted by a —~NR®R® group; (iv) heterocyclyl optionally substituted by one or more C,galkyl; (Vv) heteroaryl optionally substituted by one or more halogen or Cy alkyl (vi) -NR°R" (2) a group of formula (b) \ 0
NY
Hj 8B 0 (b) in which B is Cqsalkyl; (3) —C(ONR®R”;
(4) —S(O)NRR’; (5) Cisalkoxy optionally substituted by NR*R®;
R% R" and Rare independently hydrogen or Cigalkyl;
R? is halogen, Ci.salkyl, CFs, hydroxy or Cyealkoxy;
R® is halogen, CF3, hydroxy, C,salkoxy, CH,OH or CHF,
R*is hydrogen, halogen, Cyalkyl or CF;
R®and R® are independently hydrogen, halogen or Cysalkyl; and nisOor1.
In one embodiment the R' group is substituted at the meta position (3 position).
In one embodiment R' is a group of formula (a) in which A is Cysalkyl such as methyl, ethyl, isopropyl or t- butyl.
In a further embodiment R' is a group of formula (a) in which A is Cysalkyl substituted by one or more —NR?R® (such as NH,, NHMe or NMe,), -OR® (such as OH or OMe), -C(O)NR®R® (such as C(O)NH,), -C(O)OR® (such as C(O)OH or C(O)OMe), pyrrolidinyl, phenyl or imidazolyl.
In a yet further embodiment R' is a group of formula (a) in which A is a heterocyclyl selected from the group consisting of pyrrolidinyl, piperidinyl and morpholinyl.
In a yet further embodiment R" is a group of formula (a) in which A is a heteroaryl selected from the group consisting of furyl, imidazolyl, pyrazolyl and oxazolyl.
In one embodiment, when n is 1 R? is selected from the group consisting of halogen (such as fluorine or chlorine), Cqgalkyl (such as methyl) or Cy galkoxy (such as methoxy).
In one embodiment R® is halogen (such as fluorine), hydroxy or Ci4alkoxy (such as methoxy). In a further embodiment R® is methoxy.
In one embodiment R* is hydrogen or fluorine.
In one embodiment R® and R® are independently hydrogen, halogen (such as chlorine) or
Cialkyl (such as methyl). In a further embodiment R® is chlorine and R® is hydrogen.
In one embodiment R?, R” and Rare independently hydrogen or methyl.
In a particular embodiment the present invention provides for compounds of formula (la) or a salt thereof
Oo vo
W Ss Cl
TC
Ey in which R" and R® are as defined above.
While the embodiments for each variable have generally been listed above separately for each variable this invention includes those compounds in which several or each embodiment in formula (I) is selected from each of the embodiments listed above.
Therefore, this invention is intended to include all combinations of embodiments for each variable described hereinabove including salts thereof.
Specific compounds according to the invention include Examples 1 - 166 as described herein or a salt thereof.
Particular compounds according to the invention are
N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyllacetamide,
N-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]Jamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-3-morpholinecarboxamide,
N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-hydroxy-2-methylpropanamide
N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-hydroxypropanamide,
(2S5)-N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyllamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-hydroxypropanamide or a salt thereof.
Throughout the present specification, unless otherwise stated: e the term "halogen" is used to describe a group selected from fluorine, chlorine or bromine; oe the term" Cqgalkyl" is used to describe a group or a part of the group comprising a linear or branched alkyl group containing from 1 to 6 carbon atoms respectively.
Suitable examples of such groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, t- butyl, pentyl and hexyl; oe the term" C galkoxy" is used to describe a group or a part of the group comprising a linear or branched alkyl group containing from 1 to 6 carbon atoms. Suitable examples include methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, t- butoxy, pentoxy or hexoxy; o the term “heterocyclyl” or “heterocyclyl ring” is used to describe a saturated 4 — 7 membered monocyclic ring containing one or two heteroatoms selected from nitrogen, oxygen or sulphur. Suitable examples include azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydropyranyl; e the term "heteroaryl" is used to describe an aromatic or a benzofused aromatic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur.
Suitable examples of such aromatic rings include thienyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyrazolyl, pyrimidyl, pyridazinyl, pyrazinyl and pyridyl. Suitable examples of such benzofused aromatic rings include quinolinyl, isoquinolinyl, indolyl, benzofuryl, benzothienyl, benzimidazolyl, benzoxazolyl; oe the term “Csscycloalkyl” is used to describe a non aromatic carbocyclic ring containing at least three and at most seven carbon atoms. Examples of Ca. zeycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
It will be appreciated that the present invention covers compounds of formula (I) as the free base and as salts thereof, for example as a pharmaceutically acceptable salt thereof.
In one embodiment the invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof.
Because of their potential use in medicine, salts of the compounds of formula (I) are desirably pharmaceutically acceptable. Suitable pharmaceutically acceptable salts can include acid or base addition salts. For a review on suitable salts see Berge et al., J.
Pharm. Sci., 66:1-19, (1977). Typically, a pharmaceutically acceptable salt may be readily prepared by using a desired acid or base as appropriate. The resultant salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
A pharmaceutically acceptable base addition salt can be formed by reaction of a compound of formula (I) with a suitable inorganic or organic base, (e.g. triethylamine, ethanolamine, triethanolamine, choline, arginine, lysine or histidine), optionally in a suitable solvent, to give the base addition salt which is usually isolated, for example, by crystallisation and filtration. Pharmaceutically acceptable base salts include ammonium salts, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium and salts with organic bases, including salts of primary, secondary and tertiary amines, such as isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexyl amine and N-methyl-D-glucamine.
A pharmaceutically acceptable acid addition salt can be formed by reaction of a compound of formula (I) with a suitable inorganic or organic acid (such as hydrobromic, hydrochloric, sulphuric, nitric, phosphoric, succinc, maleic, acetic, propionic, fumaric, citric, tartaric, lactic, benzoic, salicylic, glutamaic, aspartic, p-toluenesulfonic, benzenesulfonic, methanesulfonic, ethanesulfonic, naphthalenesulfonic such as 2- naphthalenesulfonic, or hexanoic acid), optionally in a suitable solvent such as an organic solvent, to give the salt which is usually isolated for example by crystallisation and filtration. A pharmaceutically acceptable acid addition salt of a compound of formula (I) can comprise or be for example a hydrobromide, hydrochloride, sulfate, nitrate, phosphate, succinate, maleate, acetate, propionate, fumarate, citrate, tartrate, lactate, benzoate, salicylate, glutamate, aspartate, p-toluenesulfonate, benzenesulfonate, methanesulfonate, ethanesulfonate, naphthalenesulfonate (e.g. 2-naphthalenesulfonate) or hexanoate salt.
Other non-pharmaceutically acceptable salts, e.g. formates, oxalates or trifluoroacetates, may be used, for example in the isolation of the compounds of formula (I), and are included within the scope of this invention.
The invention includes within its scope all possible stoichiometric and non-stoichiometric forms of the salts of the compounds of formula (1).
It will be appreciated that many organic compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as “solvates”. For example, a complex with water is known as a “hydrate”. Solvents with high boiling points and/or capable of forming hydrogen bonds such as water, xylene, N-methyl pyrrolidinone, methanol and ethanol may be used to form solvates. Methods for identification of solvates include, but are not limited to, NMR and microanalysis. Solvates of the compounds of formula (I) are within the scope of the invention.
The invention includes within its scope all possible stoichiometric and non-stoichiometric forms of the solvates of the compounds of formula (I).
The compounds of formula (I) may be in crystalline or amorphous form. Furthermore, some of the crystalline forms of the compounds of formula (I) may exist as polymorphs, which are included within the scope of the present invention. Polymorphic forms of compounds of formula (I) may be characterized and differentiated using a number of conventional analytical techniques, including, but not limited to, X-ray powder diffraction (XRPD) patterns, infrared (IR) spectra, Raman spectra, differential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and solid state nuclear magnetic resonance (SSNMR).
Certain of the compounds described herein may contain one or more chiral atoms so that optical isomers, e.g. — enantiomers or diastereocisomers may be formed. Accordingly, the present invention encompasses all isomers of the compounds of formula (I) whether as individual isomers isolated such as to be substantially free of the other isomer (i.e. pure) or as mixtures (i.e. racemates and racemic mixtures). An individual isomer isolated such as to be substantially free of the other isomer (i.e. pure) may be isolated such that less than 10%, particularly less than about 1%, for example less than about 0.1% of the other isomer is present.
Separation of isomers may be achieved by conventional techniques known to those skilled in the art, e.g. by fractional crystallisation, chromatography or HPLC.
Certain compounds of formula (I) may exist in one of several tautomeric forms. It will be understood that the present invention encompasses all tautomers of the compounds of formula (1) whether as individual tautomers or as mixtures thereof.
It will be appreciated from the foregoing that included within the scope of the invention are solvates, hydrates, complexes, isomers and polymorphic forms of the compounds of formula (1) and salts thereof.
The compounds of the invention may be made by a variety of methods, including standard chemistry. Any previously defined variable will continue to have the previously defined meaning unless otherwise indicated. Illustrative general synthetic methods are set out below and then specific compounds of the invention are prepared in the working
The present invention further provides for a process for the preparation of a compound of formula (I) or a salt thereof which comprises a process selected from (a), (b), (¢) or (d) in which: (a) involves reacting a compound of formula (ll) or a salt thereof
R5 oO
A oO S or mr (R2),
HN
(I) in which R? = R® and n are as hereinbefore defined with a compound of formula (Illa), (Ib), (llc) or (llld) or a protected derivative thereof
7 7 7
Le —~g__ O=—C=N—-A
HO LG" Il A
A A 0 (Ila) (Ib) (llc) (1d) in which A is as hereinbefore defined; e and optionally thereafter de-protecting the resulting product; (b) involves reacting a compound of formula (IV) or a protected derivative thereof
R5
A
R3 H —S RS ! \ oO 8
N N
/
N
R# H (IV) in which R® — R® are as hereinbefore defined with a compound of formula (Va) or (Vb)
Hal HO 2 \ , (RY), \ FO
R? R! (Va) (Vb) in which R', R? and n are as hereinbefore defined and Hal is halogen; e and optionally thereafter de-protecting the resulting product; (c) involves reacting a compound of formula (VI)
R3
NH,
Cr
N mr \ , (RY),
R1
(VI) in which R' — R* and n are as hereinbefore defined with a compound of formula (VII)
R5
Oo
Hal ae © Ns (VII) in which R® and R® are as hereinbefore defined and Hal is halogen; (d) involves converting a compound of formula (I) or a salt thereof into a further compound of formula (1) or a salt thereof.
Process (a)
The compounds of formula (ll) and carboxylic acid of formula (Illa) are reacted under amide forming conditions that are familiar to those skilled in the art. Such reactions may be carried out in a suitable organic solvent (e.g. DMF or acetonitrile) with a base (e.g. DIPEA or triethylamine) in the presence of a suitable activating group (e.g. HATU or
TBTU).
The compounds of formula (ll) and carboxylic acid of formula (Illa) may also be reacted in the presence of an activating reagent such as 1-chloro N,N,2-trimethyl-1-propen-1-amine in a suitable organic solvent (e.g. THF or dichloromethane) with a suitable base (e.g.
DIPEA or triethylamine). Such methodology is described in Schmidt et al (Synthesis, 1988, 475).
Suitable examples of the compounds of formula (lllb) are acid chlorides or acid anhydrides (i.e. in which leaving group LG" is Cl or OC(O)R). The reaction between compounds of formula (II) and formula (llIb) is typically carried out in an inert organic solvent (such as tetrahydrofuran, DMF, chloroform or dichloromethane) at ambient or lower temperature, optionally in the presence of a suitable base e.g. an organic base (such as triethylamine or diisopropylethylamine), an alkali metal carbonate (such as potassium carbonate) or an alkali metal hydrogen carbonate (such as sodium hydrogen carbonate).
Suitable examples of the compounds of formula (llic) are those in which leaving group
LG? is chloro. The compounds of formula (Il) and formula (llic) are typically reacted in a suitable solvent (such as tetrahydrofuran or dichloromethane) in the presence of a suitable base (such as triethylamine or pyridine).
The compounds of formula (ll) and formula (llId) are typically reacted in a suitable organic solvent (e.g. dichloromethane) in the presence of a suitable amine (e.g. triethylamine).
It will be appreciated that in the reaction of a compound of formula (II) and a compound of formula (lll) it may be advantageous to protect one or more functional groups of the compounds of formula (Ill). Examples of protecting groups and the means for their removal can be found in T. W. Greene ‘Protective Groups in Organic Synthesis’ (3" edition, J. Wiley and Sons, 1999). Suitable amine protecting groups include acyl (e.g. acetyl, carbamate (e.g. 2',2’,2'-trichloroethoxycarbonyl, benzyloxycarbonyl or t- butoxycarbonyl) and arylalkyl (e.g. benzyl), which may be removed by hydrolysis (e.g. using an acid such as hydrochloric acid in dioxane or trifluoroacetic acid in dichloromethane) or reductively (e.g. hydrogenolysis of a benzyl or benzyloxycarbonyl group or reductive removal of a 2’,2’,2'-trichloroethoxycarbonyl group using zinc in acetic acid) as appropriate. Other suitable amine protecting groups include ftrifluoroacetyl (-
COCF;) which may be removed by base catalysed hydrolysis.
Compounds of formula (II) may be prepared by methods described herein. By way of illustration, a representative compound of formula (Il) (i.e. in which n is 0, R* and R°® are hydrogen, R® is chloro and R® is methoxy) can be prepared by methods described in
Scheme 1.
Scheme 1
~~ ~~ ~~ ® _N © NH, QO NH, =~ a A b A C —_— N —_— N —_—
F N N
N cl cl oS oS 0” 23 0” 23
Ne) Ne)
ON d oN
N —_— N
HN HCl
Reagents and conditions: a) NH,NH,.H,O, 1-butanal, reflux, 92%; b) KOH, DMSO, 3-cyanobenzyl chloride, 60%; c) 5-chloro-2-thiophenesulfonyl chloride, pyridine, 85%; d) 1M LiAIH, solution in ether, THF, 2M HCI, MeOH, 77%
The compounds of formula (lll)(a) - (d) can be obtained from commercial sources.
Process (b)
For compounds of formula (Va) a suitable Hal group is chlorine, bromine, iodine particularly chlorine. Typically the compounds of formula (IV) is in the form of a protected derivative thereof (e.g. using a silyl ether such as B- (trimethylsilyl)ethoxy)methyl (SEM) as a protecting group). The alkylation reaction between the protected derivatives of the compounds of formula (IV) and the compounds of formula (Va) may be carried out under microwave irradiation in an inert organic solvent (such as DMF) at ambient or elevated temperature, optionally in the presence of a suitable base such as potassium or caesium carbonate. The silyl ether protecting group can be removed from the product thus formed by standard procedures such as by reaction with tetra-n-butylammonium fluoride (TBAF) in a suitable solvent such as THF.
The reaction between the compounds of formula (IV) and (Vb) may be carried out using conditions of the Mitsunobu reaction which are familiar to those skilled in the art. The compounds of formula (IV) are typically in the form of a protected derivative thereof (e.g.
using a sulphonamide protecting group). Typically the reaction is carried out using triphenylphosphine with an azodicarboxylate compound (such as TBAD, DIAD or DEAD) in a suitable organic solvent (such as THF or DMF). The sulphonamide protecting group may be removed from the product thus formed by treatment with sodium hydroxide in methanol.
Compounds of formula (IV) or a protected derivative thereof may be prepared by methods described herein. Compounds of formula (Va) or (Vb) are either commercially available or can be prepared by methods described herein.
Process (c)
The reaction between a compound of formula (VI) and (VII) is typically carried out in a suitable organic solvent (such as pyridine).
Compounds of formula (VI) may be prepared by methods described herein. By way of illustration, a representative compound of formula (VI) (i.e. in which n is 0, R* is hydrogen,
R® is methoxy and R' is C(O)NH,) can be prepared by methods described in the Scheme 2.
Scheme 2 0 1) Cl NH, ry } . 2 o K,CO, Cr >No NN DMF, rt N
N
N N,H,. H,0 : 2 Bohn
HN" "0
Suitable compounds of formula (VII) e.g. 5-chloro-2-thiophenesulfonyl chloride, 5-methyl- 2-thiophenesulfonyl chloride and 5-bromo-2-thiophenesulfonyl chloride are commercially available.
Process (d)
It will be appreciated that certain compounds of formula (I) may be reacted to form further compounds of formula (1). For example, compounds in which R® is Cqsalkoxy (such as methoxy) can be converted into the corresponding compounds in which R® is hydroxy by reaction with a demethylating agent (such as boron tribromide) in a suitable organic solvent (such as DCM).
It will be appreciated that in any of the routes (a) to (d) described above, the precise order of the synthetic steps by which the various groups and moieties are introduced into the molecule may be varied. It will be within the skill of the practitioner in the art to ensure that groups or moieties introduced at one stage of the process will not be affected by subsequent transformations and reactions, and to select the order of synthetic steps accordingly.
In a further aspect of the present invention there is provided a compound of formula (I) or a salt thereof.
Certain compounds of formulae (IV) and (VI) are also believed to be novel and therefore form a yet further aspect of the invention.
The compounds of formula (I) and salts thereof are believed to be inhibitors of CC chemokine receptor activity, particularly CCR4 receptor activity, and thus have potential utility in the treatment of diseases or conditions for which a CCR4 compound is indicated.
The present invention thus provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in therapy. The compound of formula (I) or pharmaceutically salt thereof can be for use in the treatment of a disease or condition for which a CCR4 receptor antagonist is indicated.
The present invention thus provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of a disease or condition for which a CCR4 receptor antagonist is indicated.
Also provided is the use of a compound of formula (1) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease or condition for which a CCR4 receptor antagonist is indicated.
Also provided is a method of treating a disease or conditions for which a CCR4 receptor antagonist is indicated in a subject in need thereof which comprises administering a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof.
Suitably the subject in need thereof is a mammal, particularly a human.
As used herein, the term "effective amount” means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.
Furthermore, the term “therapeutically effective amount” means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function. CCR4 antagonists are believed to be useful in the treatment of a variety of diseases or conditions such as immunoregulatory, inflammatory and/or allergic diseases. Examples include: asthma, chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema, idiopathic pulmonary fibrosis, atopic or contact dermatitis, urticaria, allergic rhinitis (seasonal or perennial), vasomotor rhinitis, nasal polyps, allergic conjunctivitis, vernal conjunctivitis, occupational conjunctivitis, infective conjunctivitis, eosinophilic syndromes, eosinophilic granuloma, psoriasis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, thrombosis, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, sepsis, adult respiratory distress syndrome, multiple sclerosis, memory impairment (including Alzheimer's disease), pain and cancer.
CCR4 antagonists are also believed to useful in the treatment of diseases or conditions such as allergic bronchopulmonary aspergillosis, allergic fungal sinusitis, severe asthma with fungal sensitization and diseases involving a pathogenic role for fungi including invasion or colonisation (such as invasive aspergillosis, aspergilloma or candidiasis)
The term “disease or condition for which a CCR4 inhibitor is indicated”, is intended to include any or all of the above disease states.
In one embodiment the disease or condition for which a CCR4 inhibitor is indicated is selected from asthma, COPD, rhinitis, idiopathic pulmonary fibrosis, psoriasis and contact dermatitis. In a particular emdodiment the disease or condition for which a CCR4 inhibitor is indicated is asthma.
While it is possible that for use in therapy, a compound of formula (I) as well as pharmaceutically acceptable salts thereof may be administered as the raw chemical, it is common to present the active ingredient as a pharmaceutical composition.
The present invention therefore provides in a further aspect a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt and one or more or pharmaceutically acceptable carriers, diluents and/or excipients. The compounds of the formula (I) and pharmaceutically acceptable salts, are as described above. The carrier(s), diluent(s) or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.
In accordance with another aspect of the invention there is also provided a process for the preparation of a pharmaceutical composition including admixing a compound of the formula (I), or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable carriers, diluents or excipients. The pharmaceutical composition can be for use in the treatment of any of the conditions described herein.
Further provided is a pharmaceutical composition for the treatment of diseases or conditions for which a CCR4 inhibitor is indicated comprising a compound of formula (1) or a pharmaceutically acceptable salt thereof.
Further provided is a pharmaceutical composition comprising 0.05 to 1000mg of a compound of formula (I) or a pharmaceutical salt thereof and 0.1 to 2g of one or more pharmaceutically acceptable carriers, diluents or excipients.
Since the compounds of formula (1) are intended for use in pharmaceutical compositions it will be readily understood that they are each preferably provided in substantially pure form, for example, at least 60% pure, more suitably at least 75% pure and preferably at least 85% pure, especially at least 98% pure (% in a weight for weight basis).
Pharmaceutical compositions may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose. Preferred unit dosage compositions are those containing a daily dose or sub-dose, or an appropriate fraction thereof, of an active ingredient. Such unit doses may therefore be administered more than once a day. Preferred unit dosage compositions are those containing a daily dose or sub-dose (for administration more than once a day), as herein above recited, or an appropriate fraction thereof, of an active ingredient.
Pharmaceutical compositions may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, inhaled, intranasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) route. Such compositions may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s).
In one embodiment the pharmaceutical composition is adapted for oral administration.
Pharmaceutical compositions adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Powders suitable for incorporating into tablets or capsules may be prepared by reducing the compound to a suitable fine size (e.g. by micronisation) and mixing with a similarly prepared pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing and coloring agent can also be present.
Capsules may be made by preparing a powder mixture, as described above, and filling formed gelatin sheaths. Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol can be added to the powder mixture before the filling operation. A disintegrating or solubilizing agent such as agar- agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.
Moreover, when desired or necessary, suitable binders, glidants, lubricants, sweetening agents, flavours, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like. Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets. A powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aliginate, gelatin, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or an absorption agent such as bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen. As an alternative to granulating, the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules. The granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil. The lubricated mixture is then compressed into tablets. The compounds of the present invention can also be combined with a free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps. A clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided.
Dyestuffs can be added to these coatings to distinguish different unit dosages.
Oral fluids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound. Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the compound in a non-toxic vehicle. Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additive such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, and the like can also be added.
Where appropriate, dosage unit compositions for oral administration can be microencapsulated. The formulation can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax or the like.
The compounds of the invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
Pharmaceutical compositions adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time.
Pharmaceutical compositions adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
For treatments of the eye or other external tissues, for example mouth and skin, the compositions are preferably applied as a topical ointment or cream. When formulated in an ointment, the active ingredient may be employed with either a paraffinic or a water- miscible ointment base. Alternatively, the active ingredient may be formulated in a cream with an oil-in-water cream base or a water-in-oil base.
Pharmaceutical compositions adapted for topical administrations to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.
Pharmaceutical compositions adapted for topical administration in the mouth include lozenges, pastilles and mouth washes.
Pharmaceutical compositions adapted for rectal administration may be presented as suppositories or as enemas.
Dosage forms for nasal or inhaled administration may conveniently be formulated as aerosols, solutions, suspensions, gels or dry powders.
For compositions suitable and/or adapted for inhaled administration, it is preferred that the compound of the invention is in a particle-size-reduced form, and more preferably the size-reduced form is obtained or obtainable by micronisation. The preferable particle size of the size-reduced (e.g. micronised) compound or salt is defined by a D50 value of about 0.5 to about 10 microns (for example as measured using laser diffraction).
Aerosol formulations, e.g. for inhaled administration, can comprise a solution or fine suspension of the active substance in a pharmaceutically acceptable aqueous or non- aqueous solvent. Aerosol formulations can be presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device or inhaler. Alternatively the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve (metered dose inhaler) which is intended for disposal once the contents of the container have been exhausted.
Where the dosage form comprises an aerosol dispenser, it preferably contains a suitable propellant under pressure such as compressed air, carbon dioxide or an organic propellant such as a hydrofluorocarbon (HFC). Suitable HFC propellants include 1,1,1,2,3,3,3-heptafluoropropane and 1,1,1,2-tetrafluoroethane. The aerosol dosage forms can also take the form of a pump-atomiser. The pressurised aerosol may contain a solution or a suspension of the active compound. This may require the incorporation of additional excipients e.g. co-solvents and/or surfactants to improve the dispersion characteristics and homogeneity of suspension formulations. Solution formulations may also require the addition of co-solvents such as ethanol. Other excipient modifiers may also be incorporated to improve, for example, the stability and/or taste and/or fine particle mass characteristics (amount and/or profile) of the formulation.
For pharmaceutical compositions suitable and/or adapted for inhaled administration, the pharmaceutical composition may be a dry powder inhalable composition. Such a composition can comprise a powder base such as lactose, glucose, trehalose, mannitol or starch, the compound of formula (I) or salt thereof (preferably in particle-size-reduced form, e.g. in micronised form), and optionally a performance modifier such as L-leucine or another amino acid and/or metals salts of stearic acid such as magnesium or calcium stearate. Preferably, the dry powder inhalable composition comprises a dry powder blend of lactose and the compound of formula (I) or salt thereof. The lactose is preferably lactose hydrate e.g. lactose monohydrate and/or is preferably inhalation-grade and/or fine-grade lactose. Preferably, the particle size of the lactose is defined by 90% or more (by weight or by volume) of the lactose particles being less than 1000 microns (micrometres) (e.g. 10-1000 microns e.g. 30-1000 microns) in diameter, and/or 50% or more of the lactose particles being less than 500 microns (e.g. 10-500 microns) in diameter. More preferably, the particle size of the lactose is defined by 90% or more of the lactose particles being less than 300 microns (e.g. 10-300 microns e.g. 50-300 microns) in diameter, and/or 50% or more of the lactose particles being less than 100 microns in diameter. Optionally, the particle size of the lactose is defined by 90% or more of the lactose particles being less than 100-200 microns in diameter, and/or 50% or more of the lactose particles being less than 40-70 microns in diameter. Most importantly, it is preferable that about 3 to about 30% (e.g. about 10%) (by weight or by volume) of the particles are less than 50 microns or less than 20 microns in diameter. For example, without limitation, a suitable inhalation-grade lactose is E9334 lactose (10% fines) (Borculo Domo Ingredients, Hanzeplein 25, 8017 JD Zwolle, Netherlands).
Optionally, in particular for dry powder inhalable compositions, a pharmaceutical composition for inhaled administration can be incorporated into a plurality of sealed dose containers (e.g. containing the dry powder composition) mounted longitudinally in a strip or ribbon inside a suitable inhalation device. The container is rupturable or peel-openable on demand and the dose of e.g. the dry powder composition can be administered by inhalation via the device such as the DISKUS TM device, marketed by GlaxoSmithKline.
The DISKUS TM inhalation device is for example described in GB 2242134 A, and in such a device at least one container for the pharmaceutical composition in powder form (the container or containers preferably being a plurality of sealed dose containers mounted longitudinally in a strip or ribbon) is defined between two members peelably secured to one another; the device comprises: a means of defining an opening station for the said container or containers; a means for peeling the members apart at the opening station to open the container; and an outlet, communicating with the opened container, through which a user can inhale the pharmaceutical composition in powder form from the opened container.
The compounds of the invention thereof may be formulated as a fluid formulation for delivery from a fluid dispenser, for example a fluid dispenser having a dispensing nozzle or dispensing orifice through which a metered dose of the fluid formulation is dispensed upon the application of a user-applied force to a pump mechanism of the fluid dispenser.
Such fluid dispensers are generally provided with a reservoir of multiple metered doses of the fluid formulation, the doses being dispensable upon sequential pump actuations. The dispensing nozzle or orifice may be configured for insertion into the nostrils of the user for spray dispensing of the fluid formulation into the nasal cavity. A fluid dispenser of the aforementioned type is described and illustrated in WO-A-2005/044354, the entire content of which is hereby incorporated herein by reference. The dispenser has a housing which houses a fluid discharge device having a compression pump mounted on a container for containing a fluid formulation. The housing has at least one finger-operable side lever which is movable inwardly with respect to the housing to cam the container upwardly in the housing to cause the pump to compress and pump a metered dose of the formulation out of a pump stem through a nasal nozzle of the housing. A particularly preferred fluid dispenser is of the general type illustrated in Figures 30-40 of WO-A-2005/044354.
Pharmaceutical compositions adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
Pharmaceutical compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the composition isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The compositions may be presented in unit- dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
A therapeutically effective amount of a compound of the present invention will depend upon a number of factors including, for example, the age and weight of the subject, the precise condition requiring treatment and its severity, the nature of the formulation, and the route of administration, and will ultimately be at the discretion of the attendant physician or veterinarian. In the pharmaceutical composition, each dosage unit for oral or parenteral administration preferably contains from 0.01 to 3000 mg, more preferably 0.5 to 1000 mg, of a compound of the invention calculated as the free base. Each dosage unit for nasal or inhaled administration preferably contains from 0.001 to 50 mg, more preferably 0.01 to 5 mg, of a compound of the formula (I) or a pharmaceutically acceptable salt thereof, calculated as the free base.
The pharmaceutically acceptable compounds the invention can be administered in a daily dose (for an adult patient) of, for example, an oral or parenteral dose of 0.01 mg to 3000 mg per day or 0.5 to 1000 mg per day, or a nasal or inhaled dose of 0.001 to 50 mg per day or 0.01 to 5 mg per day, of the compound of the formula (I) or a pharmaceutically acceptable salt thereof, calculated as the free base. This amount may be given in a single dose per day or more usually in a number (such as two, three, four, five or six) of sub-doses per day such that the total daily dose is the same. An effective amount of a salt thereof, may be determined as a proportion of the effective amount of the compound of formula (I) per se.
The compounds of the invention and may be employed alone or in combination with other therapeutic agents. Combination therapies according to the present invention thus comprise the administration of at least one compound of formula (I) or a pharmaceutically acceptable salt thereof, and the use of at least one other pharmaceutically active agent.
Preferably, combination therapies according to the present invention comprise the administration of at least one compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one other pharmaceutically active agent. The compound(s) of the invention and the other pharmaceutically active agent(s) may be administered together in a single pharmaceutical composition or separately and, when administered separately this may occur simultaneously or sequentially in any order. The amounts of the compound(s) of the invention and the other pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect.
Thus in a further aspect, there is provided a combination comprising a compound of the invention and at least one other pharmaceutically active agent.
Thus in one aspect, the compound and pharmaceutical compositions according to the invention may be used in combination with or include one or more other therapeutic agents, for example selected from anti-inflammatory agents (including a steroid), anticholinergic agents (particularly an M4/M,/M3 receptor antagonist), ,-adrenoreceptor agonists, anti-allergy agents, antiinfective agents (such as antibiotics or antivirals), or antihistamines. The invention thus provides, in a further aspect, a combination pharmaceutical product comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with one or more other therapeutically active agents, for example selected from an anti-inflammatory agent such as a corticosteroid or an NSAID, an anticholinergic agent, a p,-adrenoreceptor agonist, an anti-allergy agent, an antiinfective agent (such as an antibiotic or an antiviral), or an antihistamine.
It will be appreciated that when the compound of the present invention is administered in combination with other therapeutic agents normally administered by the inhaled, intravenous, oral or intranasal route, that the resultant pharmaceutical composition may be administered by the same routes. Alternatively the individual components of the composition may be administered by different routes.
One embodiment of the invention encompasses combinations comprising one or two other therapeutic agents.
Suitable anti-inflammatory agents include corticosteroids. Anti-inflammatory corticosteroids are well known in the art. Representative examples include fluticasone propionate, beclomethasone 17-propionate ester, beclomethasone 17,21-dipropionate ester, dexamethasone or an ester thereof, mometasone or an ester thereof (e.g. mometasone furoate), ciclesonide, budesonide, flunisolide, methyl prednisolone, prednisolone, and dexamethasone. Further examples of anti-inflammatory corticosteroids are described in WO 02/12266 A1 (Glaxo Group Ltd), in particular, the compounds of
Example 1 ( 6a,9a-difluoro-17a-[(2-furanylcarbonyl)oxyl-11p-hydroxy-16a-methyl-3-oxo- androsta-1,4-diene-17p-carbothioic acid S-fluoromethyl ester) and Example 41 (6a,9a- difluoro-11p-hydroxy-16oa-methyl-17a-[(4-methyl-1,3-thiazole-5-carbonyl)oxy]-3-oxo- androsta-1,4-diene-173-carbothioic acid S-fluoromethyl ester), or a pharmaceutically acceptable salt thereof.
Examples of B,-adrenoreceptor agonists include salmeterol (e.g. as racemate or a single enantiomer such as the R-enantiomer), salbutamol, formoterol, salmefamol, fenoterol or terbutaline and salts thereof, for example the xinafoate salt of salmeterol, the sulphate salt or free base of salbutamol or the fumatrate salt of formoterol. In one embodiment, the B,- adrenoreceptor agonists are long-acting B,-adrenoreceptor agonists, for example, those having a therapeutic effect over a 24 hour period, such as salmeterol or formoterol. A further example of a B,-adrenoreceptor agonist is the compound 4-{(1R)-2-[(6-{2-[(2,6- dichlorophenyl)methyoxylethoxy}hexyl)aminol-1-hydroxyethyl}-2-(hydroxyethyl)phenol triphenylacetete (Vilanterol Trifenatate).
Examples of anticholinergic compounds which may be used in combination with a compound of formula (I) or a pharmaceutically acceptable salt thereof are described in
WO 03/011274 A2 and WO 02/069945 A2 / US 2002/0193393 A1 and US 2002/052312
A1. For example, anticholinergic agents include muscarinic receptor antagonists, in particular, compounds which are antagonists of the M; or M3 receptors, dual antagonists of My/Mj; or M,/Mjs receptors or pan antagonists of M/My/M3 receptors such as ipratropium bromide, oxitropium bromide or tiotropium bromide.
An anti-histamine usable in a combination of a compound of the invention can for example be methapyrilene or H1 antagonists. Examples of H1 antagonists include, without limitation, amelexanox, astemizole, azatadine, azelastine, acrivastine, brompheniramine, cetirizine, levocetirizine, efletirizine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine, doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, mizolastine, mequitazine, mianserin, noberastine, meclizine, norastemizole, olopatadine, picumast, pyrilamine, promethazine, terfenadine, tripelennamine, temelastine, trimeprazine and triprolidine, particularly cetirizine, levocetirizine, efletirizine and fexofenadine. In a further embodiment the invention provides a combination comprising a compound of the invention together with an H3 antagonist (and/or inverse agonist). Examples of H3 antagonists include, for example, those compounds disclosed in W0O2004/035556 and in W0O2006/045416.
Other suitable combinations include, for example combinations comprising a compound of the invention together with other anti-inflammatory agents such as an anti-flammatory corticosteroid; or a non-steroidal anti-inflammatory drug (NSAID) such as leukotriene antagonist (e.g. montelukast), an iNOS inhibitor, a tryptase inhibitor, IKK2 inhibitors, a p38 inhibitor, Syk inhibitors, an elastase inhibitor, a beta-2 integrin antagonist, an adenosine aZa agonist, a chemokine antagonist such as a CCR3 antagonist, a mediator release inhibitor such as sodium chromoglycate, a 5-lipoxygenase inhibitor, a DP1 antagonist, a
DP2 antagonist, a CTTh2 inhibitor, a pl3K delta inhibitor, an ITK inhibitor, a LP (lysophosphatidic) inhibitor and a FLAP (five lipoxygenase activating protein) inhibitor.
Other suitable combinations include a compound of the invention together with an anti- nfective agent (e.g. an antibiotic or an antiviral), an anti-hypertensive agent, an anti- thrombotic agent, a statin or a cholinesterase inhibitor.
The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical composition and thus pharmaceutical compositions comprising a combination as defined above together with a pharmaceutically acceptable diluent or carrier represent a further aspect of the invention.
In one aspect, the present invention also provides for so-called “triple combination” therapy, comprising a compound of the invention together with 3,-adrenoreceptor agonist and an anti-inflammatory corticosteroid. Preferably this combination is for treatment and/or prophylaxis of asthma, COPD or allergic rhinitis. The B,-adrenoreceptor agonist and/or the anti-inflammatory corticosteroid can be as described above and/or as described in WO 03/030939 A1. A representative example of such a “triple” combination comprises a compound of the invention, salmeterol or a pharmaceutically acceptable salt (e.g. salmeterol xinafoate) and fluticasone propionate. A further representative example of a “triple” combination comprises a compound of the invention, 4-{(1R)-2-[(6-{2-[(2,6- dichlorophenyl)methyoxylethoxythexyl)amino]-1-hydroxyethyl}-2-(hydroxyethyl)phenol triphenylacetete (Vilanterol Trifenatate) and 6a,9a-difluoro-17a-[(2-furanylcarbonyl)oxy]- 11B-hydroxy-16a-methyl-3-oxo-androsta-1,4-diene-173-carbothioic acid S-fluoromethyl ester (fluticasone furoate).
Rheumatoid arthritis (RA) is a further inflammatory disease where combination therapy may be contemplated. Thus in a further aspect, the present invention provides a compound of the invention in combination with a further therapeutic agent useful in the treatment of rheumatoid arthritis, said combination being useful for the treatment of rheumatoid arthritis.
The compound and pharmaceutical compositions according to the invention may be used in combination with or include one or more other therapeutic agents, for example selected from NSAIDS, corticosteroids, COX-2 inhibitors, cytokine inhibitors, anti-TNF agents, inhibitors of oncostatin M, anti-malarials, immunosuppressive and cytostatics.
Anti-TNF agents include infliximab (Remicade), etanercept (Enbrel) and adalimum (Humira). Other “biological” treatments include anakinra (Kineret), Rituximab,
Lymphostat-B, BAFF/APRIL inhibitors and CTLA-4-lg or mimetics thereof. Other cytokine inhibitors include lefluonomide (Arava). Further second line drugs include gold preparations (Auranofin (Ridaura tablets) or Aurothiomalate (Myocrisin injection)), medicines used for malaria: (Hydroxychloroquine (Plaquenil)), medicines that suppress the immune system (Azathioprine (Imuran, Thioprine), methotrexate (Methoblastin,
Ledertrexate, Emethexate), cyclosporine (Sandimmun, Neoral)), Cyclophosphamide (Cycloblastin), Cytoxan, Endoxan), D-Penicillamine (D-Penamine), Sulphasalazine (Salazopyrin), nonsteroidal anti inflammatory drugs (including aspirin and ibrufen).
It will be clear to a person skilled in the art that, where appropriate, the other therapeutic ingredient(s) may be used in the form of salts, for example as alkali metal or amine salts or as acid addition salts, or prodrugs, or as esters, for example lower alkyl esters, or as solvates, for example hydrates, to optimise the activity and/or stability and/or physical characteristics, such as solubility, of the therapeutic ingredient. It will be clear also that, where appropriate, the therapeutic ingredients may be used in optically pure form.
The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical composition and thus pharmaceutical compositions comprising a combination as defined above together with a pharmaceutically acceptable diluent or carrier represent a further aspect of the invention.
The individual compounds of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical compositions. Preferably, the individual compounds will be administered simultaneously in a combined pharmaceutical composition. Appropriate doses of known therapeutic agents will be readily appreciated by those skilled in the art.
General Experimental Details
Analytical LCMS
Analytical LCMS was conducted on one of the following systems A to F.
The UV detection to all systems was an averaged signal from wavelength of 220 nm to 350 nm and mass spectra were recorded on a mass spectrometer using alternate-scan positive and negative mode electrospray ionization.
Experimental details of LCMS systems A -F as referred to herein are as follows:
System A
Column: 50 mm x 2.1 mm ID, 1.7 um Acquity ultra performance liquid chromatography (UPLC)BEH Cys
Flow Rate: 1 mL/min.
Temp.: 40°C
Solvents: A: 0.1% v/v formic acid in water
B: 0.1% v/v formic acid in acetonitrile
Gradient: Time (min) A% B% 0 97 3 1.5 0 100 1.9 0 100 2.0 97 3
System B
Column: 30 mm x 4.6 mm ID, 3.5 um Sunfire Cg column
Flow Rate: 3 mL/min.
Temp.: 30°C
Solvents: A: 0.1% v/v solution of formic acid in water
B: 0.1% v/v solution of formic acid in acetonitrile
Gradient: Time (min) A% B% 0 97 3 0.1 97 3 4.2 0 100 4.8 0 100 4.9 97 3 5.0 97 3
System C
Column: 50 mm x 4.6 mm ID, 3.5 um XBridge C4 column
Flow Rate: 3 mL/min.
Temp.: 30°C
Solvents: A: 10 mM ammonium bicarbonate in water adjusted to pH10 with ammonia solution
B: Acetonitrile
Gradient: Time (min) A% B% 0 99 1 0.1 99 1 4.0 3 97 5.0 3 97
System D
Column: 50 mm x 2.1 mm ID, 1.7 um Acquity UPLC BEH Cs
Flow Rate: 1 mL/min.
Temp.: 40°C
Solvents: A: 0.1% v/v solution of trifluoroacetic acid in water
B: 0.1% v/v solution of trifluoroacetic acid in acetonitrile
Gradient: Time (min) A% B% 0 97 3 1.5 0 100 1.9 0 100 2.0 97 3
System E
Column: 30 mm x 4.6 mm ID, 3.5 um Sunfire C1 column
Flow Rate: 3 mL/min.
Temp.: 30°C
Solvents: A: 0.1% v/v solution of trifluoroacetic acid in water
B: 0.1% v/v solution of trifluoroacetic acid in acetonitrile
Gradient: Time (min) A% B% 0 97 3 0.1 97 3 4.2 0 100 4.8 0 100
4.9 97 3 5.0 97 3
System F
Column: 50 mm x 2.1 mm ID, 1.7 um Acquity UPLC BEH C4 column
Flow Rate: 1 mL/min.
Temp.: 40°C
Solvents: A: 10 mM ammonium bicarbonate in water adjusted to pH10 with ammonia solution
B: Acetonitrile
Gradient: Time (min) A% B% 0 99 1 1.5 3 97 1.9 3 97 2.0 0 100
Mass directed auto-preparative HPLC
Crude products were purified by MDAP HPLC by one of the following methods A - D. The run time was 15 min unless otherwise stated. The UV detection for all methods was an averaged signal from wavelength of 220 nm to 350 nm and mass spectra were recorded on a mass spectrometer using alternate-scan positive and negative mode electrospray ionization.
Method A:
Method A was conducted on a Sunfire Cg column (typically 150 mm x 30 mm i.d. 5 ym packing diameter) at ambient temperature. The solvents employed were:
A =0.1% v/v solution of Formic acid in water
B = 0.1% v/v solution of Formic acid in acetonitrile.
The gradient employed was:
Cs [wi w
Ee [Tw
Method B:
Method B was conducted on a Sunfire Cg column (typically 150 mm x 30 mm i.d. 5 ym packing diameter) at ambient temperature. The solvents employed were:
A =0.1% v/v solution of trifluoroacetic acid in water
B = 0.1% v/v solution of trifluoroacetic acid in acetonitrile.
The gradient employed was: oe [Tre
Cs | ® [rpe
Ee [Tw
Method C:
Method C was conducted on an XBridge C4s column (typically 150 mm x 19 mm i.d. 5 ym packing diameter) at ambient temperature. The solvents employed were:
A = 10 mM aqueous ammonium bicarbonate adjusted to pH 10 with ammonia solution.
B = acetonitrile.
The gradient employed was: 0 1 Jet td JT
EE EN
EE EN
Method D:
Method D was conducted on an ATLANTIS dC18 column (typically 100 mm x 19 mm i.d. um packing diameter). The solvents employed were:
A = 0.1% v/v solution of Formic Acid in Water.
B= 0.05% v/v solution of Formic Acid in 95% Acetonitrile plus 5% Water. 5 The gradient employed was: oo Jo les [5 86 lo 5 [es 95 lo Is 96 Jo les [5 11.0
Method E:
Method E was conducted on a Sunfire C18 column (typically 100 mm x 19 mm i.d. 5 um packing diameter). The solvents employed were:
A = 0.1% v/v solution of Formic Acid in Water.
B= 0.1% v/v solution of Formic Acid in Acetonitrile.
The gradient employed was: 00 Jo ~~ l70 [30 14
Abbreviations
The following list provides definitions of certain abbreviations as used herein. It will be appreciated that the list is not exhaustive, but the meaning of those abbreviations not herein below defined will be readily apparent to those skilled in the art.
Ac (acetyl)
Bu (butyl)
CV (column volume)
DCM (dichloromethane)
DEAD (diethyl azodicarboxylate)
DIAD (diisopropyl azodicarboxylate)
DIBAL-H (Diisobutylaluminium hydride)
DMF (N,N-dimethylformamide)
DMSO (dimethylsulfoxide)
Et (ethyl)
EtOAc (ethyl acetate) h (hour/hours)
HATU [O-(7-Azabenzotriazol-1-y1)-N, N, N’, N’-tetramethyluronium hexafluorophosphate
HCI (Hydrochloric acid)
L (liters)
M (molar)
MDAP (mass directed auto-preparative HPLC)
Me (methyl)
MeOH (methanol)
NOE (nuclear overhauser effect)
Ph (phenyl) 'Pr (isopropyl)
Si (Silica)
SEM ( {[2-(trimethylsilyl)ethyl]loxy)}methyl)
SPE (solid phase extraction)
TBAD (tert-butyl azodicarboxylate)
TBD (1,3,4,6,7,8-hexahydro-2H-pyrimido[1,2-a]pyrimidine)
TBTU [O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate]
TEA (triethylamine)
TFA (trifluoroacetic acid)
THF (tetrahydrofuran)
TLC (thin layer chromatography)
TMS (trimethylsilyl)
All references to ether are to diethyl ether and brine refers to a saturated aqueous solution of NaCl.
Intermediate 1 4-(Methyloxy)-1H-indazol-3-amine ~~ o NH, od /
N
H
A mixture of 2-fluoro-6-(methyloxy)benzonitrile (available from Apollo) (10 g, 66 mmol) and hydrazine hydrate (9.63 mL, 198 mmol) in n-butanol (100 mL) was heated at reflux under nitrogen for 18 hours. The reaction mixture was allowed to cool, water (300 mL) was added, and the organic phase was removed. The solid in the aqueous phase was collected by filtration and dried in vacuo at 40°C to give a white solid (0.6g). The butanol phase was evaporated in vacuo, and the residue and the aqueous mother liquors were combined and extracted using ethyl acetate (2 x 200 mL). The combined ethyl acetate extractions were dried over magnesium sulphate and evaporated in vacuo. The residue was dissolved in DCM and applied to a 100g silica cartridge. This was eluted with cyclohexane (500 ml), cyclohexane-ethyl acetate (1:1v/v, 500 mL) and ethyl acetate (500 mL). The required fractions were combined and evaporated in vacuo to give the title compound (9.92 g, 92%) as an off-white solid. LCMS (System A) RT=0.5 min, ES+ve m/z 164 (M+H)".
Intermediate 2 3-{[3-Amino-4-(methyloxy)-1H-indazol-1-ylJmethyl}benzonitrile o” NH,
Cop
N
3
To a solution of ground potassium hydroxide (6.75 g, 120 mmol) in DMSO (300 mL) at room temperature under nitrogen was added 4-(methyloxy)-1H-indazol-3-amine (for a preparation see Intermediate 1)(7.85 g, 48.1 mmol), and this gave a deep red solution.
After 5 minutes 3-(chloromethyl)benzonitrile (8.84 g, 58.3 mmol) was added in one portion. The reaction mixture was stirred for 20 minutes and then poured into water (500 mL), forming an emulsion. This was extracted using chloroform (3x500mL). The combined organic solutions were washed with water (400 mL) and passed through a hydrophobic frit. The solvent was removed in vacuo, the residue was applied to a 340g silica cartridge, and eluted with a gradient of 0-100% ethyl acetate in cyclohexane over 8CV. This gave an orange solid which was treated with ethyl acetate (10 mL) and cyclohexane (90 mL). The solid was collected by filtration and washed with cyclohexane (50 mL). The solid was dried in vacuo to give the title compound (7.89 g, 59%) as a pale orange solid. LCMS (System A) RT=0.93 min, ES+ve m/z 279 (M+H)".
Intermediate 3 5-Chloro-N-[1-[(3-cyanophenyl)methyl]-4-(methyloxy)-1H-indazol-3-yl]-2- thiophenesulfonamide ss cl 1 2 so
N
N
3
To 3-{[3-amino-4-(methyloxy)-1H-indazol-1-ylJmethyl}benzonitrile (for a preparation see
Intermediate 2) (7.89 g, 28.3 mmol) was added a solution of 5-chloro-2-thiophenesulfonyl chloride (Aldrich)(6.15 g, 28.3 mmol) in pyridine (9.17 mL, 113 mmol) under nitrogen at room temperature. Reaction was exothermic and went deep red. After 40 minutes the reaction mixture was separated between ethyl acetate (500 mL) and 2N hydrochloric acid
(500 mL). The aqueous phase was washed with ethyl acetate (400 mL). The combined organic solutions were dried over magnesium sulphate and evaporated in vacuo. The deep red residue was dissolved in DCM and applied to a 340g silica cartridge. The cartridge was eluted with a gradient of 0-10% ethyl acetate in dichloromethane over 8CV.
Evaporation of the appropriate fractions gave the title compound (11.1 g, 85%) as an off- white solid. LCMS (System A) RT=1.15 min, ES+ve m/z 459/461 (M+H)".
Intermediate 4
N-[1-{[3-(Aminomethyl)phenyl]methyl}-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide hydrochloride
Cl rat
Cop
N
N g
To a cooled, 0°C, solution of 5-chloro-N-[1-[(3-cyanophenyl)methyl]-4-(methyloxy)-1H- indazol-3-yl]-2-thiophenesulfonamide (for a preparation see Intermediate 3) (11.1 g, 24.2 mmol) in THF (150 mL) was added, dropwise maintaining temp below 10°C, 1.0M lithium aluminium hydride solution in ether (60.5 mL, 60.5 mmol), effervescence occurred, and the suspension was stirred at room temperature for one hour. The reaction was guenched by addition of water (7 mL), followed by a 2.0M solution of sodium hydroxide (42.5 mL). After stirring for 30 minutes the solid was removed by filtration and washed with THF. The combined filtrate and washings were treated with 140g SCX silica. This was filtered and washed with methanol (1 L), and then 10% 2N hydrochloric acid in methanol (2 L). The required fractions were combined and concentrated. The resultant solid was collected by filtration and washed with water. The solid was dried in vacuo to give the title compound (N7916-76-1) (9.3 g, 77%) as a white solid. LCMS (System A)
RT=0.85 min, ES+ve m/z 463/465 (M+H)".
Intermediate 5 1,1-Dimethylethyl 3-amino-4-(methyloxy)-1H-indazole-1-carboxylate o” NH,
CL
N
=o
TL
To a solution of 4-(methyloxy)-1H-indazol-3-amine (5.56 g, 34 mmol), DMAP (2.08 g, 17 mmol) and triethylamine (4.75 mL, 34 mmol) in DCM (30 mL) was added dropwise at 0 °C a solution of di-fert-butyl dicarbonate (7.44 g, 34 mmol) in DCM (20 mL). The reaction mixture was stirred at room temperature for 1 h, then 50 mL of brine were added. The organic layer was partitioned and the aqueous phase was further extracted with 50 mL of
DCM. The organic solutions were combined, washed with brine (100 mL), dried over an hydrophobic frit and concentrated under reduced pressure. The crude solid was triturated with 50 mL of Et,0, the filtrate was concentrated under reduced pressure, and triturated again with 20 mL of Et,O. Solids were combined to give the title compound (8.97 g, 67%) which was used without further purification. LCMS (System B) RT=2.9 min, ES+ve m/z 264 (M+H)".
Intermediate 6 1,1-Dimethylethyl 3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazole- 1-carboxylate
PY, 0 Hs TT) ol
Cry
N
Jo 0 pa
To a solution of 1,1-dimethylethyl 3-amino-4-(methyloxy)-1H-indazole-1-carboxylate (for a preparation see Intermediate 5) (6.03 g, 22.9 mmol) and 5-chloro-2-thiophenesulfonyl chloride (3.07 mL, 22.9 mmol) in DCM (30 mL) was added dropwise at 0 °C a solution of pyridine (3.7 mL, 46 mmol) in DCM. The reaction mixture was stirred allowing to warm from 0 °C to room temperature over 2 h, then stirred at room temperature over the weekend. Pyridine (50 mL) were added and resulting mixture was stirred at 50 °C for another 24 h. The reaction mixture was then quenched with 50 mL of a saturated
NaHCOj; solution. The organic layer was partitioned and the aqueous layer was further extracted with 50 mL of DCM. The organic solutions were combined, washed with water (50 mL) then brine (50 mL), and dried with an hydrophobic frit. The crude product was purified by chromatography on two 100g Si cartridges on Flashmaster, eluting with 0 to 25% gradient of EtOAc in DCM, over 60 min to give the desired product as a pale orange solid: (2.21 g, 22%). LCMS (System A) RT=1.35 min, ES+ve m/z 444 (M+H)".
Intermediate 7 1,1-Dimethylethyl 3-[[(5-chloro-2-thienyl)sulfonyl]({[2- (trimethylsilyl)ethyl]oxy}methyl)amino]-4-(methyloxy)-1H-indazole-1-carboxylate + 2% 0 00 0” wie cl oh
N
N
~o oY.
To a solution of 1,1-dimethylethyl 3-{[(5-chloro-2-thienyl)sulfonyllJamino}-4-(methyloxy)- 1H-indazole-1-carboxylate (for a preparation see Intermediate 6) (2.21 g, 4.98 mmol) in
DCM (20 mL) was added at 0 °C 2-(trimethylsilyl)ethoxymethyl chloride (1.23 mL, 6.97 mmol). Then was added at 0 °C in a dropwise fashion diisopropylamine (1.419 mL, 9.96 mmol) and the reaction mixture was stirred at room temperature. The reaction was guenched with water (50 mL), the organic layer was seperated, and the aqueous layer was further extracted with 30 mL of DCM. The organic solutions were combined, dried with an hydrophobic frit and concentrated under reduced pressure to give a yellow oil that was used without further purification (3.12 g) LCMS (System A) RT = 1.64 min, ES+ve m/z 574/576 (M+H)".
Intermediate 8 5-Chloro-N-[4-(methyloxy)-1H-indazol-3-yl]-N-({[2-(trimethylsilyl)ethyl]oxy}methyl)-2- thiophenesulfonamide
Si <
Oo
Lag 0 N-S TT) o on
N
To a solution of 1,1-dimethylethyl 3-[[(5-chloro-2-thienyl)sulfonyl]({[2- (trimethylsilyl)ethylloxy}methyl)amino]-4-(methyloxy)-1H-indazole-1-carboxylate ~~ (for a preparation see Intermediate 7) (3.12 g, 5.43 mmol) in DMF (20 mL) was added a solution of sodium carbonate (0.864 g, 8.15 mmol) in water (20 mL) at room temperature. A white suspension was obtained and a warming of the medium was noticed. The resulting suspension was stirred overnight at 80 °C, the reaction mixture was then cooled to room temperature, and more sodium carbonate (300 mg) was added. The resulting mixture was then stirred at 85 °C. After 3 h of stirring, 50 mL of water and 50 mL of DCM were added to the reaction mixture. The organic layer was partitioned and the aqueous layer was further extracted with 30 mL of DCM. The organic solutions were combined, dried with an hydrophobic frit and concentrated under reduced pressure. The crude oil was purified by chromatography on two 100g Si cartridges on Flashmaster, eluting with a 0 to 25% gradient of EtOAc in cyclohexane, over 25 min. The pure fractions were combined to give the title product as an orange gum (1.62 g, 63 %) LCMS (System A) RT = 1.41 min, ES+ve m/z 474/476 (M+H)’. Impure fractions were combined and repurified by chromatography on a 70g silica cartridge on Flashmaster, eluting with a 0 to 25% gradient of EtOAc in cyclohexane over 40 min. Fractions containing pure product were combined to give more of the desired product (277 mg, 11%)
Intermediate 9 1,1-Dimethylethyl 3-{bis[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H- indazole-1-carboxylate
Cl - ~ Osd R.0 o J NS S
N
3
To a solution of 1,1-dimethylethyl 3-amino-4-(methyloxy)-1H-indazole-1-carboxylate (for a preparation see Intermediate 5) (3.24 g, 12.31 mmol) and 5-chloro-2-thiophenesulfonyl chloride (8.01 g, 36.9 mmol) in DCM (50 mL) was added pyridine (9.95 mL, 123 mmol).
The reaction mixture was stirred at 45°C under nitrogen for 3 days. The reaction mixture was quenched using saturated sodium bicarbonate solution (100 mL) and diluted with
DCM (100 mL). The phases were separated and the aqueous phase was extracted using
DCM (100 mL). The combined organic solutions were washed with brine and filtered through an hydrophobic frit. The solvent was removed in vacuo and the residue was dissolved in DCM (30 mL). This was applied to a 330g silica cartridge and eluted with a gradient of 0-25% ethyl acetate in DCM over 10CV. The required fractions were evaporated in vacuo to give the title compound (4.17 g, 54%) as a white solid LCMS (System B) RT=4.12 min, ES+ve m/z 624/626/628, and 1,1-dimethylethyl 3-{[(5-chloro-2- thienyl)sulfonyllamino}-4-(methyloxy)-1H-indazole-1-carboxylate (1.45 g, 26%) as a pale yellow solid LCMS (System B) RT= 3.72 min, ES+ve m/z 444/446 (M+H)".
Intermediate 10 5-Chloro-N-[(5-chloro-2-thienyl)sulfonyl]-N-[4-(methyloxy)-1H-indazol-3-yl]-2- thiophenesulfonamide
Cl ;
S —_ ~ Ox 0 0 J ‘N—S
S
Crp Os
N
To a cooled, ice/water bath, solution of 1,1-dimethylethyl 3-{bis[(5-chloro-2- thienyl)sulfonyllamino}-4-(methyloxy)-1H-indazole-1-carboxylate (for a preparation see
Intermediate 9) (4.17 g, 6.68 mmol) in DCM (20 mL) was added TFA (10.29 mL, 134 mmol) and the solution was stirred at room temperature for 4 hours. The reaction mixture was diluted with DCM (100 mL) and water (50 mL). The organic phase was passed through an hydrophobic frit and the solvent was removed in vacuo to give the product (3.78 g) as a white solid. This was dried in vacuo at 45°C for 2 days to give the title compound (3.55 g, 100%) as a white solid. LCMS (System A) RT = 1.33 min, ES+ve m/z 524/526/528 (M+H)".
Intermediate 11 2-[4-(Methyloxy)-1H-indazol-3-yl]-1H-isoindole-1,3(2H)-dione 0) ~o = ;
Cry
N
4-(Methyloxy)-1H-indazol-3-amine (for a preparation see Intermediate 1) (500 mg, 3 mmol) and phthalic anhydride (680 mg, 4.6 mmol) (available from Aldrich) were dissolved in 1,4-dioxane (5 mL) at room temperature. The reaction mixture was stirred at 110 °C overnight, and then it was cooled and concentrated under reduced pressure. The residue was triturated and sonicated with 50 mL of ether. The solid was collected by filtration and dried in a vacuum oven to obtain a brown solid (711 mg, 81%). LCMS (System B) RT= 2.82 min, ES+ve m/z 294 (M+H)".
Intermediate 12 3-{[3-Amino-4-(methyloxy)-1H-indazol-1-yllmethyl}benzamide he NH, 2
To a solution of 2-[4-(methyloxy)-1H-indazol-3-yl]-1H-isoindole-1,3(2H)-dione (for a preparation see Intermediate 11) (1 g, 3.4 mmol) in DMF (3 mL) was added at ambient temperature potassium carbonate (0.707 g, 5.11 mmol) and 3-(chloromethyl)benzamide (Maybridge) (0.752 g, 4.43 mmol) and the resulting mixture was stirred at 80 °C overnight.
The solvent was evaporated under a nitrogen stream in a blowdown unit. The residue was dissolved in 20 mL of DCM and 20 mL of water added. A precipitate formed which was collected by filtration, and used directly in the next step. LCMS (System A) RT=0.92 min, ES+ve m/z 459 (M+H)".
The solid was dissolved in ethanol (3 mL) and added dropwise at ambient temperature to hydrazine hydrate (0.497 mL, 10.2 mmol). The resulting suspension was stirred at ambient temperature for 1 h, then acetone (3 mL) was added, and the resulting suspension was stirred overnight. The rection mixture was diluted with DCM (30 mL) and water (30 mL). A precipitate formed, which was collected by filtration, LCMS however, showed that the reaction was incomplete. The solid was re-suspended in ethanol (3 mL) and treated with hydrazine hydrate (0.497 mL, 10.2 mmol) and stirred at ambient temperature overnight. The reaction mixture was treated with acetone (3 mL) and the resulting suspension was stirred overnight. The solid was collected by filtration, washed with DCM (10 mL) to give the title compound (785 mg, 78%) as a white solid. LCMS
RT=0.81 min, ES+ve m/z 297 (M+H)".
Intermediate 13 2-[7-Fluoro-4-(methyloxy)-1H-indazol-3-yl]-1H-isoindole-1,3(2H)-dione o0=
No \ ; > N os
F
2,3-Difluoro-6-methoxybenzonitrile (600 mg, 3.5 mmol) (available from JRD Fluorochemicals) was dissolved in dry N-methylpyrrolidinone (3 mL). and then treated with hydrazine hydrate (4 equiv., 0.65 mL) (available from Aldrich) and the resulting mixture was heated in a Biotage microwave vial at high absorption level for 15 minutes at 150 °C. Acetone (3 mL) was added, and the solution stirred for 15 minutes and left to stand overnight. The solution was then loaded onto a 50g SCX-2 cartridge. The column was eluted with methanol, and then 2M ammonia solution in ethanol. The basic fractions were combined and evaporated under reduced pressure. The crude oil obtained was treated with phthalic anhydride (789 mg, 5.3 mmol) (available from Aldrich) and dry 1,4- dioxane (10 mL). The reaction mixture was stirred for 48 hours at 110 °C. The dioxane was removed under reduced pressure, and the residue was partitioned between dichloromethane (50 mL) and water (50 mL). The organic phase was seperated and the aqueous was further extracted with 50mL of dichloromethane. The combined organic solutions were dried through an hydrophobic frit, and concentrated under reduced pressure. The residue was purified by chromatography on silica (100g cartridge) on Flashmaster eluting with a gradient of 0-100% ethyl acetate in cyclohexane over 80 minutes to give the title compound (510 mg, 47%). LCMS (System A) RT=0.98 min,
ES+ve m/z 312 (M+H)".
Intermediate 14 3-{[3-Amino-7-fluoro-4-(methyloxy)-1H-indazol-1-yllmethyl}benzamide ~o NH,
St
N
F
7 NH,
A solution of 2-[7-fluoro-4-(methyloxy)-1H-indazol-3-yl]-1H-isoindole-1,3(2H)-dione (for a preparation see Intermediate 13) (62.0 mg, 0.2 mmol) in anhydrous DMF (2.5 mL) was treated with potassium carbonate (55.1 mg, 0.4 mmol), followed by 3- (chloromethyl)benzamide (40.5 mg, 0.24 mmol) and stirred at 80°C for 17 hours. The cooled reaction mixture was partitioned between saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer was separated, washed with brine-water (1:1), passed through an hydrophobic frit and evaporated in-vacuo to yield a pale brown solid which was used in the next stage without further purification. LCMS (System B) RT=2.45 min, ES+ve m/z 445 (M+H)"
The solid was suspended in anhydrous ethanol (3 mL) and treated at room temperature with hydrazine monohydrate (0.048 mL, 1 mmol). The resulting suspension was stirred at room temperature for 1 hour. The reaction mixture was treated with acetone (3 mL) and stirred at room temperature for 30 min. The mixture was evaporated in-vacuo to yield an orange solid, which was partitioned between saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer was separated, passed through an hydrophobic frit and evaporated in-vacuo to yield an orange solid. The residue was dissolved in MeOH-DMSO (1 mL) and purified by MDAP on Sunfire C18 column, eluting with solvents A/B (A: 0.1% v/v solution of formic acid in water, B: 0.1% v/v solution of formic acid in acetonitrile) over 25 min. Appropriate fraction was partitioned between saturated aqueous sodium hydrogen carbonate solution and dichloromethane. The organic layer was passed through an hydrophobic frit and evaporated in-vacuo to yield a white solid (22 mg, 35%) LCMS (System B) RT = 1.96 min, ES+ve m/z 315 (M+H)".
Intermediate 15 N-(1-{[3-(Aminomethyl)phenyl]methyl}-4-hydroxy-1H-indazol-3-yl)-5-chloro-2- thiophenesulfonamide formate salt
Cl
OH HT
Oo a
NH, Lon
A suspension of N-[1-{[3-(aminomethyl)phenyl]methyl}-4-(methyloxy)-1H-indazol-3-yl]-5- chloro-2-thiophenesulfonamide hydrochloride (for a preparation see Intermediate 4) (266 mg, 0.533 mmol) in anhydrous DCM (7.5 mL) under nitrogen atmosphere was treated dropwise with boron tribromide solution in DCM (1M, 0.533 mL, 0.533 mmol) at room temperature, and the reaction mixture was stirred at room temperature for 1 hour (reaction not in solution - sticky orange gum had formed). A further portion of boron tribromide (1M, 0.533 mL) was added and the reaction mixture was stirred at room temperature for 1 hour (reaction still not in solution). Anhydrous methanol was added dropwise until the reaction was in solution. Reaction mixture was then stirred at room temperature for a further 30 min. Saturated aqueous sodium bicarbonate solution (10 mL) was added dropwise with care to quench the reaction, on addition of which both a white precipitate (suspended in the aqueous layer) and a dark green sticky gum (stuck to the side of the flask) formed.
The aqueous and organic layers were applied to a hydrophobic frit and the organic layer collected and retained. The remaining green gum in the flask was dissolved in 1:1 methanol-dichloromethane, passed through a hydrophobic frit, combined with the retained organic and evaporated in-vacuo to yield a dark green sticky solid (265 mg). This was dissolved in DMSO (3x1mL) and purified by MDAP Sunfire C18 column, eluting with solvents A/B (A: 0.1% v/v solution of formic acid in water, B: 0.1% v/v solution of formic acid in acetonitrile) (25 min run). Appropriate fractions were combined and evaporated in- vacuo to yield the title compound as a colourless oil (86 mg, 33%). LCMS (System B) RT = 1.63 min, ES+ve m/z 449/451 (M+H)+.
Intermediate 16
Methyl 3-{[2-(dimethylamino)-2-oxoethyl]loxy}benzoate 0 0 ~ NT
A mixture of methyl 3-hydroxybenzoate (Aldrich) (1.52 g, 10 mmol) and K,CO; (1.38 g, 10 mmol) in DMF (10 mL) was stirred for 1 h. 2-Chloro-N,N-dimethylacetamide (Merck) (1.03 mL, 10 mmol) was added and the mixture was stirred for 1 h at RT and then stood at RT for 6 days. The mixture was then acidified with 2M HCI and extracted with EtOAc. The aqueous layer was extracted twice more with EtOAc and the combined organic solutions were washed with 2M HCI (x3), ag. sat NaHCOg3, brine, dried (MgSO,) and evaporated under reduced pressure to give the title compound (2.22 g, 94%) as a white solid. LCMS (System A) RT=0.80 min, 91%, ES+ve m/z 238 (M+H)".
Intermediate 17 (3-{[2-(Dimethylamino)ethyl]loxy}phenyl)methanol
AO
Methyl 3-{[2-(dimethylamino)-2-oxoethyl]loxy}benzoate (for a preparation see Intermediate 16) (2.22 g, 9.36 mmol) was dissolved in THF (15 mL) and cooled in ice. The solution was then treated dropwise with an ether solution of LiAlHs (1M, 10 mL) under nitrogen, and the mixture was stirred in an ice-bath for 1.5 h. LCMS indicated only completion.
The mixture was cooled in ice and aqueous saturated sodium sulfate solution was added until a white precipitate formed. The mixture was stirred for 2 h and then allowed to stand
O/W at RT. The mixture was then filtered, the solid was washed with ethyl acetate, and the filtrate and washings concentrated under reduced pressure. The resulting colourless oil was dissolved in methanol and applied to a pre-washed SCX-2 cartridge. The cartridge was washed with methanol and then eluted with 10% aqueous ammonia in methanol. The ammoniacal fractions were combined and evaporated under reduced pressure to give the title compound (1.236 g, 68%). LCMS (System A) RT=0.36 min,
ES+ve m/z 196 (M+H)".
Intermediate 18 5-Chloro-N-[(5-chloro-2-thienyl)sulfonyl]-N-[1-[(3-{[2- (dimethylamino)ethyl]oxy}phenyl)methyl]-4-(methyloxy)-1 H-indazol-3-yl]-2- thiophenesulfonamide cl
C
O=5 0 9
So J pd S
Cr Cs
N a o—""N\
A mixture of 5-chloro-N-[(5-chloro-2-thienyl)sulfonyl]-N-[4-(methyloxy)-1H-indazol-3-yl]-2- thiophenesulfonamide (for a preparation see Intermediate 10) (150 mg, 0.28 mmol), (3- {[2-(dimethylamino)ethylJoxy}phenyl)methanol (73 mg, 0.37 mmol), triphenylphosphine (113 mg, 0.43 mmol) and di-tert-butyl azodicarboxylate (132 mg, 0.57 mmol) in THF (15 mL) was heated to 65°C O/N. The mixture was evaporated under reduced pressure, the residue was dissolved in MeOH, and then loaded on a SCX-2 ion-exchange cartridge (20 g) and eluted with sequential solvents methanol, 2M ammonia in methanol. The appropriate fractions were combined and evaporated in vacuo to give the crude product.
This was dissolved in DCM and purified by chromatography on silica (20g cartridge) on
Flashmaster using a 0-15% methanol (containing 1%Et;N)-dichloromethane over 20 min.
The appropriate fraction was evaporated in vacuo to give the title product (140 mg, 70%) as a white foam. LCMS (System F) RT=1.27 min, ES+ve m/z 701/703 (M+H)".
Intermediate 19
Methyl 4-{[2-(dimethylamino)-2-oxoethyl]loxy}benzoate 0
NOL oY N~ 0
Methyl 4-hydroxybenzoate (Fluka) (1.52 g, 10 mmol) and potassium carbonate (1.38 g, 10 mmol) in DMF (10 mL) was treated with 2-chloro-N,N-dimethylacetamide (Merck) (1.03 ml, 10 mmol) and the mixture was stirred at RT overnight. The reaction mixture was worked up by partitioning between ethyl acetate and 2M hydrochloric acid, washing with
HCI, brine, dried (MgSQO,) and evaporating to dryness. The residue was dissolved in DMF (5 mL) and treated with potassium carbonate (1.38 g, 10 mmol) and 2-chloro-N,N- dimethylacetamide (Merck) (1.03 ml, 10 mmol). The mixture was stirred at RT over the weekend, and then worked up. Partitioned between ethyl acetate and 2M HCI and the organic solution was washed with HCI (X2), brine (X3), dried (MgSQO,), and evaporated to give the title compound (1.62 g, 68%) as a white solid. LCMS (System A) RT=0.73 min,
ES+ve m/z 238 (M+H)".
Intermediate 20 (4-{[2-(Dimethylamino)ethylloxy}phenyl)methanol “TL 0 NN
Methyl 4-{[2-(dimethylamino)-2-oxoethyl]loxy}benzoate (for a preparation see Intermediate 19) (1.61 g, 6.79 mmol) in THF (40 mL) was cooled in ice and then treated with a 1M solution of LiAlH, in diethyl ether (6.8 ml) and the mixture was stirred under nitrogen for 4 h. The reaction mixture was cautiously treated with saturated ag. sodium sulfate solution until the hydrogen evolution ceased. The mixture was then stirred under nitrogen for 1 h and filtered. The solid was washed with diethyl ether and the combined filtrate and washings evaporated under reduced pressure to give the title compound (1.32 g, 100%).
LCMS (System B) RT=1.70 min, ES+ve m/z 196 (M+H)".
Intermediate 21 5-Chloro-N-[(5-chloro-2-thienyl)sulfonyl]-N-[1-[(4-{[2- (dimethylamino)ethyl]oxy}phenyl)methyl]-4-(methyloxy)-1 H-indazol-3-yl]-2- thiophenesulfonamide
Cl
Z
~o SRL
S
Cry B-
N
~ —
N—~
A mixture of 5-chloro-N-[(5-chloro-2-thienyl)sulfonyl]-N-[4-(methyloxy)-1H-indazol-3-yl]-2- thiophenesulfonamide (for a preparation see Intermediate 10) (0.262 g, 0.5 mmol) and (4- {[2-(dimethylamino)ethyl]loxy}phenyl)methanol (98 mg, 0.5 mmol), triphenylphosphine (197 mg, 0.75 mmol) and di tert-butyl azodicarboxylate (230 mg, 1 mmol) in THF (30 mL) was heated to 65°C for h. LCMS indicated complete reaction. The mixture was concentrated and the residue was dissolved in methanol and applied to an SCX-2 ion- exchange cartridge (50 g) eluting with methanol, followed by 10% aq. ammonia in methanol. The ammoniacal fractions were combined and evaporated in vacuo to give the crude product (400 mg) as a yellow gum. The mixture was loaded in dichloromethane on a silica cartridge (20 g) and purified by chromatography on Flashmaster using a gradient of 0-15% methanol (containing 1% Et;N)-dichloromethane over 40 min. The appropriate fractions were combined and evaporated in vacuo to give impure product (167 mg) as a colourless gum. The sample was dissolved in 1:1 MeOH-DMSO (2 mL) and purified by MDAP on Xbridge column using acetonitrile water with an ammonium carbonate modifier
Appropriate fractions were combined and the solvent was evaporated in vacuo to give the title compound (91 mg, 26%) LCMS (System C) (5 min run) RT=3.76 min, ES+ve m/z 701/703 (M+H)".
Intermediate 22
Methyl 4-{[2-(dimethylamino)-2-oxoethyl]oxy}-3-(methyloxy)benzoate 0
YY
No
O
Methyl 4-hydroxy-3-(methyloxy)benzoate (methyl vanillate, Aldrich) (3.85 g, 21.1 mmol) and potassium carbonate (2.92 g, 21.1 mmol) in DMF (10 mL) was treated at RT with 2- chloro-N,N-dimethylacetamide (Merck) (2.18 mL, 21.1 mmol) and the mixture was stirred over the weekend. The mixture was partitioned between ethyl acetate and 2M HCI. The organic phase was washed with, 2M HCI, saturated sodium bicarbonate solution (turns lightly coloured), acid (loses colour), brine, dried (MgSQO,), and evaporated under reduced pressure, to give the product contaminated with starting material (5.0 g). The mixture was therefore re-dissolved in DMF (5 mL) and treated with potassium carbonate (1.38 g, 10 mmol) and 2-chloro-N,N-dimethylacetamide (1 mL, 10 mmol) for another day. The mixture was then partitioned between ethyl acetate and 2M HCI and treated as above.
The filtrate was evaporated to give a solid (2.614 g) which was loaded in chloroform to a silica cartridge (70 g) and purified by chromatography on Flashmaster using a 0-100% ethyl acetate-cyclohexane gradient over 30 min. The appropriate fractions were combined and evaporated in vacuo to give the title compound (1.4 g, 25%) as a white solid. LCMS (System A) RT=0.69 min, ES+ve m/z 268 (M+H)".
Intermediate 23 [4-{[2-(Dimethylamino)ethyl]oxy}-3-(methyloxy)phenyllmethanol
On"
Ww JLT 0
Methyl 4-{[2-(dimethylamino)-2-oxoethyl]oxy}-3-(methyloxy)benzoate (for a preparation see Intermediate 22) (1.4 g, 5.2 mmol) was dissolved in THF (50 ml) and cooled in an ice- bath under nitrogen. The mixture was then treated cautiously with 1M ether solution of lithium aluminium hydride (5.5 mL) and the mixture was stirred at 5°C allowing to warm to
RT overnight. The reaction mixture was quenched by cautious addition of aq. saturated
NaHCO; solution (1 mL), followed by MgSO, (2 g) and stirring for 30 min. The solids were removed by filtration, washed with ethyl acetate, and the filtrate was evaporated to give the title compound (1.18 g, 100%) as a yellow oil: LCMS (System A) RT=0.34 min,
ES+ve m/z 226 (M+H)".
Intermediate 24 3-(Hydroxymethyl)benzenesulfonamide
Aon
HN Tr
To a solution of 3-(aminosulfonyl)benzoic acid (Fluorochem) (150 mg, 0.746 mmol) in
THF (1 mL) was added dropwise at 0 °C Borane-THF complex (3.73 mL, 3.73 mmol).
The resulting solution was stirred 10 min at 0 °C, and then at room temperature overnight.
The reaction mixture was carefully quenched with 10 mL of water at 0 °C. The reaction mixture was diluted with 30 mL of EtOAc and 20 ml of water. The aqueous layer was further extracted with 30 mL of EtOAc. The combined organic solutions were washed with brine (30 mL), dried over an hydrophobic frit and concentrated under reduced pressure.
The residue was loaded in dichloromethane to a silica cartridge (20 g), and purified by chromatography on Flashmaster using a 0-100% ethyl acetate-dichloromethane over 40 min. The appropriate fractions were combined and evaporated in vacuo to give the title compound (86.4 mg, 62%) as a gum. LCMS (System A) RT = 0.41 min, ES+ve m/z 188 (M+H)".
Intermediate 25 1-{[3,4-Bis(methyloxy)phenyl]methyl}-4-(methyloxy)-1H-indazol-3-amine 0” NH,
Cr
N ae 0
Powdered KOH (0.494 g, 8.80 mmol) was dissolved in DMSO (20 mL) under nitrogen and 4-(methyloxy)-1H-indazol-3-amine (for a preparation see Intermediate 1) (0.653 g, 4 mmol) was added. The mixture was stirred for 15 min to give a deep red solution. 4- (Chloromethyl)-1,2-bis(methyloxy)benzene (0.896 g, 4.80 mmol) was added in one portion and the mixture was stirred for 2 h. The mixture was added to water (150 mL) and extracted with dichloromethane (3 x 50 mL). The dried (Na,SO,) extract was evaporated and the residue was triturated with diethyl ether (3 x 3 mL) to give the title compound (1.05 g, 84%) as an orange solid. LCMS (System B) RT=1.42 min, ES+ve m/z 314 (M+H)".
Intermediate 26 5-Chloro-N-[4-(methyloxy)-1H-indazol-3-yl]-2-thiophenesulfonamide
0
DY
Ss
A solution of 1,1-dimethylethyl 3-{[(5-chloro-2-thienyl)sulfonyllamino}-4-(methyloxy)-1H- indazole-1-carboxylate (for a preparation see Intermediate 6) (155 mg, 0.35 mmol) was dissolved in DCM (0.2 mL) and TFA (0.4 mL) was added. The solution was stood at room temperature for 30 min, and then blown down to dryness under a stream of nitrogen in a
Radley's blow down unit to give the title compound (200 mg). LCMS (System D) RT = 1.02 min, ES+ve m/z 344 (M+H)".
Intermediate 27 2-{[(3<{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]amino}-1,1-dimethyl-2-oxoethyl acetate
Cl 0 S
Co
J
0
ON
A stirring suspension of N-[1-{[3-(aminomethyl)phenyl]methyl}-4-(methyloxy)-1H-indazol- 3-yl]-5-chloro-2-thiophenesulfonamide (40.5 g, 87 mmol) in dichloromethane (1000 mL) and triethylamine (36.4 mL, 262 mmol) was cooled down and then 2-chloro-1,1-dimethyl- 2-oxoethyl acetate (12.52 mL, 87 mmol) was added dropwise. The reaction mixture was stirred at room temperature under nitrogen for 1 h and 20 min. It was then washed with 2M HCI (300 ml), NaHCO3 solution (300 ml), brine, dried over magnesium sulphate and filtered. The filtrate was evaporated in vacuo to give a white solid. The residue was dissolved in DCM and loaded onto a 1500g silica column and eluted with 40-100% ethyl acetate in cyclohexane over 8 CV. The required fractions were combined and evaporated in vacuo to give the title compound in two batches (37.87 g, 73%) and (3.39 g) as white foams. HPLC showed that the latter batch was not pure, therefore it was purified again on a 120g silica column using a gradient of 40-75% ethyl acetate in cyclohexane over 8 CV.
The required fractions were combined and evaporated in vacuo to give the title compound (2.16 g, 4%) as a white foam.
LCMS (System A) RT=1.10 min, ES+ve m/z 591/593 (M+H)".
Intermediate 28 1,1-Dimethylethyl [(4-{[3-{bis[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H- indazol-1-yllmethyl}phenyl)methyl]carbamate
Cl o
Ox O
So IAN
S
Cr O~
Oo
N O
Le
A solution of 5-chloro-N-[(5-chloro-2-thienyl)sulfonyl]-N-[4-(methyloxy)-1H-indazol-3-yl]-2- thiophenesulfonamide (for a preparation see Intermediate 10)(400 mg, 0.763 mmol), triphenylphosphine (400 mg, 1.52 mmol) and 1,1-dimethylethyl ~~ {[4- (hydroxymethyl)phenyllmethyl}carbamate (Maybridge) (362 mg, 1.52 mmol) in THF (3 mL) was added at room temperature DIAD (0.300 mL, 1.52 mmol). The resulting mixture was stirred at 65 °C for 3 hours. The reaction mixture was partitioned between DCM (3 mL) and water (3 mL). The organic phase was separated, and the aqueous layer was further extracted with DCM (3 mL). The combined organic solutions were dried over an hydrophobic frit and evaporated under a nitrogen stream in a blowdown unit. The residue was loaded in dichloromethane on a silica (50 g) cartridge and purified by chromatography on Flashmaster Il using a gradient of 0-100% dichloromethane- cyclohexane over 40 min. The appropriate fractions were combined and evaporated in vacuo to give the title compound (498 mg, 88%) as a gum.
LCMS (System A) RT=1.48 min, ES+ve m/z 760/762 (M+NH,)".
Intermediate 29 1,1-Dimethylethyl [(4-{[3-{[(5-chloro-2-thienyl)sulfonyl]Jamino}-4-(methyloxy)-1H- indazol-1-yllmethyl}phenyl)methyl]carbamate
- of 0 aN O cl
HN.__O jo
To a solution of 1,1-dimethylethyl [(4-{[3-{bis[(5-chloro-2-thienyl)sulfonyllamino}-4- (methyloxy)-1H-indazol-1-yllmethyl}phenyl)methyl]jcarbamate (for a preparation see intermediate 28) (497 mg, 0.67 mmol) in methanol (3 mL) was added sodium hydroxide (2M, 3.34 mL) and the mixture was stirred at 60 °C for 3 h. The solvents were evaporated off under a nitrogen stream in a blowdown unit. The residue was partitioned between
DCM (5 mL) and water (6 mL) and a solution of dilute HCI solution was added until the pH of the aqueous layer was around 1. The organic phase was separated and the aqueous layer was further extracted with DCM (5 mL). The combined organic solutions were washed with brine (2 mL), dried over an hydrophobic frit, and concentrated under a stream of nitrogen in a blowdown unit. The residue was dissolved in 1:1 MeOH-DMSO (1 mL) and purified by Mass Directed AutoPrep (supelcosil ABZ+Plus column) eluting with solvents A/B (A: Water + 0.1% Formic acid, B: MeCN:Water 95:5 + 0.05% Formic acid).
The solvent was removed under a stream of nitrogen in the Radleys blowdown apparatus to give the title compound (112 mg, 30%) as a white solid. LCMS (System A) RT=1.26 min, ES+ve m/z 563/565 (M+H)".
Intermediate 30
N-[1-{[4-(Aminomethyl)phenyl]methyl}-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide formate salt
- of 0 ne lp cl
CL t
OH
NH,
To a solution of 1,1-dimethylethyl [(4-{[3-{[(5-chloro-2-thienyl)sulfonyllamino}-4- (methyloxy)-1H-indazol-1-yllmethyl}phenyl)methyl]jcarbamate (for a preparation see
Intermediate 29) (92 mg, 0.16 mmol) in dichloromethane (3 mL) was added dropwise hydrogen chloride (0.041 mL, 0.163 mmol). The resulting mixture was stirred at room temperature for 4 h, and then additional portion of hydrogen chloride (0.041 mL, 0.163 mmol) was added dropwise and the mixture was stirred at room temperature overnight.
The solvents were then evaporated in a nitrogen blowdown unit. The residue was dissolved in 1:1 MeOH-DMSO (1 mL) and purified by Mass Directed AutoPrep (supelcosil
ABZ+Plus column) eluting with solvents A/B (A: Water + 0.1% Formic acid, B:
MeCN:Water 95:5 + 0.05% Formic acid). The solvent was dried under a stream of nitrogen in the Radleys blowdown apparatus to give the title compound (69 mg, 83%).
LCMS (System E) RT=2.10 min, ES+ve m/z 463/465 (M+H)".
Intermediate 31
Methyl 3-{[3-[[(5-chloro-2-thienyl)sulfonyl]({[2- (trimethylsilyl)ethyl]oxy}methyl)amino]-4-(methyloxy)-1H-indazol-1- yllmethyl}benzoate
% 7 o 0 O
LC Po
J
8 /
N o oO
A solution of 5-chloro-N-[4-(methyloxy)-1H-indazol-3-yl]-N-({[2- (trimethylsilyl)ethylloxy}methyl)-2-thiophenesulfonamide ~~ (for a preparation see
Intermediate 8) (1g, 2.11 mmol) in DMF (10 mL) was treated at ambient temperature with potassium carbonate (0.583 g, 4.22 mmol) and methyl 3-(bromomethyl)benzoate (Alfa
Aesar) (0.580 g, 2.53 mmol). The resulting mixture was stirred at 50 °C for 2 h and the
LCMS then showed product as the major peak. The mixture was diluted with DCM (20 mL) and of water (20 mL). The organic phase was separated and the aqueous layer was further extracted with DCM (20 mL). The combined organic solutions were washed with brine (30 mL), dried over an hydrophobic frit, and concentrated under reduced pressure.
The residue was loaded in dichloromethane to a silica 100 g cartridge and purified by chromatography on Flashmaster II using a 0-100% gradient B in A, A beeing neat DCM and B being a 5 % EtOAC in DCM solution over 40 min. and then further purified on a second cartridge silica 70g using a 0-100% gradient B in A, A beeing neat DCM and B being a 5 % EtOAC in DCM solution over 40 min. The appropriate fractions were combined and evaporated in vacuo to give the title compound (571 mg, 44%) as a gum.
LCMS (System A) RT=1.60 min, ES+ve m/z 639/641 (M+NH,)".
Intermediate 32 4-{[3-Amino-4-(methyloxy)-1H-indazol-1-yllmethyl}benzamide
So NH, oO
To a solution of 4-(methyloxy)-1H-indazol-3-amine ( for a preparation see Intermediate 1) (0.816 g, 5 mmol) in DMSO (50 mL) at room temperature under nitrogen was added potassium hydroxide (0.561 g, 10.0 mmol). After stirring the resulting deep red solution for 25 min 4-(chloromethyl)benzamide (0.848 g, 5.00 mmol) was added in one portion.
The reaction mixture was stirred for a further 30 min and then poured into water (250 mL), forming an emulsion. The reaction mixture was extracted using chloroform (3 x 250 mL).
The combined organic solutions were washed with water (250 mL) and passed through hydrophobic frit. The solvent was removed in vacuo and the residue was loaded in dichloromethane to a silica (100 g) cartridge and purified by chromatography on
Flashmaster eluting with 0-100% ethyl acetate-cyclohexane + 0-20% methanol-ethyl acetate over 60 min. The appropriate fractions were combined and evaporated in vacuo to give the title compound (1.18 g, 80%). LCMS: (System A) RT = 0.69 min, ES+ve m/z 297 (M+H)".
Intermediate 33 1-{[3,4-Bis(methyloxy)phenyl]methyl}-4-(methyloxy)-1H-indazol-3-amine ( 0” NH, —0 »
Powdered KOH (0.494 g, 8.80 mmol) was dissolved in DMSO (20 mL) under nitrogen and 4-(methyloxy)-1H-indazol-3-amine (for a preparation see Intermediate 1) (0.653 g, 4 mmol) was added. The mixture was stirred for 15 min to give a deep red solution. 4- (Chloromethyl})-1,2-bis(methyloxy)benzene (0.896 g, 4.80 mmol) was added in one portion and the mixture was stirred for 2 h. The mixture was added to water (150 mL) and extracted with dichloromethane (3 x 50 mL). The dried (Na,SO,) extract was evaporated and the residue was triturated with diethyl ether (3 x 3 mL) to give the title compound (1.05 g, 84%) as an orange solid. LCMS (System B) RT=2.22 min, ES+ve m/z 314 (M+H)".
Intermediate 34
N-[(3-{[3-amino-4-(methyloxy)-1H-indazol-1-ylJmethyl}phenyl)methyl]lacetamide ~N
Q NH, rd /
G
HN
=o
The title compound was prepared in array format according to the procedure described for
Intermediate 33.
LCMS (System A) RT=0.76 min, ES+ve m/z 325 (M+H)".
Intermediate 35 1,1-Dimethylethyl (3R)-3-({[(3-{[3-amino-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]amino}carbonyl)-4-morpholinecarboxylate
So NH,
Cr / 0
O HN
O
+ I
L
The title compound was prepared in array format according to the procedure described in
Intermediate 33. LCMS (System A) RT=0.98 min, ES+ve m/z 496 (M+H)".
Intermediate 36
4-Fluoro-1H-indazol-3-amine
F NH, gs
N
To a solution of 2,6-difluorobenzonitrile (3 g, 21.6 mmol) in anhydrous ethanol (50 mL) was added hydrazine hydrate (4.18 mL, 86 mmol). The reaction was heated at 90 °C under nitrogen for 4 hours. Reaction mixture was cooled to room temperature, treated with acetone (20 mL) and left to stand for 18 hours. The mixture was evaporated in-vacuo to yield an orange/brown solid which was partitioned between saturated aqueous sodium hydrogen carbonate solution and dichloromethane. The organic layer was passed through a hydrophobic frit and evaporated in-vacuo to yield a brown solid (4.58 g), which was absorbed onto Florisil (60-100 mesh), applied to a 100g silica SPE cartridge and purified on a Flashmaster Il using a 0-10% methanol in dichloromethane gradient over 60 min. Fractions 48-57 were combined and the solvent was evaporated in-vacuo to yield the title compound as a brown solid (3.08 g, 94%). LCMS (System B) RT= 1.38 min,
ES+ve m/z 152 (M+H)".
Intermediate 37 3-[(3-Amino-4-fluoro-1H-indazol-1-yl)methyl]benzonitrile
F NH,
To a suspension of ground potassium hydroxide (0.483 g, 8.60 mmol) in anhydrous dimethyl sulfoxide (15 mL) at room temperature under nitrogen was added a solution of 4- fluoro-1H-indazol-3-amine (for a preparation see Intermediate 36) (0.52 g, 3.44 mmol) in anhydrous dimethyl sulfoxide (10 mL). The resulting deep red solution was treated after 10 minutes with 3-cyanobenzyl bromide (0.843 g, 4.30 mmol) in one portion. The reaction mixture was stirred for 30 min and then poured into water (100 mL), forming a yellow emulsion. This was extracted using chloroform (2 x 100 mL). The combined organic solutions were washed with water-brine (1:1) (100 mL), passed through a hydrophobic frit and evaporated in-vacuo to yield a red oil (2.263 g). The residue was applied to a 100g silica SPE cartridge and purified by chromatography on Flashmaster Il eluting with a 0-
100% ethyl acetate in cyclohexane gradient over 80 min. Fractions 159-173 were combined and the solvent was evaporated in-vacuo to yield a yellow solid the title compound (0.77 g, 84%) LCMS (System B) RT = 2.32 min, ES+ve m/z 267 (M+H)".
Intermediate 38 5-Chloro-N-{1-[(3-cyanophenyl)methyl]-4-fluoro-1H-indazol-3-yl}-2- thiophenesulfonamide oxy S\_~Cl
FHT ~~
To a solution of 3-[(3-amino-4-fluoro-1H-indazol-1-yl)methyllbenzonitrile (for a preparation see Intermediate 37) (695 mg, 2.61 mmol) in anhydrous pyridine (3 mL) cooled in an ice/water bath was added 5-chloro-2-thiophenesulfonyl chloride (567 mg, 2.61 mmol) dropwise over 1 minute and the reaction mixture was stirred in the ice/water bath for 1 hour. The reaction mixture was partitioned between ethyl acetate (150 mL) and 2N hydrochloric acid (100 mL). The organic layer was separated, passed through a hydrophobic frit and evaporated in-vacuo to yield a dark red oil (1.264 g). The oil was dissolved in the minimum volume of dichloromethane, applied to a 100g silica SPE cartridge and purified by chromatography on Flashmaster Il using a 0-50% ethyl acetate in cyclohexane gradient over 60 min. Fractions 66-69 were combined and evaporated in- vacuo to yield a white foam (540 mg), which was further purified by chromatography on 100g silica SPE cartridge on Flashmaster Il using a 0-10% methanol in dichloromethane gradient over 60 min. Fractions 23-26 were evaporated in-vacuo to yield the title compound as a white foam (493 mg, 42%). LCMS (SystemB) RT = 3.01 min, ES+ve m/z 447/449 (M+H)+.
Intermediate 39
N-(1-{[3-(Aminomethyl)phenyl]methyl}-4-fluoro-1H-indazol-3-yl)-5-chloro-2- thiophenesulfonamide oxy S\_-Cl
Fan ~~ or
To an ice/water bath cooled solution of 5-chloro-N-{1-[(3-cyanophenyl)methyl]-4-fluoro- 1H-indazol-3-yl}-2-thiophenesulfonamide (for a preparation see Intermediate 38) (493 mg, 1.10 mmol) in anhydrous tetrahydrofuran (7 mL) under nitrogen atmosphere was added dropwise over 5 min lithium aluminium hydride (1M solution in diethyl ether) (2.76 mL, 2.76 mmol). The reaction was stirred in the ice/water bath for 30 min and then at room temperature for 1 hour. Further quantity of lithium aluminium hydride (1M solution in diethyl ether, 1 mL) was added dropwise over 1 min. Reaction stirred at room temperature for 1 hour. The reaction mixture was cooled in an ice/water bath and quenched with water (10 mL) (dropwise with care). The reaction was then partitioned between saturated aqueous sodium hydrogen carbonate solution and 20% methanol in dichloromethane - large amount of white solid suspended in the aqueous layer. The organic layer was passed through a hydrophobic frit and evaporated in-vacuo to yield a white solid (<20 mg). Product not soluble in organic layer - majority of material either soluble in aqueous or suspended in aqueous. Methanol was added to the retained aqueous layer until an opaque milky solution formed - applied to two methanol pre- conditioned 50 g SCX-2 ion-exchange cartridges. The cartridges were washed with methanol and then eluted using 2M ammonia in methanol. The 2M ammonia in methanol fractions from each cartridge were combined and evaporated in-vacuo to yield a pale yellow solid (480 mg), which was absorbed onto Florisil (60-100 mesh), applied to a 100g silica SPE cartridge and purified by chromatography on Flashmaster Il using a 0-25% methanol in dichloromethane gradient over 60 min. Appropriate fractions were combined and evaporated under reduced pressure to give the title compound (284 mg, 57%) as a white solid. LCMS (System B) RT=1.67 min, ES+ve m/z 451/453 (M+H)".
Intermediate 40 4-Chloro-1H-indazol-3-amine
¢ NH,
N
To a solution of 2-chloro-6-fluorobenzonitrile (ABCR) (3 g, 19 mmol) in anhydrous ethanol (50 mL) was added hydrazine hydrate (3.74 mL, 77 mmol). The reaction was heated at 90 "C under a nitrogen for 3.5 hours. The reaction mixture was cooled to room 5 temperature, treated with acetone (20 mL) and left to stand for 19 hours. The mixture was evaporated in-vacuo to yield an orange/brown solid, which was partitioned between saturated aqueous sodium hydrogen carbonate solution and dichloromethane. The organic layer was passed through a hydrophobic frit and evaporated in-vacuo to yield a brown solid, which was absorbed onto Florisil (60-100 mesh), applied to a 100g silica SPE cartridge and purified by chromatography on Flashmaster Il using a 0-10% methanol in dichloromethane gradient over 60 min. Fractions 24-29 were combined and the solvent was evaporated in-vacuo to yield the title compound as a yellow solid (2.14 g, 66%)
LCMS (System B) RT= 1.58 min, ES+ve m/z 168 (M+H)".
Intermediate 41 3-[(3-Amino-4-chloro-1H-indazol-1-yl)methyl]benzonitrile
Cl NH,
Qs
N
To a suspension of ground potassium hydroxide (421 mg, 7.50 mmol) in anhydrous dimethyl sulfoxide (5 mL) at room temperature under nitrogen was added a solution of 4- chloro-1H-indazol-3-amine (for a preparation see Intermediate 40) (503 mg, 3.0 mmol) in anhydrous dimethyl sulfoxide (15 mL). After 30 minutes 3-cyanobenzyl bromide (Aldrich) (735 mg, 3.75 mmol) was added in one portion. The reaction mixture was stirred for 2 hours. The reaction mixture was poured into water (200 mL), forming a yellow/brown emulsion. This was extracted using chloroform (2 x 200 mL). The combined organic solutions were washed with water:brine (1:1) (200 mL), passed through a hydrophobic frit, and evaporated in-vacuo to yield a brown oil. The oil was applied to a 100g silica SPE cartridge and purified by chromatography on Flashmaster Il using a 0-100% ethyl acetate in cyclohexane gradient over 80 min. Fractions 32-34 were combined and the solvent was evaporated in-vacuo to yield the title compound as an off white solid (216 mg, 25%).
LCMS (System B) RT = 2.51 min, ES+ve m/z 283 (M+H)".
Intermediate 42 5-Chloro-N-{4-chloro-1-[(3-cyanophenyl)methyl]-1H-indazol-3-yl}-2- thiophenesulfonamide
Oy 5 al S S
TT)
To a solution of 3-[(3-amino-4-chloro-1H-indazol-1-yl)methyl]benzonitrile (for a preparation see Intermediate 41)(201 mg, 0.711 mmol) in anhydrous pyridine (2 mL) under nitrogen was added 5-chloro-2-thiophenesulfonyl chloride (154 mg, 0.711 mmol) dropwise, and the reaction mixture was stirred at room temperature for 30 min. The reaction mixture was partitioned between ethyl acetate (150 mL) and 2N hydrochloric acid (100 mL). The organic layer was separated, passed through a hydrophobic frit, and evaporated in-vacuo to vield a dark red oil. This was dissolved in the minimum volume of dichloromethane, applied to a 100g silica SPE cartridge and purified by chromatography on Flashmaster II using a 0-50% ethyl acetate in cyclohexane gradient over 60 min. Fractions 149-154 were combined and evaporated in-vacuo to yield a white solid (90 mg). Fractions 155 and 156 were combined and evaporated in-vacuo to yield a yellow solid (78 mg) which was dissolved in MeOH:DMSO (1:1) (1 mL) and further purified by Mass Directed
AutoPreparative HPLC (Sunfire C18 column 150mm x 30mm i.d. 5 um packing diameter at ambient temperature) eluting with solvents A/B (A: 0.1% v/v solution of formic acid in water, B: 0.1% v/v solution of formic acid in acetonitrile) over 25 min. Appropriate fractions were evaporated in-vacuo to yield a white solid (5 mg) which was combined with the earlier white solid to give the title compound (95 mg, 29%) LCMS (System B) RT = 3.01 min, ES+ve m/z 463/465 (M+H)".
Intermediate 43 7-Fluoro-4-(methyloxy)-1H-indazol-3-amine o” NH,
N
(x
F
To a suspension of 2-[7-fluoro-4-(methyloxy)-1H-indazol-3-yl]-1H-isoindole-1,3(2H)-dione (for a preparation see Intermediate 13) (1.36 g, 4.37 mmol) in ethanol (15 mL) at 0 °C (ice/water bath) was added hydrazine hydrate (0.638 mL, 13.11 mmol) dropwise. The ice/water bath was removed and the reaction mixture was allowed to warm to room temperature. Stirring was continued for a further 40 min. During this time the reaction mixture became very viscous. Acetone (10 mL) was added to the reaction and the resultant reaction mixture was allowed to stand at room temperature overnight. The solid was removed by filtration and washed with acetone (x 2). The combined filtrates were concentrated in vacuo. The solid was triturated in cyclohexane-ethyl acetate (2:1; ~25 mL) and then collected by filtration to give the title compound (479 mg, 60%) as a light brown powder. LCMS (System A) RT=0.69 min, ES+ve m/z 182 (M+H)". The filtrate was concentrated and the resultant oil was loaded in dichloromethane (and minimum amount of methanol) to a silica cartridge 70 g and purified by chromatography on Flashmaster eluting with a 0-50% ethyl acetate-cyclohexane over 30 min. The appropriate fractions were combined and evaporated in vacuo to give another batch of the required product (316 mg, 40%) as a brown oil. LCMS (System A) RT=0.62 min, ES+ve m/z 182 (M+H)".
Intermediate 44 3-{[3-Amino-7-fluoro-4-(methyloxy)-1H-indazol-1-yllmethyl}benzonitrile
So NH, atv!
To a fine suspension of ground potassium hydroxide (566 mg, 10.09 mmol) in dimethyl sulfoxide (5 mL) at room temperature under nitrogen was added a solution of 7-fluoro-4- (methyloxy)-1H-indazol-3-amine (for a preparation see Intermediate 43)(727 mg, 4.01 mmol) in dimethyl sulfoxide (2 mL). After 5 min the resulting dark brown solution was treated with 3-(chloromethyl)benzonitrile (730 mg, 4.82 mmol). The reaction mixture was stirred for 30 min and then the mixture was poured into water, forming an emulsion. This was extracted with DCM and the combined extracts were washed with water and passed through a hydrophobic frit. The aqueous was extracted with ethyl acetate and the combined organic solutions were washed with water and brine, dried (Na,SO,) and then combined with the initial DCM extracts and concentated in vacuo to leave a brown oil. The residue was loaded in dichloromethane to a silica 100 g cartridge and purified by chromatography on Flashmaster eluting with 0-100% ethyl acetate-cyclohexane over 40 min. The appropriate fractions were combined and evaporated in vacuo to give the required product (665 mg, 56%) as a yellow powder. LCMS (System A) RT=1.02 min,
ES+ve m/z 297 (M+H)".
Intermediate 45 5-Chloro-N-[1-[(3-cyanophenyl)methyl]-7-fluoro-4-(methyloxy)-1 H-indazol-3-yl]-2- thiophenesulfonamide 0” N/ Sq \ wr cag of
To a solution of 3-{[3-amino-7-fluoro-4-(methyloxy)-1H-indazol-1-ylJmethyl}benzonitrile (for a preparation see Intermediate 44)(665 mg, 2.24 mmol) in dry DCM (10 mL) was added 5- chloro-2-thiophenesulfonyl chloride (0.300 mL, 2.24 mmol), followed with pyridine (2 mL).
The resultant dark yellow solution was stirred at room temperature overnight. More 5- chloro-2-thiophenesulfonyl chloride was added (0.100 mL) and the reaction stirred for a further 1 h. The reaction mixture was partitioned between ethyl acetate and 2N hydrochloric acid. The aqueous phase was extracted with ethyl acetate (x2). The combined organic solutions were washed with water and brine, dried (Na,SO,4) and concentrated in vacuo to leave a deep red oil. This residue was loaded in dichloromethane to a silica 100 g cartridge and purified by chromatography on
Flashmaster eluting with a 0-100% ethyl acetate-dichloromethane over 40 min. The appropriate fractions were combined and evaporated in vacuo to give the title compound (323 mg, 30%) as a pale yellow powder. LCMS (System A) RT=1.2 min, ES+ve m/z 476/478 (M+H)".
Intermediate 46 N-[1{[3-(Aminomethyl)phenyl]methyl}-7-fluoro-4-(methyloxy)-1H-indazol-3-yl]-5- chloro-2-thiophenesulfonamide
No N%
S do
NH, 5-Chloro-N-[1-[(3-cyanophenyl)methyl]-7-fluoro-4-(methyloxy)-1H-indazol-3-yl]-2- thiophenesulfonamide (for a preparation see Intermediate 45)(600 mg, 1.26 mmol) was dissolved in THF (13 mL) and stirred in an ice bath. The solution was then treated dropwise with lithium aluminium hydride (1M in diethyl ether) (0.881 mL, 0.881 mmol) and stirred under nitrogen overnight. Further six portions of lithium aluminium hydride (1M in diethyl ether, 0.126 mL at a time) were added dropwise to the reaction and stirred for another day. The reaction was quenched with 2M NaOH solution (4 mL) and extracted with ethyl acetate (100 mL). The organic layer was washed with brine (100 mL) before being dried over anhydrous magnesium sulphate and evaporated in vacuo. The residue was dissolved in methanol and loaded onto a methanol conditioned sulfonic acid cartridge (SCX-2) 50g. The cartridge was washed with methanol and eluted with 2M ammonia in methanol. Ammoniacal fractions were evaporated to give a brown gum (100 mg). The aqueous layer was back extracted with ethyl acetate (100 mL). The organic layer was washed with brine (100 mL) and dried over anhydrous magnesium sulphate before being evaporated in vacuo to give a brown gum (60 mg). The aqueous layer was back extracted with chloroform-isopropanol 3:1 (100 mL). The organic layer was dried over anhydrous magnesium sulphate before being evaporated in vacuo to a further 40 mg.
The solids in the aqueous layer were collected by filtration. The solid was dissolved in methanol and filtered to remove any insoluble material. The filtrate was evaporated in vacuo to a further batch of 300 mg. The combined batches were dissolved in methanol and loaded onto a methanol pre-conditioned 50g sulfonic acid (SCX-2) cartridge. The cartridge was washed with methanol and then eluted with 2M ammonia in methanol.
Ammoniacal fractions were evaporated in vacuo to give the title compound as a brown gum (220 mg) LCMS (System A) RT = 0.81 min, ES+ve m/z 481/483 (M+H)".
Intermediate 47 2,4-Difluoro-6-methoxybenzaldehyde
~ ? TiCl,, DCM Too
QO, 8
F Foo” F F 3,5-Difluoroanisole (50 g, 0.35 mol) was charged to a 3-neck flask fitted with thermometer, dropping funnel and argon bubbler. Dichloromethane (200 mL) was added and the solution was cooled in ice-water. Titanium (IV) chloride (61.5 mL, 0.56 mol) was added dropwise (15 min), followed by dropwise addition of a,a—dichloromethyl methyl ether (31.5 mL, 0.35 mol) so that the temperature was maintained <10°C (approx 20 min). The reaction was stirred in ice-water for a further 140 min, poured into ice-water (1 L), then extracted thrice with DCM. The organic solutions were washed with water, brine then dried (MgSO,) and evaporated. The crude product was purified using the Versaflash (80 x 300 mm SiO; cartridge, gradient from DCM to 5% EtOAc) in 7 separate batches to give the title compound (34.5 g, 57%) as an orange solid.
Intermediate 48 2,4-Difluoro-6-methoxybenzonitrile
So 0 ~o
NH,OSOzH ZN
Water
F F F F
2,4-Difluoro-6-methoxybenzaldehyde (for a preparation see Intermediate 47)(34.5 g, 0.20 mol) and hydroxylamine-o-sulfonic acid (24.95 g, 0.22 mol) were charged to a round- bottom flask. Water (500 mL) was added and the suspension was heated at 110 °C for 3 h. After TLC shows reaction to be complete, it was cooled in ice-water and extracted thrice with ethyl acetate. The organic solutions were dried (MgSO,) and evaporated, and the residue was purified by dry flash chromatography (DCM eluent) to give the title compound (32.05 g, 95%) as a pale pink solid.
Intermediate 49 6-Fluoro-4-methoxy-1H-indazol-3-amine
0 ZN NHNH,.H,0 TO oC n-Butanol Or
F F F N
2,4-Difluoro-6-methoxybenzonitrile (for a preparation see Intermediate 48)(29.2 g, 0.17 mol) was suspended in n-butanol (250 mL) and hydrazine hydrate (16.6 mL, 0.34 mol) was added. The suspension was heated at 110 °C for 19 h, then 115°C for 4 h. The reaction was allowed to cool and a solid formed overnight. The solid was collected by filtration, and washed with n-butanol. Solid is mainly an aryl hydrazine by-product (uncyclised or regioisomer). The filtrate was concentrated and azeotroped with toluene to give 15.6 g of crude product (84% by LCMS). The crude product was taken up in ~400 mL water, ~5 mL AcOH and ~350 mL ethyl acetate and any insoluble material was discarded. The organic layer was washed with water, dried (MgSO,) and evaporated.
The residue was taken up in hot ethyl acetate (75 mL, 55°C) and heptane was added (20 mL). The solid was collected by filtration, washed with heptane. This was repeated twice to give the title compound (6.7 g, 21%) as a purple solid.
Intermediate 49 — Alternative preparation
To a solution of a 1:1 mixture of 2,4-difluoro-6-(methyloxy)benzonitrile (for a preparation see Intermediate 50) (5.15 g, 30.4 mmol) in anhydrous ethanol (50 mL) was added hydrazine hydrate (5.91 mL, 122 mmol) dropwise. The reaction was stirred at 80 °C under a nitrogen overnight. The reaction was cooled to room temperature, treated with acetone (20 mL) and left to stand for 18 hours. The mixture was evaporated in-vacuo and the residue was partitioned between saturated aqueous sodium hydrogen carbonate solution (50 mL) and dichloromethane (50 mL). Aqueous phase was further extracted with DCM (50 mL). The organic layers were combined and passed through a hydrophobic frit and evaporated in-vacuo to yield a brown solid, which was absorbed onto Florisil, and purified on a silica 100g cartridge eluting with 0-100% B in A, A being neat CHCl; and B being a 10% MeOH in CHCl; over 60 min. The purest fractions were combined and evaporated in vacuo, and residue was loaded in a 1:1 mixture DMSO-MeOH and further purified by reverse phase (C18) chromatography on 330g cartridge eluting with a gradient of acetonitrile (containing 0.1% NHs;)-water (containing 0.1% NH3) starting from 5 to 35% over 3 CV, then from 35 to 55% in 8 CV, and from 55 to 85 over 4 CV. The appropriate fractions were combined and evaporated in vacuo to give the title compound (1.1 g, 20%) as a pale brown solid LCMS (System A) RT=0.58 min and 0.59 min, ES+ve m/z 182
(M+H)".
Intermediate 50 2,4-Difluoro-6-(methyloxy)benzonitrile and 2,6-difluoro-4-(methyloxy)benzonitrile
I
_© F
F
A solution of 2,4,6-trifluorobenzonitrile (10 g, 63.7 mmol) in methanol (30 mL) was treated dropwise at 0 °C with 30% sodium methoxide solution in methanol (12.13 mL, 63.7 mmol).
The resulting mixture was stirred at room temperature for 2 h. The reaction mixture was evaporated in vacuo and the crude solid obtained was partitioned between water (100 mL) and EtOAc (100 mL). The organic layer was separated and the aqueous one was further extracted with EtOAc (100 mL). The combined organic solutions were washed with water (100 mL) and brine (100 mL), dried through an hydrophobic frit, and concentrated under reduced pressure. The sample was loaded in cyclohexane and dichloromethane (1:1) to a 750 g silica cartridge, and purified by chromatography on Flashmaster Il eluting with 0-100% methyl tert-butyl ether - cyclohexane over 40 min. The appropriate fractions were combined and evaporated in vacuo to give a mixture of the expected product (2,4-difluoro-6-(methyloxy)benzonitrile) and its regioisomer (2,6-difluoro- 4-(methyloxy)benzonitrile) (1:1) LCMS (System A) RT=0.92 min, 0.95 min, ES+ve m/z 170 (M+H)".
Intermediate 51 3-{[3-Amino-6-fluoro-4-(methyloxy)-1H-indazol-1-ylJmethyl}benzonitrile ~ ? NH, oh /
F N
N
Potassium hydroxide (85% pure, 0.84 g, 12.7 mmol) was powdered and added to DMSO
(25 mL) and the mixture was stirred for 5 min. A solution of 1:1 mixture of 6-fluoro-4- (methyloxy)-1H-indazol-3-amine and 4-fluoro-6-(methyloxy) regioisomer) (1.085 g, 6 mmol) in DMSO (5 mL) was added and the mixture was stirred for 5 min. The colour of the reaction mixture turned to dark red. Solid 3-(chloromethyl)benzonitrile (1.0 g, 7.1 mmol) was added and the mixture stirred for 1 h. The mixture was diluted with water, treated with 2M HCI (3 mL) and extracted with ethyl acetate. The organic solution was washed with water (4 times) and once with brine, dried (MgSO,) and evaporated. The residue was dissolved in DCM and MeOH and pre-absorbed on florisil (5 g). The pre- absorbed compound was placed on two 100g Silica cartridges and purified by chromatography on Flashmaster using a 0-100% ethyl acetate-cyclohexane over 60 min.
The appropriate fractions (RT=48 min) were evaporated under reduced pressure to give impure title compound as an orange solid. This required further purification and was pre- absorbed on florisil and purified by chromatography on Flashmaster silica 100g using a 0- 100% ethyl acetate-cyclohexane over 100 min. The appropriate fractions (RT=46-70 min) were combined and evaporated in vacuo to give the title compound (362 mg, 20%) as a yellow solid: LCMS (System A) RT= 0.96 min, ES+ve m/z 297 (M+H)", NMR & (CDCl5) 7.57-7.53 (1H, m), 7.43-7.38 (3H, m), 6.37 (1H, dd, J 10, 2 Hz), 6.15 (1H, dd, J 12, 2 Hz), 5.23 (2H, s), 4.45 (2H, br), 3.94 (3H, s).
Intermediates 52 and 53 5-Chloro-N-[1-[(3-cyanophenyl)methyl]-6-fluoro-4-(methyloxy)-1H-indazol-3-yl]-2- thiophenesulfonamide (Intermediate 52) and 5-chloro-N-[(5-chloro-2- thienyl)sulfonyl]-N-[1-[(3-cyanophenyl)methyl]-6-fluoro-4-(methyloxy)-1H-indazol-3- yl]-2-thiophenesulfonamide (Intermediate 53)
Cl 0” LS
Oo 3
A suspension of 3-{[3-amino-6-fluoro-4-(methyloxy)-1H-indazol-1-yllmethyl}benzonitrile (for a preparation see Intermediate 51) (362 mg, 1.22 mmol) in chloroform (6 mL) and pyridine (2 mL) was added to 5-chloro-2-thiophenesulfonyl chloride (398 mg, 1.83 mmol) at room temperature and the mixture was stirred for 5 h. The reaction mixture was partitioned between chloroform and 2M HCI solution. The organic phase was washed three times with HCI, dried (MgSQO,), and evaporated under reduced pressure. The residual gum (1 g) was dissolved in chloroform and applied to one silica 100 g cartridge and purified by chromatography on Flashmaster using a 0-100% ethyl acetate- cyclohexane over 60 min. The appropriate fractions were combined and evaporated in vacuo to give Intermediate 52 (260 mg, 45%) as an off-white solid. LCMS (System A)
RT= 1.17 min, ES+ve m/z 477/479 (M+H)’. Less polar fractions were combined and evaporated to give 5-chloro-N-[(5-chloro-2-thienyl)sulfonyl]-N-[1-[(3-cyanophenyl)methyl]- 6-fluoro-4-(methyloxy)-1H-indazol-3-yl]-2-thiophenesulfonamide (Intermediate 53) (53 mg, 7%) LCMS (System A) RT= 1.42 min, ES+ve m/z 657/659 (M+H)".
Intermediate 54
N-1-{[3-(Aminomethyl)phenyl]methyl}-6-fluoro-4-(methyloxy)-1H-indazol-3-yl]-5- chloro-2-thiophenesulfonamide formic acid salt cl
S
0” wie! lo
Cc
F N
0 3
OH
H,N
A solution of 5-chloro-N-[1-[(3-cyanophenyl)methyl]-6-fluoro-4-(methyloxy)-1H-indazol-3- yl]-2-thiophenesulfonamide (for a preparation see Intermediate 52)(260 mg, 0.54 mmol) in
THF (10 mL) was cooled in an ice-bath and treated under nitrogen with a lithium aluminium hydride solution in ether (1M, 0.38 mL). After 3 h the reaction mixture was quenched by addition of 2M NaOH solution (1 mL) and the mixture was stirred under nitrogen for 0.5 h. The mixture was then partitioned between ethyl acetate and water, and the organic solution was evaporated under reduced pressure. The residue was dissolved in MeOH and applied to an ion-exchange SCX-2 cartridge eluting with MeOH, followed by 10% aqueous ammonia in MeOH. The ammoniacal solution was evaporated under reduced pressure to give impure product as a yellow solid (100.2 mg). The solid was treated with 2M HCI and chloroform was added. An emulsion formed which was concentrated under reduced pressure, and the residue was dissolved in MeOH-DMSO (1:1) (2 mL) and purified by Mass Directed AutoPrep on Sunfire C18 column using
Acetonitrile Water with a Formic acid modifier (Method A) collecting fraction with RT=6 min. The solvent was evaporated in vacuo to give the title compound (53 mg, 18%) as the formate salt. LCMS (System A) RT=0.82 min, ES+ve m/z 481/483 (M+H)".
Intermediate 55 3,6-Difluoro-2-methoxy-benzonitrile ~o
F
Methanol (600 mL) was treated portionwise with sodium (Alfa, 16.1 g, 0.702 gatoms, 1.05 equiv.). The sodium methoxide solution was cooled to room temperature and added dropwise to a solution of 2,3,6-trifluorobenzonitrile (Matrix, 105 g, 0.699 mol) in methanol (600ml) at room temperature. After addition was complete the mixture was stirred for 1 hour at room temperature before removing the methanol under reduced pressure. The residue was partitioned between diethyl ether (500ml) and water (500 mL). The organic layer was removed, dried over MgSO, filtered and evaporated to give the crude product.
This was purified by distillation using a 6” vigreux column @ 20 mmHg, oil bath 160 °C, head temp 120 °C to give the title compound as a white solid (108 g, 91%)
Intermediate 56 5-Fluoro-4-(methyloxy)-1H-indazol-3-amine he NH,
F
N
H
A mixture of 3,6-difluoro-2-methyloxybenzonitrile (for a preparation see Intermediate 55) (30 g, 184 mmol) in ethanol (300 mL) was reacted with Hydrazine Monohydrate (Alfa, 89 mL, 1.84 mol, 10 equiv.). The resulting mixture was heated at reflux overnight then allowed to cool to room temperature. Silica was added to the mixture which was then evaporated to dryness. The pre-absorbed crude reaction mixture was then purified by chromatography eluting with petrol up to EtOAc (10% steps, 500 mL per step) to give the title compound ( 8.4 g, 25%) as a yellow solid.
Intermediate 57
3-{[3-Amino-5-fluoro-4-(methyloxy)-1H-indazol-1-ylmethyl}benzonitrile ~o NH,
ADS
N
N vi
N
Finely ground potassium hydroxide (6.59 g, 118 mmol, 2.5 equiv.) was treated with DMSO (100 mL). To this was added 5-fluoro-4-(methyloxy)-1H-indazol-3-amine (for a preparations see Intermediate 56) (8.5 g, 47 mmol) and the mixture stirred at room temperature for 50 minutes. To the red coloured mixture was added 3-chloromethyl benzonitrile (8.9 g, 59 mmol, 1.25 equiv.) in one portion. A small exotherm of ~5 °C was observed. The mixture was allowed to stir at room temperature for 25 minutes before pouring into water (600 mL) and extracting with chloroform (400 mL). The aqueous was re-extracted with chloroform (2 x 400 mL). The organic extracts were combined, washed with water (3 x 500 mL), dried over MgSO,, filtered and evaporated to give the crude product. This was dry loaded onto silica and chromatographed eluting with 20% petrol up to 70% EtOAc-petrol. The material came off impure so was re-chromatographed on a suction column. The impure material was loaded in DCM and eluted with DCM up to 30%
EtOAc-DCM to give the title compound (8.25 g, 48%) as an off-white solid. LCMS (System A) RT=0.96 min, ES+ve m/z 297 (M+H)".
Intermediate 58 3-{[3-Amino-5-fluoro-4-(methyloxy)-1H-indazol-1-ylmethyl}benzonitrile o” NH, or 'N
N o
To a solution of 3-{[3-amino-5-fluoro-4-(methyloxy)-1H-indazol-1-ylJmethyl}benzonitrile (for a preparation see Intermediate 57)(470 mg, 1.59 mmol) in dry DCM (3 mL) and pyridine (1 mL, 12 mmol) was added 5-chloro-2-thiophenesulfonyl chloride (517 mg, 2.38 mmol).
The reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate (15 mL) and 2 M hydrochloric acid (15 mL). The aqueous was extracted with ethyl acetate and the combined organic solutions washed with water and brine, passed through a hydrophic frit and then concentrated in vacuo to leave a dark red oil. This was loaded in dichloromethane on to a silica 100 g cartridge and purified by chromatography on Flashmaster eluting with 0-100% ethyl acetate- cyclohexane over 40 min. The appropriate fractions were combined and evaporated in vacuo to give the title compound (206 mg, 27%) as a pale brown powder. LCMS (System
A) RT=1.17 min ES+ve m/z 477/479 (M+H)".
Intermediate 59 1,1-Dimethylethyl [(3-{[3-amino-5-fluoro-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyllcarbamate 0” NH, or I
N \ 0 3 3-{[3-Amino-5-fluoro-4-(methyloxy)-1H-indazol-1-yllmethyl}benzonitrile (for a preparation see Intermediate 58)(5 g, 16.9 mmol), Nickel (II) chloride (4.37 g, 33.7 mmol) and di-tert- butyl dicarbonate (5.52 g, 25.3 mmol) were dissolved in a mixture of THF (75 mL) and
Methanol (113 mL). The reaction was cooled to -10 °C and sodium borohydride (4.47 g, 118 mmol) was added portion wise to the reaction. The reaction was left to stir at room temperature overnight. LCMS showed no starting material remaining so the reaction mixture was concentrated in vacuo to give a black residue. The residue was disolved in ethyl acetate (500 mL) and washed 3 times with water (500 mL). The organic layer was washed with brine (500 mL) and dried over anhydrous magnesium sulfate before being evaporated in vacuo to give a residue (5.5 g). A 500 mg portion of the residue was dissolved in dichloromethane, loaded onto a 20g silica cartridge and purified by chromatography on Flashmaster Il using a 0-100% ethyl acetate-cyclohexane gradient over 30 min. Appropriate fractions were combined and the solvent was evaporated. The remaining residue was dissolved in dichloromethane and loaded onto two 100g silica cartridges and purified on Flashmaster Il using a 0-100% ethyl acetate-cyclohexane gradient over 60 min. Appropriate fractions were combined and the solvent was evaporated. The products from all three columns were combined to give the title compound (4.4 g, 65%) as a yellow solid. LCMS (System A) RT=1.08 min, ES+ve m/z 401 (M+H)".
Intermediate 60 1,1-Dimethylethyl [(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-5-fluoro-4- (methyloxy)-1H-indazol-1-yllmethyl}phenyl)methyl]carbamate
Cl - _— 0” 7
F Q oF = 1,1-Dimethylethyl [(3-{[3-amino-5-fluoro-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyllcarbamate (for a preparation see Intermediate 59)(3.4 g, 8.49 mmol) was dissolved in a mixture of dichloromethane (14 mL) and pyridine (21 mL) and the reaction was left to stir under nitrogen for 2 h. LCMS showed starting material remaining, so an extra portion of 5-chloro-2-thiophenesulfonyl chloride (0.461 g, 2.12 mmol) was added to the reaction mixture and stirred for 45 min. The reaction mixture was evaporated in vacuo and the residue was dissolved in ethyl acetate (250 mL) and washed with water (3 x 250 mL). The organic layer was washed once with brine (200mL) and dried over anhydrous magnesium sulfate before being evaporated in vacuo. The residue was dissolved in dichloromethane, loaded onto a 100g silica cartridge and purified by chromatography on Flashmaster Il using a 0-100% ethyl acetate-cyclohexane gradient over 80 min. Appropriate fractions were combined and the solvent was evaporated to give the title compound (2.7 g, 55%) as an orange solid. LCMS (System A) RT=1.27 min,
ES+ve m/z 581/583 (M+H)".
Intermediate 61
N-[1-{[3-(Aminomethyl)phenyllmethyl}-5-fluoro-4-(methyloxy)-1H-indazol-3-yl]-5- chloro-2-thiophenesulfonamide cl ay ¢ 0” H_d
F ! do
NN
1,1-Dimethylethyl [(3-{[3-{[(5-chloro-2-thienyl)sulfonyllamino}-5-fluoro-4-(methyloxy)-1H- indazol-1-yllmethyl}phenyl)methyl]carbamate (for a preparation see Intermediate 60) (2.7 g, 4.65 mmol) was dissolved in dichloromethane (20 mL). Trifluoroacetic acid (5.00 mL) was added to the reaction and stirred for 1 h. The reaction mixture was concentrated in vacuo to leave a purple residue. The residue was dissolved in methanol and loaded onto a methanol pre-conditioned SCX-2 ion-exchange cartridge (70 g). The cartridge was washed well with methanol, followed by HCI in methanol, then methanol and finally ammonia in methanol. Fractions were combined and evaporated in vacuo to give an off white solid, which was dissolved in DMSO, filtered and loaded onto a methanol pre- conditioned SCX-2 ion-exchange cartridge (70 g). The cartridge was washed well with
Methanol followed by 2M ammonia in methanol. Evaporation of the solvent from the ammoniacal fractions gave the title compound (1 g, 45%) as a white solid: LCMS (System
A) RT=0.84 min, ES+ve m/z 481/483 (M+H)".
Intermediate 62 3-Amino-1H-indazole-4-carbonitrile
CN NH,
Cp
N
3-Fluoro-1,2-benzenedicarbonitrile (APIN) (5 g, 34.2 mmol) was dissolved in ethanol (80 ml) and hydrazine monohydrate (4.98 mL, 103 mmol) was added to the solution. The reaction was heated at 70 °C overnight. The reaction mixture was concentrated in vacuo and the residue was partitioned between ethyl acetate (200 mL) and water (200 mL). The organic layer was washed with water (100 mL). The aqueous layers were extracted with ethyl acetate (200 mL). Organic layers were combined, dried over anhydrous magnesium sulfate and evaporated in vacuo to give the title compound (4.7 g, 87%) as a yellow solid.
LCMS (System A) RT=0.53 min, ES+ve m/z 159 (M+H)".
Intermediate 63 1,1-Dimethylethyl 3-amino-4-cyano-1H-indazole-1-carboxylate
N os
NH,
AY
/
N
=o 5
Di-tert-butyl dicarbonate (7.13 g, 32.7 mmol) in dichloromethane (150 mL) was added to a solution of 3-amino-1H-indazole-4-carbonitrile (for a preparation see Intermediate 62)(4.7 g, 29.7 mmol), 4-dimethylaminopyridine (0.726 g, 5.94 mmol) and triethylamine (8.28 mL, 59.4 mmol) in acetonitrile (150 mL) and stirred for 0.5 h under nitrogen. LCMS showed no starting material remaining so the reaction mixture was concentrated in vacuo to give a residue which was partitioned between DCM (250 mL) and water (250 mL). The organic layer was washed a further two times with water (250 mL) and once with brine (200 mL) before being dried over anhydrous magnesium sulfate and evaporated in vacuo to give the title compound (4.3 g, 56%) as a yellow solid. LCMS (System A): RT= 0.94 min,
ES+ve m/z 259 (M+H)".
Intermediate 64 1,1-Dimethylethyl 3-{bis[(5-chloro-2-thienyl)sulfonyl]amino}-4-cyano-1H-indazole-1- carboxylate cl ol —
N —
Ox
ANE
[ 0
AY
/
N
Jo 5 1,1-Dimethylethyl 3-amino-4-cyano-1H-indazole-1-carboxylate (for a preparation see
Intermediate 63)(4.3 g, 16.65 mmol) was dissolved in a mixture of dichloromethane (40 mL) and pyridine (40 mL). 5-Chloro-2-thiophenesulfonyl chloride (7.23 g, 33.3 mmol) was added to the solution and it was stirred at 45 °C under nitrogen for 60 h. LCMS showed approx 30% starting material remaining, so further quantity of 5-chloro-2- thiophenesulfonyl chloride (3.5 g, 16.12 mmol) was added to the reaction, and the mixture was stirred for 2 h. LCMS showed no change in product so the reaction was concentrated under vacuo. The residue was dissolved in DCM (200 mL) and washed 3 times with water (200 mL). The organic layer was dried over anhydrous magnesium sulfate and evaporated in vacuo. The residue (10 g) was dissolved in DCM and loaded onto a 750 g silica column and purified by chromatography on the Companion system using a 0-25% ethyl acetate-DCM gradient. Appropriate fractions were evaporated in vacuo to give the title compound (5.8 g, 56%) as an orange solid. LCMS (System A) RT=1.45 min, ES+ve m/z 636/638 (M+NH,)".
Intermediate 65 5-Chloro-N-[(5-chloro-2-thienyl)sulfonyl]-N-(4-cyano-1H-indazol-3-yl)-2- thiophenesulfonamide cl al — ope
N — [5&0 0
N
N
1,1-Dimethylethyl 3-{bis[(5-chloro-2-thienyl)sulfonyl]Jamino}-4-cyano-1H-indazole-1- carboxylate (for a preparation see Intermediate 64)(5.6 g, 9.04 mmol) was dissolved in a mixture of dichloromethane (44 mL) and trifluoroacetic acid (11 mL) and stirred for 40 min.
LCMS showed starting material remaining so the reaction was left to stir for a further 30 min. LCMS showed no starting material remaining so the mixture was evaporated in vacuo to give a cream soild (5.7 g). A portion of this solid (1 g) of was adsorbed onto florisil and loaded onto a 50g silica cartridge and purifed by chromatography on
Flashmaster Il using a 0-100% ethyl acetate cyclohexane gradient over 80 min.
Appropriate fractions were combined and evaporated to give the title compound (400 mg, 9%). The rest of the residue was dissolved in THF and loaded onto a 360g pre- condtioned C18 cartridge and purifed on a 50-99% acetonitrile-water gradient with an ammonium carbonate modifier. Appropriate fractions were combined and evaporated in vacuo to give the title compound (1.6 g, 34%) as a yellow solid. LCMS (System A)
RT=1.20 min, ES+ve m/z 536/538 (M+NH,)".
Intermediate 66 1,1-Dimethylethyl {[3-(hydroxymethyl)phenyllmethyl}carbamate
OH O
3-(Hydroxymethyl)benzonitrile (1 g, 7.51 mmol), Nickel (II) Chloride (0.973 g, 7.51 mmol) and di-fert-butyl dicarbonate (3.28 g, 15.02 mmol) were dissolved in a solution of methanol (48 mL) and THF (32 mL) and cooled to 0 °C in an ice-bath. Sodium borohydride (1.989 g, 52.6 mmol) was added portionwise and the mixture was stirred for 3 h. LCMS showed the reaction had gone to completion so the reaction mixture was evaporated in vacuo to leave a black residue. The residue was partitioned between ethyl acetate (100 mL) and water (100 mL). The aqueous layer was washed a further two times with ethyl acetate (100 mL). The combined organic solutions were washed with brine (100 mL) and dried over anhydrous magnesium sulfate before being evaporated in vacuo. The residue was dissolved in dichloromethane, loaded onto a 100 g silica cartridge and purified by chromatography on Flashmaster Il using a 0-100% ethyl acetate- cyclohexane gradient over 80 min. Appropriate fractions were combined and the solvent was evaporated to give the title compound (1.248 g, 70%) as a colourless oil.
LCMS (System A) RT=0.82 min.
Intermediate 67 1,1-Dimethylethyl ({3-[(3-{bis[(5-chloro-2-thienyl)sulfonyl]amino}-4-cyano-1H- indazol-1-yl)methyl]phenyl}methyl)carbamate
Cl cl = los £0 © Qo
SET ak
N
; - 5-Chloro-N-[(5-chloro-2-thienyl)sulfonyl]-N-(4-cyano-1H-indazol-3-yl)-2- thiophenesulfonamide (for a preparation see Intermediate 65) (1.1 g, 2.118 mmol),
triphenylphosphine (1.111 g, 4.24 mmol) and 1,1-dimethylethyl ~~ {[3- (hydroxymethyl)phenylmethyl}carbamate (for a preparation see Intermediate 66) (1.005 g, 4.24 mmol) were suspended in tetrahydrofuran (10 mL) and treated with DIAD (0.824 mL, 4.24 mmol). The reaction mixture became homogeneous and was stirred at 60 °C for 1 h. LCMS showed no starting material remaining so the solution was concentrated in vacuo, and the residue was partitioned between ethyl acetate (100 mL) and water (100 mL). The organic layer was washed two further times with water (100 mL) and once with brine (100 mL) before being dried over anhydrous magnesium sulfate and evaporaed in vacuo to give a yellow oil (4 g). The residue was dissolved in DCM and loaded onto two 100g silica cartridges and purified by chromatography on Flashmaster Il using a 0-100% ethyl acetate-cyclohexane gradient over 80 min. Appropriate fractions were combined and the solvent was evaporated to give the title compound (1.5 g, 96%) as a yellow oil.
LCMS (System A) RT=1.48 min, ES+ve m/z 755/757 (M+NH,)".
Intermediate 68 1,1-Dimethylethyl ({3-[(3-{bis[(5-chloro-2-thienyl)sulfonyl]Jamino}-4-formyl-1H- indazol-1-yl)methyl]phenyl}methyl)carbamate cl _ ol po le —
On a © 0
A J
= 1,1-Dimethylethyl ({3-[(3-{bis[(5-chloro-2-thienyl)sulfonyllamino}-4-cyano-1H-indazol-1- yl)methyl]phenylimethyl)carbamate (for a preparation see Intermediate 67) (1.5 g, 2.031 mmol) was dissolved in toluene (5 mL) and cooled to -10 °C. DIBAL-H (4.06 mL, 6.09 mmol) was added over 1 h, monitoring the temperature and keeping it under 0 °C. The reaction was stirred for 75 min, and then more DIBAL-H (1.354 mL, 2.031 mmol) was added dropwise, and the reaction mixture was stirred overnight. LCMS showed some starting material remaining so the reaction was cooled to -10 °C and DIBAL-H (0.677 mL, 1.015 mmol) was added dropwise and the reaction was stirred for 90 min. LCMS showed only 5% starting material remaining so the reaction was quenched with methanol, acidified to pH3 with 5M HCI and neutralised with 2M NaOH. The mixture was extracted with ethyl acetate (100 mL). The organic layer was washed 3 times with water (100 mL) and once with brine (100 mL), before being dried over anhydrous magnesium sulfate and evaporated in vacuo to give a yellow foam (1.4 g). A portion of this (200 mg) was dissolved in DCM and loaded onto a 50 g silica cartridge and purified by chromatography on Flashmaster Il using a 0-100% ethyl acetate-cyclohexane gradient over 60 min. The sample degraded on the silica and the rest of the product was used in the next step without any further purification.
Intermediate 69 1,1-Dimethylethyl [(3-{[3-{bis[(5-chloro-2-thienyl)sulfonyl]amino}-4-(difluoromethyl)- 1H-indazol-1-yllmethyl}phenyl)methyl]carbamate
Cl _ cl
F F570 Co 0 N—Sg oO orn 1,1-Dimethylethyl ({3-[(3-{bis[(5-chloro-2-thienyl)sulfonyllJamino}-4-formyl-1H-indazol-1- yl)methyl]phenyl}methyl)carbamate (for a preparation see Intermediate 68) (400 mg, 0.539 mmol) was dissolved in dichloromethane (6 mL). (Diethylamino)sulfur trifluoride (DAST) (Aldrich) (0.107 mL, 0.809 mmol) was added to the solution and it was stirred for 5 h. Furthe portion of DAST (0.071 mL, 0.539 mmol) was added to the reaction mixture and stirred overnight. The reaction mixture was treated with water (2 mL) and stirred 15 min. The reaction mixture was diluted with DCM (50 mL), washed three times with water (50 mL) and once with brine (50 mL) before being dried over anhydrous magnesium sulfate and evaporated in vacuo. The residue (200 mg) was dissolved in dichloromethane, loaded onto a 50 g silica cartridge and purified by chromatography on
Flashmaster Il using a 0-100% ethyl acetate-cyclohexane gradient over 80 min.
Appropriate fractions were combined and the solvent was evaporated to give the title compound (60 mg, 15%) as a yellow solid. LCMS (System A) RT=1.48 min, ES+ve m/z 780/782/784 (M+NH,)".
Intermediate 70
N-[1-{[3-(Aminomethyl)phenyllmethyl}-4-(difluoromethyl)-1H-indazol-3-yl]-5-chloro-
N-[(5-chloro-2-thienyl)sulfonyl]-2-thiophenesulfonamide
Cl ol —— se Ss 0 — >s [ 0
Ny /
N
1,1-Dimethylethyl [(3-{[3-{bis[(5-chloro-2-thienyl)sulfonyl]Jamino}-4-(difluoromethyl)-1H- indazol-1-yllmethyl}phenyl)methyljcarbamate (for a preparation see Intermediate 69) (60 mg, 0.079 mmol) was dissolved in dichloromethane (0.5 mL) and trifluoroacetic acid (0.125 mL) was added to the solution. and stirred for 1 h under nitrogen. The solution was concentrated under a stream of nitrogen and the off-white residue was dissolved in methanol and loaded onto a methanol conditioned sulphonic acid (SCX-2) cartridge (10 g)- The cartridge was washed well with methanol, followed by 2M ammonia in methanol.
Evaporation of the solvent from the ammoniacal fractions gave the title compound (26 mg, 54%) as a white solid. LCMS (System A) RT=1.11 min, ES+ve m/z 663/665 (M+H)".
Intermediate 71 1,1-Dimethylethyl [(3-{[3-{bis[(5-chloro-2-thienyl)sulfonyl]amino}-4-(hydroxymethyl)- 1H-indazol-1-yllmethyl}phenyl)methyl]carbamate
Cl cl — ho =
Ox =
HO N°
Oo
NN
/
N O
Orv
H
1,1-Dimethylethyl ({3-[(3-{bis[(5-chloro-2-thienyl)sulfonyllJamino}-4-formyl-1H-indazol-1- yDmethyllphenylimethyl)carbamate (for a preparation see Intermediate 68)(400 mg, 0.539 mmol) was dissolved in methanol (3 mL) and sodium borohydride (30.6 mg, 0.809 mmol) was added portionwise to the solution and the reaction mixture was stirred under nitrogen at room temperature for 3 h. The reaction mixture was concentrated under vacuo and partitioned between ethyl acetate (50 mL) and water (50 mL). The organic layer was washed 2 times with water (50 mL) and once with brine (50 mL) before being dried over anhydrous magnesium sulfate and evaporated in vacuo. The residue was dissolved in dichloromethane, loaded onto a 50g silica cartridge and purified by chromatography on
Flashmaster II using a 0-100% ethyl acetate-cyclohexane gradient over 80 min.
Appropriate fractions were combined and the solvent was evaporated to give the title compound (67 mg, 17%) as an off-white gum. LCMS (System A) RT=1.35 min, ES+ve m/z 743/745 (M+H)".
Intermediate 72 N-[1-{[3-(Aminomethyl)phenyl]methyl}-4-(hydroxymethyl)-1H-indazol-3-yl]-5-chloro-
N-[(5-chloro-2-thienyl)sulfonyl]-2-thiophenesulfonamide cl _ cl —
HO TNL
N
0 or 1,1-Dimethylethyl [(3-{[3-{bis[(5-chloro-2-thienyl)sulfonyllamino}-4-(hydroxymethyl)-1H- indazol-1-yllmethyl}phenyl)methyl]jcarbamate (for a preparation see Intermediate 71)(93 mg, 0.125 mmol) was dissolved in dichloromethane (0.5 mL), trifluoroacetic acid (0.125 mL) was added to the solution and stirred for 1 h under nitrogen. The reaction mixture was concentrated under a stream of nitrogen and the residue was dissolved in methanol and loaded onto a methanol pre-conditioned sulphonic acid (SCX-2) cartridge (10 g). The cartridge was washed well with methanol, followed by 2M ammonia in methanol.
Evaporation of the solvent from the ammoniacal fractions gave the title compound (53 mg, 66%) as a white solid. LCMS (System A) RT=0.89 min, ES+ve m/z 643/645 (M+H)".
Intermediate 73 1,1-Dimethylethyl ({3-[(3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-cyano-1H-indazol-1- yl)methyl]phenyl}methyl)carbamate (
cl -
S
N —
Hs” 0
Ny /
N 0
Ory
H
2M Sodium hydroxide (54.8 mL, 40.6 mmol) was added to 1,1-dimethylethyl ({3-[(3- {bis[(5-chloro-2-thienyl)sulfonyllJamino}-4-cyano-1H-indazol-1- yhmethyl]phenylmethyl)carbamate (for a preparation see Intermediate 68)(5.4 g, 7.3 mmol) dissolved in methanol (100 mL) and THF (20 mL) and the reaction was stirred at 45 °C for 1 h. The solvents were evaporated in vacuo and the product was extracted with
EtOAc (300 mL x 2). The combined organic layers were washed with 1M HCI (150 mL), brine (100 mL), dried by passing through a hydrophobic frit, and concentrated to afford the crude title compound as a white solid. LCMS (System A) RT = 1.17 min, ES+ve m/z 558/560 (M+H)".
Intermediate 74
N-({3-[(3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-cyano-1H-indazol-1- yl)methyl]phenyl}methyl)acetamide cl -
Ss
N —_
HZ” o
AY
/
N 0 ye
H
TFA (1 mL) was added to 1,1-dimethylethyl ({3-[(3-{[(5-chloro-2-thienyl)sulfonyllamino}-4- cyano-1H-indazol-1-yl)methyllphenyl}methyl)carbamate (for a preparation see
Intermediate 73)(630 mg, 1.13 mmol) in DCM (4 mL) and the reaction was stirred at room temperature for 30 min. LCMS showed the boc group was removed and the reaction mixture was concentrated. The residue was dissolved in DCM (7 mL), triethylamine (1.573 mL, 11.29 mmol) and acetic anhydride (0.128 mL, 1.355 mmol) were added, and the reaction mixture was stirred for 30 min. The reaction was treated with water (10 mL) and the product was extracted with DCM (2 x 30 mL). The combined organic layers were dried by passing through a hydrophobic frit and concentrated to affford the crude product as a yellow oil (0.57 g). The residue was purified by chromatography on Flashmaster (silica 20 g cartridge), eluting with a gradient 25-100% EtOAc in DCM, followed by 0-30%
MeOH in DCM) and the appropiate fractions were combined and concentrated to afford the title compound as a white solid (44 mg, 7%). Other fractions from the column were combined and concentrated to afford a yellow oil, (0.25 g), which was dissolved in MeOH (5 mL), potassium carbonate (300 mg) was added and the mixture was stirred at room temp for 30 min. LCMS showed one of the two acetyl groups was cleaved to afford more of the desired product. The mixture was concentrated and acidified with 2N HCI. The product was extracted with EtOAc (3 x 15 mL) and the combined organic layers were washed with saturated brine (5 mL), dried using a hydrophobic frit and evaporated in vacuo to give the crude product as a brown oil. The residue was dissolved in DMSO (1 mL) and purified by Mass Directed AutoPrep on Sunfire C18 column using Acetonitrile
Water with a Formic acid modifier (Method A). The solvent was evaporated in vacuo to give the title compound (70 mg, 12%). LCMS (System A) RT = 0.92 min, ES+ve m/z 500/502 (M+H)".
Intermediate 75
N-({3-[(4-Acetyl-3-{[(5-chloro-2-thienyl)sulfonylJamino}-1H-indazol-1- yl)methyl]phenyl}methyl)acetamide cl
ES
¢ 0 (2° o ore
Methylmagnesium bromide (3M solution in diethyl ether) (0.176 mL, 0.528 mmol) was added slowly to a stirring solution of N-({3-[(3-{[(5-chloro-2-thienyl)sulfonyllamino}-4- cyano-1H-indazol-1-yl)methyllphenyl}methyl)acetamide (for a preparation see
Intermediate 74)(44 mg, 0.088 mmol) in tetrahydrofuran (1 mL) at room temp. The reaction was stirred for 2 hours. LCMS showed starting material still remaining, so more methylmagnesium bromide (3M solution in diethyl ether) (0.176 mL, 0.528 mmol) was added and stirred at room temp. overnight. LCMS showed no more starting material remaining. The reaction mixture was cooled to 0°C, 0.5M HCI (4 mL) was added and the product was extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine, dried by passing through a hydrophobic frit, and concentrated in vacuo to give the title compound as a yellow oil. LCMS (System A) RT = 1.03 min, ES+ve m/z 517/519 (M+H)".
Intermediate 76 1,1-Dimethylethyl ({3-[(4-acetyl-3-{[(5-chloro-2-thienyl)sulfonyl]amino}-1H-indazol-1- yl)methyl]phenyl}methyl)carbamate cl = 5 0 8 ¢g° 0
N N
N 0
Methylmagnesium bromide (3M solution in diethyl ether) (1.792 mL, 5.38 mmol) was added dropwise to a stirring solution of 1,1-dimethylethyl ({3-[(3-{[(5-chloro-2- thienyl)sulfonyl]Jamino}-4-cyano-1H-indazol-1-yl)methyl]phenyl}methyl)carbamate (for a preparation see Intermediate 73)(1 g, 1.792 mmol) in tetrahydrofuran (8 mL) at 0 °C. The reaction was slowly warmed to room temp. and stirred for 1 h. More methylmagnesium bromide (3M solution in diethyl ether) (0.896 mL, 2.69 mmol) was added and stirred for a further 1 hours. LCMS showed starting material still remaining. The reaction mixture was cooled again and more methylmagnesium bromide (3M solution in diethyl ether) (1.792 mL, 5.38 mmol) was added and stirred for a further 1 h. The reaction mixture was cooled to 0 °C and 0.5 N HCI (20 mL) was slowly added. The product was extracted with EtOAc (100 mL x 3) and the combined organic layers were washed with brine, dried by passing through a hydrophobic frit and concentrated in vacuo. The residue (1.07g) was loaded in dichloromethane to a silica 100g cartridge and purified by chromatography using a 0-25% ethyl acetate-dichloromethane over 40 min. The appropriate fractions were combined and evaporated in vacuo to give the title compound (550 mg, 53%) as a yellow solid. LCMS
(System A) RT=1.27 min, ES+ve m/z 575/577 (M+H)".
Intermediate 77
N-[1-{[3-(Aminomethyl)phenyl]methyl}-4-(1-hydroxyethyl)-1H-indazol-3-yl]-5-chloro- 2-thiophenesulfonamide cl -
S
—_
HO
X eC” 0
Ny /
N
Oy
Sodium borohydride (20.52 mg, 0.543 mmol) was added to a stirring solution of 1,1- dimethylethyl ({3-[(4-acetyl-3-{[(5-chloro-2-thienyl)sulfonyllJamino}-1H-indazol-1- yhmethyllphenyllmethyl)carbamate (for a preparation see Intermediate 75)(260 mg, 0.452 mmol) in MeOH (5 mL) at 25 °C under No. The reaction mixture was stirred at room temp for 2 h. About~2/3 of the methanol was evaporated in vacuo and the residue was treated slowly with 1M HCI (5 mL). The product was extracted with EtOAc (2 x 40 mL) and the combined organic layers were dried by pasing through a hydrophobic frit and concentrated to afford a yellow oil. 4N HCI in Dioxane (2 mL, 8.00 mmol) was added to the residue at 25 °C and the reaction mixture was stired for 30 min. The crude sample was loaded straight on to a pre-washed (MeOH) SPE sulphonic acid (SCX-2) cartridge (20 g). The SCX cartridge was was washed with 2 column volumes of MeOH and the product was collected by washing with 3 column volumes of 2N Ammonia in MeOH. The apropriate fractions were combined and evaporated in vacuo to give the title compound (235mg, 91)%. LCMS (System A) RT=0.77 min, ES+ve m/z 477/479 (M+H)".
Intermediate 78
N-[1-{[3-(Aminomethyl)phenyllmethyl}-4-(1-hydroxy-1-methylethyl)-1H-indazol-3-yl]- 5-chloro-2-thiophenesulfonamide cl ~~ ¢
OH y [20
NS
J or
Methylmagnesium bromide (3M solution in diethyl ether) (0.730 mL, 2.191 mmol) was added slowly dropwise to a stirring solution of 1,1-dimethylethyl ({3-[(4-acetyl-3-{[(5- chloro-2-thienyl)sulfonyllamino}-1H-indazol-1-yl)methyl]phenylimethyl)carbamate (for a preparation see Intermediate 76)(210 mg, 0.365 mmol) in THF (3 mL) at room temp. The reaction was stirred for 2 h and then more methylmagnesium bromide (3M solution in diethyl ether) (0.730 mL, 2.191 mmol) was added and stirred overnight. LCMS indicated molecular ion 592 [M+1] corresponding to the desired alcohol and that the starting material co-eluted with the product. 1N HCI (5 mL) was added and the product was extracted with EtOAc (15 mL x 3). The combined organic layers were dried by passing through a hydrophobic frit and concentrated in vacuo. The residue was dissolved in 4N
HCI in Dioxane (2 mL, 8.00 mmol) and the reaction was stirrred at room temp over 1 h.
The reaction mixture was loaded on an SCX-2 ion-exchange 20g cartridge eluting with methanol and 2M ammonia in methanol. The appropriate ammoniacal fractions were combined and evaporated in vacuo to give the title compound (168 mg, 76%) as a brown oil. LCMS (System A) RT=0.79 min, ES+ve m/z 491/493 (M+H)".
Intermediate 79 4-{[3-[[(5-Chloro-2-thienyl)sulfonyl]({[2-(trimethylsilyl)ethyl]oxy}methyl)amino]-4- (methyloxy)-1H-indazol-1-yllmethyl}-N,N-dimethylbenzamide
J
4 ~~ \ 4 S 0 a
A solution of 5-chloro-N-[4-(methyloxy)-1H-indazol-3-yl]-N-({[2- (trimethylsilyl)ethyl]Joxy}methyl)-2-thiophenesulfonamide (Intermediate 8) (150 mg, 0.32 mmol) was treated with 4-(chloromethyl)-N,N-diethylbenzamide (86 mg, 0.38 mmol) and potassium hydroxide (21.3 mg, 0.38 mmol), and the mixture was heated to 50 °C overnight. Reaction mixture was partitioned between DCM (3 mL) and water (3 mL). The organic phase was separated and the aqueous layer was further extracted with 2 mL of
DCM. The combined organic solutions were dried (hydrophobic frit) and concentrated under a nitrogen stream in a blowdown unit. The residue was purified by chromatography using a Flash Master system (Solo machine), on a 50 g silica cartridge, eluting with 0 to 100% Ain B, A being a 20% EtOAC in DCM solution and B being neat DCM over 60 min.
Evaporation of the appropriate fractions gave the title compound (125 mg, 60%) LCMS (System A) RT=1.52 min, ES+ve m/z 680/682(M+NH,)".
Intermediate 80 1-{[3-Fluoro-4-(methyloxy)phenyllmethyl}-4-(methyloxy)-1H-indazol-3-amine
N
? NH, —0 y 4-(Methyloxy)-1H-indazol-3-amine (for a preparation see Intermediate 1) (490 mg, 3 mmol) and potassium hydroxide (185 mg, 3.30 mmol) were dissolved in DMSO (30 mL).
The reation was left to stir for 30 min, before 4-(bromomethyl)-2-fluoro-1- (methyloxy)benzene (657 mg, 3.00 mmol) was added to the reaction mixture and stirred for 1h at room temperature under nitrogen. The reaction mixture was diluted with ethyl acetate (250 mL) and washed with water (2 x 250 mL) and brine (250 mL). The organic layer was dried over anhydrous magnesium sulphate and filtered before being evaporated in vacuo to afford a brown oil. The residue was loaded in dichloromethane on a silica 100g cartridge and purified by chromatography on Flashmaster using a 0-100% ethyl acetate-dichloromethane over 40 min. The appropriate fractions were combined and evaporated in vacuo and the residue re-purified by chromatography on silica 70g using a 0-50% ethyl acetate-dichloromethane over 40 min. The appropriate fractions were combined and evaporated in vacuo to give the title compound (432 mg, 48%) as an off- white solid. LCMS (System A) RT = 0.96 min, ES+ve m/z 302 (M+H)".
Example 1
N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]acetamide cl 0” 2.8 0
Cy
N
J
7
To N-[1-{[3-(aminomethyl)phenyllmethyl}-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide hydrochloride (for a preparation see Intermediate 4) (700 mg, 1.40 mmol) was added triethylamine (0.583 mL, 4.20 mmol) and DCM (3 mL) to give a suspension. Acetic anhydride (0.146 mL, 1.54 mmol) was added dropwise at room temperature and the resulting mixture was stirred at ambient temperature for 2 h. LCMS showed completion of the reaction. The reaction mixture was diluted with DCM (20 mL) and a saturated solution of NaHCO; in water (20 mL). The organic solution was separated and the aqueous layer was further extracted with DCM (20 mL). Organic solutions were combined, washed with brine (20 mL), dried through an hydrophobic frit and concentrated under reduced pressure. The residue was loaded in 1:1 MeOH-DMSO and purified on reverse phase (C18) silica (330 g) using a gradient of 5% to 80 % MeCN (+ 0.1% of NEt;) in water (pH=10 with ammonium bicarbonate) over 14 column lengths.
The appropriate fractions were combined and evaporated in vacuo to give the title compound (570 mg, 81%) as a white solid. LCMS (System A) RT=1.01 min, ES+ve m/z 505/507 (M+H)".
Examples 2 - 4 were prepared in a similar way from N-[1-{3- (aminomethyl)phenyllmethyl}-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide hydrochloride and the appropriate carboxylic anhydride:
Example 2
N-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]propanamide 0, 0 0” RY
S
Cr Ue
N
9 Ys
N
H
LCMS (System A) RT=1.07 min, ES+ve m/z 519/521 (M+H)".
Example 3
N-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-methylpropanamide 0” ne ]
Crp ©
N
3 '
H
LCMS (System A) RT=1.13 min, ES+ve m/z 533/535 (M+H)".
Example 4
N-[(3{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2,2-dimethylpropanamide
0” 1
Ao
N ZC
N
Gy
FC
LCMS (System A) RT=1.19 min, ES+ve m/z 547/549 (M+H)".
Example 5 5-Chloro-N-[1-({3-[(formylamino)methyl]phenyl}methyl)-4-(methyloxy)-1H-indazol-3- yl]-2-thiophenesulfonamide o” no
Ho
ON 2 cl
N
Gs
N
To a solution of formic acid (5 pL, 0.13 mmol) in dry DMF (0.3 mL) was added TBTU (34.7 mg, 0.108 mmol) followed with triethylamine (50.2 pl, 0.360 mmol). This mixture was stired at room temperature for about 10 min before adding N-[1-{[3- (aminomethyl)phenyllmethyl}-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide hydrochloride (for a preparation see Intermediate 4) (45 mg, 0.09 mmol). The resultant pale yellow mixture was stirred at room temperature overnight.
LCMS showed very little reaction, so more acid (~0.25 mL), followed with TBTU (~30 mg) were added. This addition was repeated 3 more times over 20 h until by LCMS analysis, there was more product than SM. The reaction mixture was partitioned between ethylacetate (2 mL) and saturated sodium bicarbonate solution (2 mL). The aqueous was extracted with ethyl acetate (x2). The combined organic solutions were washed with water, brine, dried (Na,SO,) and concentrated in vacuo to leave a pale oil which crystallised on standing. This was dissolved in 1:1 MeOH:DMSO (1 mL) and purified by
Mass Directed AutoPrep on supelcosil ABZ+Plus column eluting with a gradient of MeCN-
Water (95:5 + 0.05% Formic acid) - Water (+ 0.1% Formic acid).. The solvent was evaporated in vacuo to give the title compound (15.9 mg, 36%) as a pale yellow powder:
LCMS (System A) RT=1.02 min, ES+ve m/z 491/493 (M+H)".
Example 6
N-[(3{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-3-morpholinecarboxamide trifluoroacetate
Cl os
J
7 ’ i
A solution of 3-morpholinecarboxylic acid (121 mg, 0.523 mmol) in acetonitrile (10 mL) was treated with HATU (199 mg, 0.523 mmol) and then DIPEA (0.248 mL, 1.426 mmol).
The resulting mixture was stirred for 15 min at ambient temperature and then was treated with N-[1-{[3-(aminomethyl)phenyllmethyl}-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide hydrochloride (for a preparation see Intermediate 4) (220 mg, 0.475 mmol). Tthe resulting mixture was stirred at ambient temperature over night. The reaction mixture was diluted with DCM (20 mL) and water (30 mL). The organic phase was separated and the aqueous layer was further extracted with DCM (20 mL). The combined organic solutions were washed with water (20 mL), brine (20 mL), dried through an hydrophobic frit, and concentrated under reduced pressure. The residue was dissolved in DCM (10 mL) and to this was added Hydrogen Chloride (0.6 mL, 2.4 mmol) and the resulting solution was stirred at rt 3 h. LCMS indicated a mixture of product and
Starting Material (1:1). More Hydrogen Chloride (0.6 ml, 2.4 mmol) was added to the mixture and after 3 h of stirring at ambient temperature, LCMS showed complete reaction.
The reaction mixture was concentrated under reduced pressure, the residue was treated and co-evaporate twice with DCM (20 mL). The samples were dissolved in 1:1
MeOH:DMSO (1 mL) (x 4) and purified by Mass Directed AutoPrep on standard C18 column using Acetonitrile-Water with a TFA modifier. The solvent was evaporated in vacuo to give the title product as TFA salt (244.5 mg, 75%). LCMS (System E) RT=2.18 min, ES+ve m/z 576/578 (M+H)".
Examples 7 — 16 were similarly prepared from N-[1-{[3-(aminomethyl)phenyl]methyl}-4- (methyloxy)-1H-indazol-3-yl]-5-chloro-2-thiophenesulfonamide hydrochloride and the appropriate carboxylic acid, followed by HCI deprotection .
Example 7 (3R)-N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-3-morpholinecarboxamide hydrochloride 0, 7
Cr Cl
N
!
AN
HN
—- CH
LCMS (System D) RT=0.92 min, ES+ve m/z 576/578 (M+H)".
Example 8 (3S)-N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-3-morpholinecarboxamide hydrochloride o,f
No an Ns
Cr Di
N a 0% So
S$
CH
LCMS (System D) RT=0.92 min, ES+ve m/z 576/578 (M+H)".
Example 9 (2R)-N-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-piperidinecarboxamide trifluoroacetate salt o 9 ~ H N I 0 ~S
N S
NL )—q
N
NH F oO 2) % F OH
H
LCMS (System E) RT=2.13 min, ES+ve m/z 574/576 (M+H)".
Example 10 N'-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-N*-methyl-D-alaninamide hydrochloride o 0 iS
Cr
N
H
\ CH 7
NH
LCMS (System F) RT=0.80 min, ES+ve m/z 548/550 (M+H)".
Example 11 3-Amino-N-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2,2-dimethylpropanamide hydrochloride 0, ~o in s ory B-
N
X
H,N
LCMS (System C) RT=0.81 min, ES+ve m/z 562/564 (M+H)".
Example 12
N'-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]Jamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-N*-methylglycinamide hydrochloride of
L170
Cry
N
NH
A
ANH cH
LCMS (System C) RT=0.78 min, ES+ve m/z 534/536 (M+H)".
Example 13
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-methyl-D-prolinamide o,f 110
Cry 2
N
NH
NH
LCMS (System C) RT=2.21 min, ES+ve m/z 574/576 (M+H)".
Example 14
N-[(3{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-methyl-2-piperidinecarboxamide of >So TS
Cr cl
N
/ 0
LCMS (System F) RT=0.87 min, ES+ve m/z 588/590 (M+H)".
Example 15 N-(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-1-(methylamino)cyclopropanecarboxamide hydrochloride 0, P
X10
Cr Cl
N y
N lS
NT CH
H
LCMS (System D) RT=0.94 min, ES+ve m/z 560/562 (M+H)".
Example 16
N-[(3{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-piperazinecarboxamide hydrochloride
SN i
So aN s ob
N
0 H
N
N wT)
N
H
LCMS (System C) RT=0.76 min, ES+ve m/z 575/577 (M+H)".
Examples 17 — 28
Generic method for the acylation of N-[1-{[3-(aminomethyl)phenyl]methyl}-4-(methyloxy)- 1H-indazol-3-yl]-5-chloro-2-thiophenesulfonamide in array format using HATU and HCI removal of Boc protecting group:
HATU (190 mg, 0.500 mmol) dissolved in DMF (2 mL) and aliquot dispensed (0.2 ml, 0.05 mmole) to each acid monomer (pre-weighed 0.049 mmol). DIPEA (20 «L, 3 eq) was added to each acid, capped and shaken to aid dispersion. N-[1-{[3- (aminomethyl)phenyllmethyl}-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide (255 mg, 0.551 mmol) was dissolved in DMF (2 mL) and aliquot dispensed (0.2 mL, 0.044 mmol) and added to each acid well. The reaction mixtures were shaken and stood at room temperature for 72 h (over weekend for convenience). 4N HCI in dioxane (100 zL) was added to each well, shaken and stood at room temperature for 24 h. LCMS indicated incomplete reaction, therefore DMF was removed by a nitrogen stream (Radley's blowdown unit) to almost dryness, and added more 4N
HCI in dioxane solution (500 L) and stood at room temperature for a further 18 h. To the residues was added DMSO (0.5 mL) and the solutions were purified by Mass Directed
AutoPrep on Sunfire C18 column using Acetonitrile Water with a TFA modifier. The solvent was removed under a stream of nitrogen in the Radleys blowdown apparatus to give the required products.
Example 17
N'[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]Jamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-N*-methyl-L-alaninamide trifluoroacetate
Q
~ 4 \ ? i
N
{ / Fo
H Ton
J
© i” /
LCMS (System A) RT=0.83 min, ES+ve m/z 548/550 (M+H)".
Example 18
N'-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]Jamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-L-alaninamide trifluoroacetate oO ~~ \ J \ ? La
N Fo
H bv
LCMS (System A) RT=0.82 min, ES+ve m/z 534/536 (M+H)".
Example 19
N'-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]Jamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-D-alaninamide trifluoroacetate 0
So i Ld
NTR ss” Tal 0 oo
N F
0
F
© FE OH
H
—( © NH, LCMS (System A) RT=0.82 min, ES+ve m/z 534/536 (M+H)".
Example 20
N'-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]Jamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]lglycinamide trifluoroacetate he! H IE
N"W “s7 cl 0 oo /
N Fo
F—~4 © F OH
H
N
I
NH,
LCMS (System A) RT=0.81 min, ES+ve m/z 520/522 (M+H)".
Example 21
N-[(3{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]propanediamide >So H EN
N"% s7 cl
O
N
H g
Sy 5 NH,
LCMS (System A) RT=0.93 min, ES+ve m/z 548/550 (M+H)".
Example 22 N[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-N'-methyl-L-aspartamide trifluoroacetate 0 ~o RE
Ww Ss Cl
O
N
H g ov
Fo
H,N \ ~ F< : F OH
LCMS (System A) RT=0.79 min, ES+ve m/z 591/593 (M+H)".
Example 23
Methyl N*-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]asparaginate trifluoroacetate
0 ~ n/N
Q RE
Cry
N
H g
SY p Fo wt
O— F OH
LCMS (System A) RT=0.82 min, ES+ve m/z 592/594 (M+H)".
Example 24 N-(3-[3-{[(5-chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-(2-pyrrolidinyl)acetamide trifluoroacetate
So H ES
NTH eT a
O
Cr /
N
Fo
F
© +,
H
N
0
NH
LCMS (System A) RT=0.82 min, ES+ve m/z 574/576 (M+H)".
Example 25 3-Amino-N-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]butanamide trifluoroacetate
~ a
NTR Ts” Ta o
N
H g
NH, el
Fo
LCMS (System A) RT=0.81 min, ES+ve m/z 548/550 (M+H)".
Example 26 3-Amino-N-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-methylpropanamide trifluoroacetate o ~ bl EN 0 NH Ns” al 0
N
H g 7
NH, Fo
Fon
LCMS (System A) RT=0.81 min, ES+ve m/z 548/550 (M+H)".
Example 27
N-[(3{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-methyl-L-prolinamide trifluoroacetate 0
So dN
Y S Cl
N g
N HN
Pag) Fo s F—<
F OH
LCMS (System A) RT=0.84 min, ES+ve m/z 574/576 (M+H)".
Example 28 (4S)-N-[(3-{[3-{[(5-chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-4-fluoro-L-prolinamide trifluoroacetate 0 ~o REY
Ws Cl o
N
H g H
N
Fed
F OH
LCMS (System A) RT=0.82 min, ES+ve m/z 578/580 (M+H)".
Example 29 N'-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-N*-methyl-p-alaninamide trifluoroacetate 0 ~o H Ld)
NTR s7 Tc 0
Crs /
N
H g 2
N F oO \ FH
LCMS (System A) RT=0.81 min, ES+ve m/z 548/550 (M+H)".
Examples 30 - 43 were prepared in array format from N-[1-{3- (aminomethyl)phenyllmethyl}-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide hydrochloride, HATU and the appropriate carboxylic acid as above, but required no deprotection therefore they were not treated with HCI before purification:
Example 30
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-(methyloxy)acetamide 0 >So H Ld)
N"X “sa 0
N g > © O—
LCMS (System A) RT=1.05 min, ES+ve m/z 535/537 (M+H)".
Example 31
N'-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-N? N>-dimethylalaninamide trifluoroacetate 0
So REN
N Ss Cl
N g
N
7 Fo / F——~
Fo OH
LCMS (System A) RT=0.83 min, ES+ve m/z 562/564 (M+H)".
Example 32
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-hydroxyacetamide
So H 14
N"T “s” Tcl 0
N g — © OH
LCMS (System E) RT=2.50 min, ES+ve m/z 521/523 (M+H)".
Example 33 N-(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-1H-pyrazole-4-carboxamide 0 >So 4d
W'S Cl 0
N
H g
SN
CL.
LCMS (System E) RT=2.53 min, ES+ve m/z 557/559 (M+H)".
Example 34
N'-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-N? N? 2-trimethylalaninamide trifluoroacetate 0 ve H LN
N"Y s7 Ta 0
N
Fo
F——4
H F OH
N
/ oO \
LCMS (System E) RT=1.83 min, ES+ve m/z 576/578 (M+H)".
Example 35
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]tetrahydro-3-furancarboxamide 0 ~o H td N
NY “s7 cl 0
N
H g 0 0
LCMS (System E) RT=2.69 min, ES+ve m/z 561/563 (M+H)".
Example 36
N'-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-N*-methyl-N?-[2-(methyloxy)ethyl]glycinamide trifluoroacetate 0 ~ n/N ? i
N
Fo
H —<
N F OH
I
/ \ \
LCMS (System E) RT=1.87 min, ES+ve m/z 592/594 (M+H)".
Example 37
N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-hydroxypropanamide
0
So N Ld)
N"Y% “s7 al 0
N
H
( © OH
LCMS (System E) RT=2.57 min, ES+ve m/z 535/537 (M+H)".
Example 38 N-(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-1,3-oxazole-5-carboxamide
So H 14
NW s7 Ta 0
N g \ 0 7
LCMS (System E) RT=2.59 min, ES+ve m/z 558/560 (M+H)".
Example 39
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-1-methyl-L-prolinamide trifluoroacetate of ~o Te
N
NH
Oo F oO
LCMS (System D) RT=0.94 min, ES+ve m/z 574/576 (M+H)".
Example 40
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-1-methyl-D-prolinamide trifluoroacetate of ~o Te
Crd Cl
N
\" “Ng Fo
Ch and
LCMS (System D) RT=0.95 min, ES+ve m/z 574/576 (M+H)".
Example 41
N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-3-furancarboxamide
IN RP
Cr cl
N
1
H —
LCMS (System A) RT=1.13 min, ES+ve m/z 556/558 (M+H)".
Example 42
N-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-1-methyl-2-piperidinecarboxamide trifluoroacetate o,f
Crs ame
N
Fo 0 r——
Ne F OH
LCMS (System D) RT=0.96 min, ES+ve m/z 588/590 (M+H)".
Example 43 N-(3-[3-{[(5-chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]tetrahydro-2H-pyran-4-carboxamide
Cl oS ~o + 23 oO
N
]
N
Cb
LCMS (System B) RT=2.71 min, ES+ve m/z 576/578 (M+H)".
Examples 44 — 52
Generic method for the acylation of N-[1-{[3-(aminomethyl)phenyl]methyl}-4-(methyloxy)- 1H-indazol-3-yl]-5-chloro-2-thiophenesulfonamide in array format using HATU and TFA removal of the Boc protecting group:
HATU (456 mg, 1.2 mmol) dissolved in DMF (1.2 mL) and aliquot dispensed (0.1 ml, 0.1 mmol) to each acid monomer (pre-weighed 0.1 mmol). DIPEA (40 «LL, 2.2 eq) was added to each acid, capped and shaken for 2 min to aid dispersion. N-[1-{[3- (aminomethyl)phenyllmethyl}-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide chloride (599 mg, 1.2 mmol) was dissolved in DMF (2.4 mL) and aliquot dispensed (0.2 mL, 0.1 mmol) and added to each acid well. The reaction mixtures were shaken and stood at room temperature for 48 h. DMF was removed by a nitrogen stream (Radley's blowdown unit) to half-volume. TFA (100 zL) was added to each well, shaken and stood at room temperature for 1 h. LCMS indicated incomplete reaction,
DMF was removed by a nitrogen stream (Radley's blowdown unit) to almost dryness. To the residues was added DMSO (0.5 mL) and the solutions were purified by Mass Directed
AutoPrep on Sunfire C18 column using Acetonitrile Water with a TFA modifier. The solutions were de-salted by passing through PL-HCO5 SPE(0.2 mg, 6 mL, pre- conditioned MeOH). The solvent was evaporated in vacuo using the Genevac to give the required products:
Example 44
N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]Jamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-L-histidinamide
Of ~N
LTO
Cp
NH ;
Oo”
LCMS (System B) RT=1.42 min, ES+ve m/z 600/602 (M+H)".
Example 45
N'-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-D-leucinamide oN 7 ~
LT D-
Cl /
N
NH
0
NH,
LCMS (System B) RT=1.97 min, ES+ve m/z 576/578 (M+H)".
Example 46
N'-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-D-alloisoleucinamide
N
LL
Cr ae
N
AA
NH,
LCMS (System B) RT=1.95 min, ES+ve m/z 576/578 (M+H)".
Example 47
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-L-phenylalaninamide oN 7
Cy /
N
NH
SU
NH,
LCMS (System B) RT=2.01 min, ES+ve m/z 610/612 (M+H)".
Example 48 N'-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]Jamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-D-valinamide
Oy iP
So TS cl or
N
NH
NH,
LCMS (System B) RT=1.90 min, ES+ve m/z 562/564 (M+H)".
Example 49 N'{(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-L-lysinamide oN
S cl
Cry
N
NH
0”
NH,
NH,
LCMS (System B) RT=1.46 min, ES+ve m/z 591/593 (M+H)".
Example 50 (2R)-N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-azetidinecarboxamide trifluoroacetate
So H td
N"R s” cl
O
N g bn M ¢ o., 0 7 F<
F OH
LCMS (System E) RT=1.80 min, ES+ve m/z 546/548 (M+H)".
Example 51 (2S)-N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]Jamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-piperidinecarboxamide trifluoroacetate o ~ ea
N
H Fo 0 y —<
OH
H
LCMS (System E) RT=1.85 min, ES+ve m/z 574/576 (M+H)".
Example 52 (4R)-N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-4-fluoro-L-prolinamide trifluoroacetate 0 ~ ea
O
N
NH Fo
N
~0 TX 0 5 F OH
F
LCMS (System E) RT=1.82 min, ES+ve m/z 578/580 (M+H)".
Example 53
N-[1-{[3,4-Bis(methyloxy)phenyl]lmethyl}-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide o,
So oan N—s oh
N
N pel
OO
To a solution of 5-chloro-N-[(5-chloro-2-thienyl)sulfonyl]-N-[4-(methyloxy)-1H-indazol-3-yl]- 2-thiophenesulfonamide (for a preparation see Intermediate 10) (150 mg, 0.286 mmol), triphenylphosphine (150 mg, 0.572 mmol) and [3,4-bis(methyloxy)phenyllmethanol (Aldrich) (96 mg, 0.57 mmol) in THF (3 mL) was added at room temperature di-iso-propyl azodicarboxylate (0.113 mL, 0.572 mmol). The resulting mixture was stirred at 60 °C for 3 hours. DCM ( 3 mL) and water (3 mL) were added and the organic phase was separated.
The aqueous layer was further extracted with 3 mL of DCM. The combine organic solutions were dried over an hydrophobic frit and concentrated under a nitrogen stream in a blowdown unit. The residue was purified by chromatography on silica 50g cartridge on
Flashmaster Il using a gradient of 0-100% EtOAc in DCM over 60 min. The appropriate fractions were combined and evaporated in vacuo and the residue was dissolved in methanol (5 mL) and treated with a solution of sodium hydroxide (2M, 1.43 mL, 2.86 mmol). The resulting mixture was stirred at 60°C for 2 hours. The solvents were evaporated off under reduced pressure, and the residue was partitioned between 2 mL of
DCM, 3 mL of water. A solution of dilute HCI solution was added until the pH of the aqueous layer was around 1. The organic phase was separated and the aqueous layer was further extracted with 2 mL of DCM. The combined organic solutions were dried over an hydrophobic frit and concentrated under a stream of nitrogen in a blowdown unit. The residue was dissolved in 1:1 MeOH-DMSO (1 mL) and purified by MDAP (supelcosil
ABZ+Plus column) eluting with solvents A/B (A: Water + 0.1% Formic acid, B:
MeCN:Water 95:5 + 0.05% Formic acid). The solvent was removed from appropriate fractions under a stream of nitrogen in the Radleys blowdown apparatus to give the title compound (52.6 mg, 37%). LCMS (System A) RT= 1.17 min, ES+ve m/z 494/496 (M+H)".
Example 54
N'-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-O-methylserinamide trifluoroacetate
The title compound was prepared according to the generic procedure described above by acylation of N-[1-{[3-(aminomethyl)phenyl]methyl}-4-(methyloxy)-1H-indazol-3-yl]-5- chloro-2-thiophenesulfonamide in array format using HATU and TFA removal of the Boc protecting group: 9 1-0 oo
N
N / Fo ~ © NH, F OH LCMS (System E) RT=1.83 min, ES+ve m/z 564/566 (M+H)".
Example 55
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-4,4-difluoro-D-prolinamide trifluoroacetate
SN on ae 0 F 0 2 1H
Pe CT
A solution of 1-{[(1,1-dimethylethyl)oxy]carbonyl}-4,4-difluoro-L-proline (Alfa Aesar) (215 mg, 0.857 mmol) in DIPEA(0.150 mL, 0.857 mmol) and dry tetrahydrofuran (1 mL) was stirred at room temperature for 2 min before adding dropwise 1-chloro-N,N,2-trimethyl-1- propen-1-amine (113 pL, 0.857 mmol). The resultant cloudy mixture was stirred at room temperature for 45 min before adding N-[1-{[3-(aminomethyl)phenylimethyl}-4- (methyloxy)-1H-indazol-3-yl]-5-chloro-2-thiophenesulfonamide hydrochloride (for a preparation see Intermediate 4) (214 mg, 0.428 mmol) followed with DIPEA (0.224 mL, 1.28 mmol) and more THF (5 mL). The reaction mixture was not in solution, and was allowed to stand at room temperature for 3 days. It was then concentrated in vacuo and the residue partitioned between ethyl acetate and saturated sodium bicarbonate solution.
The aqueous was extracted with ethyl acetate (x2) and the combined organic solutions were washed with water and brine, dried (Nap;SO4) and concentrated in vacuo to leave a pale yellow oil. This was divided into 3 equal portions and purified by Mass Directed
AutoPrep on Sunfire C18 column using Acetonitrile Water with a Formic acid modifier.
The required fractions were combined and concentrated in vacuo to give the product (35 mg, 12%) as a white powder. LCMS showed that there was more product in the HPLC waste, so the waste was concentrated in vacuo and the resultant residue was loaded in dichloromethane onto a silica 50g cartridge and purified by chromatography on Flashmaster using a 0-50% ethyl acetate-dichloromethane over 40 min. The appropriate fractions were combined and evaporated in vacuo to give more product 1,1-dimethylethyl (2R)-2-({[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyllamino}carbonyl)-4,4-difluoro-1-pyrrolidinecarboxylate (176 mg, as a pale yellow oil. This material was taken through to the next step without further purification. LCMS (System A) RT=1.22 min, ES+ve m/z 696/698 (M+H)".
The second batch of the product (176 mg) was dissolved in dry DCM (2 mL) and treated with a 4:1 mixture of dichloromethane and trifluoroacetic acid solution (3 mL). The resultant reaction mixture was stirred at room temperature for 1 h. LCMS showed a small amount of starting material still present, so more DCM-TFA (4:1, 1 mL) was added to the reaction mixture and allowed to stand at room temperature overnight. The reaction mixture was concentrated in vacuo, and the residue was dissolved in the minimum amount of MeOH, and then loaded onto a pre-conditioned (MeOH) SCX-2 cartridge (50 g). The cartridge was washed with MeOH (4 volumes) and then eluted with 10% aqueous
NH; in MeOH solution. The required fractions were concentrated in vacuo to give the free base of the title compound. This material was dissolved in minimum amount of methanol and treated with trifluoroacetic acid (~0.007 mL). This was then concentrated in vacuo to leave the title compound (78 mg, 36%) as a light brown oil. LCMS (System A) RT=0.89 min, ES+ve m/z 596/598 (M+H)".
Example 56
N1-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-N2,2-dimethylalaninamide formate oN
So HN S 7 work,
To a solution of N-Boc-N,2-dimethylalanine (174 mg, 0.801 mmol) in anhydrous THF (8 mL) was added dropwise at room temperature 1-chloro-N,N,2-trimethylpropenylamine (0.106 mL, 0.801 mmol) and the resulting mixture was stirred for 30 min. N-[1-{[3- (aminomethyl)phenyllmethyl}-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide hydrochloride(for a preparation see Intermediate 4) (200 mg, 0.4 mmol), followed by N,N-diisopropylethylamine (0.209 mL, 1.20 mmol) were then added and the reaction mixture was stirred at room temperature for 90 min (heterogeneous reaction). A further 8 mL of anhydrous tetrahydrofuran and 70 uL of N,N- diisopropylethylamine was added in order to try to improve solubility. The reaction mixture was stirred at room temperature for 30min and then evaporated in-vacuo and partitioned between saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer was separated, passed through a hydrophobic frit and evaporated in-vacuo to yield a cream oil. The residue (286 mg) was dissolved in MeOH:DMSO (1:1) (3x1mL) and purified by MDAP on (Sunfire C18 column 150 mm x 30 mm i.d. 5 um packing diameter at ambient temperature) eluting with solvents A/B (A: 0.1% v/v solution of formic acid in water, B: 0.1% v/v solution of formic acid in acetonitrile) over 25 min. Appropriate fractions were combined and evaporated in-vacuo to yield the title compound as a clear oil (211 mg, 87%). LCMS (System B) RT = 1.75 min, ES+ve m/z 562/564 (M+H)".
Example 57
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-hydroxy-2-methylpropanamide
Q
~ HW / \ o
N
H g 4
HO
To a solution of 2-hydroxy-2-methylpropanoic acid (Aldrich) (20.84 mg, 0.200 mmol) in
THF (2 mL) was added dropwise at room temperature 1-chloro-N,N,2-trimethyl-1-propen- 1-amine (0.026 mL, 0.200 mmol). The resulting mixture was stirred at room temperature for 30 min. To this were succesively added N-[1-{[3-(aminomethyl)phenylimethyl}-4- (methyloxy)-1H-indazol-3-yl]-5-chloro-2-thiophenesulfonamide hydrochloride (for a preparation see Intermediate 4) (50 mg, 0.100 mmol) and DIPEA (0.052 mL, 0.300 mmol).
After 1 hour of stirring at room temperature LCMS showed product as the major peak.
The reaction mixture was concentrated under a stream of nitrogen in the Radleys blowdown apparatus, the residue was dissolved in 1:1 MeOH:DMSO (1 mL) and purified by MDAP on Sunfire C18 column using Acetonitrile Water with a Formic acid modifier.
The solvent was removed under a stream of nitrogen in the Radleys blowdown apparatus to give the title compound (48.5 mg, 88%). LCMS (System A) RT = 1.05 min, ES+ve m/z 549/551 (M+H)".
Example 57 Alternative preparation
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-hydroxy-2-methylpropanamide o \ ~o AL oO
N
’ §
HH
HO
To a solution of 2-{[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyllamino}-1,1-dimethyl-2-oxoethyl acetate (for a preparation see
Intermediate 27) (37 g, 62.6 mmol) in methanol (2000 ml) was added potassium carbonate (26.0 g, 188 mmol) and the reaction mixture was stirred at room temperature.
After stirring for 10 mins the reaction mixture started to crystallise. It was stirred for 3 hours. The solid was filtered and the filtrate was evaporated in vacuo. The residue was acidified with 2M HCI and it was extracted with ethyl acetate (500 ml).
The filtered solid was treated with water (1000 ml) and the resulting suspension was acidified with 2M HCI. It was then extracted with ethyl acetate (2 x 500 ml). The combined organic layers were washed with brine, dried over magnesium sulphate and evaporated in vacuo. The residue was dissolved in DCM and loaded onto a 1500g silica column. It was eluted with 50-100% ethyl acetate in cyclohexane over 8CV. The required fractions were combined and evaporated in vacuo to give the title compound (30.42 g, 89%) as a white solid. LCMS (System A) RT=1.00 min, ES+ve m/z 549/551 (M+H)*; 'H
NMR 6 (DMSO-ds,600 MHz): 10.40 (s, 1H), 8.13 (t, J=6.0 Hz, 1H), 7.37 (d, J=4.0 Hz, 1H), 7.26 (t, J=8.0 Hz, 1H), 7.23 (t, J=7.5 Hz, 1H), 7.17 (d, J=4.0 Hz, 1H), 7.17 (d, J=8.0 Hz, 1H), 7.14 (br. s., 1H), 7.13 (d, J=8.0 Hz, 1H), 6.98 (d, J=7.5 Hz, 1H), 6.50 (d, J=7.5 Hz, 1H), 5.48 (s, 2H), 5.34 (s, 1H), 4.22 (d, J=6.0 Hz, 2H), 3.76 (s, 3H), 1.24 (s, 6H).
Example 58 5-Chloro-N-{4-(methyloxy)-1-[(3-{[(methylsulfonyl)amino]methyl}phenyl)methyl]-1H- indazol-3-yl}-2-thiophenesulfonamide
Nd ~o TT
Cr Cl
N
Q : 8
NTIS
Ho
To a suspension of N-[1-{[3-(aminomethyl)phenyl]methyl}-4-(methyloxy)-1H-indazol-3-yl]- 5-chloro-2-thiophenesulfonamide hydrochloride ((for a preparation see Intermediate 4) 51 mg, 0.10 mmol) in dry DCM (3 mL) was added methanesulfonyl chloride (8 pL, 0.1 mmol), followed by pyridine (1 mL). The resultant pale yellow solution was stirred at room temperature overnight. LCMS showed only 19% of required product. Triethylamine (14 uk, 0.10 mmol), followed by more methanesulfonyl chloride (8 pL, 0.1 mmol) were added and stirring was continued for a further 30 min. The reaction mixture was then concentrated in vacuo and the residue dissolved in 1:1 MeOH:DMSO (1 mL) and purified by MDAP (supelcosil ABZ+Plus column) eluting with solvents A/B (A: Water + 0.1%
Formic acid, B: MeCN:Water 95:5 + 0.05% Formic acid). The solvent was evaporated in vacuo to give the title product (10.7 mg, 19%) as a white solid. LCMS (System A)
RT=1.13 min, ES+ve m/z 541/543 (M+H)".
Example 59
N-[1-[(3-{[(Aminocarbonyl)amino]methyl}phenyl)methyl]-4-(methyloxy)-1H-indazol- 3-yl]-5-chloro-2-thiophenesulfonamide
Ns ~o Tr
Cr cl
N
Q
Nn,
To a suspension of N-[1-{[3-(aminomethyl)phenyl]methyl}-4-(methyloxy)-1H-indazol-3-yl]- 5-chloro-2-thiophenesulfonamide hydrochloride ((for a preparation see Intermediate 4) 47 mg, 0.094 mmol) in ethyl acetate (0.4 mL) and triethylamine (0.013 mL, 0.094 mmol) was added acetic acid (1.5 mL). A solution of potassium cyanate (11 mg, 0.14 mmol) in water (0.2 mL) was added portionwise. The resultant clear solution was stirred at room temperature overnight. LCMS showed incomplete reaction and a higher percentage of product to SM. The reaction mixture was concentrated in vacuo and the resultant oil was divided into 2 equal portions. Each was dissolved in 1:1 MeOH:DMSO (1 mL) and purified by MDAP on Xbridge column using Acetonitrile Water with an ammonium carbonate modifier. The approprate fractions were combined and concentrated in vacuo to give two respective batches, which were not clean, so these were combined and re- purified by MDAP to give the title compound (2.4 mg, 5%). LCMS (System A) RT=0.95 min, ES+ve m/z 506/508 (M+H)".
Example 60 5-Chloro-N-[1-({3-[({[(1,1- dimethylethyl)amino]carbonyl}amino)methyl]phenyl}methyl)-4-(methyloxy)-1H- indazol-3-yl]-2-thiophenesulfonamide ou ~o rT
AT O-
Q rh
To a suspension of N-[1-{[3-(aminomethyl)phenyl]methyl}-4-(methyloxy)-1H-indazol-3-yl]- 5-chloro-2-thiophenesulfonamide hydrochloride (for a preparation see Intermediate 4) (55 mg, 0.11 mmol) in dry DCM (0.5 mL) was added triethylamine (0.015 mL, 0.11 mmol), followed by tert-butyl isocyanate (0.013 mL, 0.11 mmol). The reaction mixture was stirred at room temperature for 1.5 h. LCMS showed mainly required product with 6% SM. The reaction mixture was diluted with DCM and methanol and then concentrated in vacuo.
The resultant residue was dissolved in 1:1 MeOH:DMSO (1 mL) and purified by MDAP (supelcosil ABZ+Plus column) eluting with solvents A/B (A: Water + 0.1% Formic acid, B:
MeCN:Water 95:5 + 0.05% Formic acid). The solvent was evaporated in vacuo to give the title compound (52 mg, 84%). LCMS (System A) RT=1.15 min, ES+ve m/z 562/564 (M+H)".
Example 61 5-Chloro-N-[1-({3-[({[(1-methylethyl)amino]carbonyl}amino)methyl]phenyl}methyl)- 4-(methyloxy)-1H-indazol-3-yl]-2-thiophenesulfonamide ou ~o TT
AO
0
De
To a suspension of N-[1-{[3-(aminomethyl)phenyl]methyl}-4-(methyloxy)-1H-indazol-3-yl]- 5-chloro-2-thiophenesulfonamide hydrochloride (for a preparation see Intermediate 4) (52 mg, 0.10 mmol) in dry DCM (0.5 mL) was added triethylamine (15 pL, 0.11 mmol), followed with isopropyl isocyanate (11 pL, 0.11 mmol). The reaction mixture was stirred at room temperature for 45 min. LCMS showed mainly product. The reaction mixture was diluted with DCM and methanol and then concentrated in vacuo. The resultant residue was dissolved in 1:1 MeOH:DMSO (1 mL) and purified MDAP (supelcosil
ABZ+Plus column) eluting with solvents A/B (A: Water + 0.1% Formic acid, B:
MeCN:Water 95:5 + 0.05% Formic acid). The solvent was evaporated in vacuo to give the title compound (43 mg, 75%) as a white powder. LCMS (System A) RT=1.11 min, ES+ve m/z 548/550 (M+H)".
Example 62
N-[1-{[4-(Aminosulfonyl)phenyl]methyl}-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide
So dN
Cr 5 S Cl
Wn
N
V8
P=0
HN
5-Chloro-N-[4-(methyloxy)-1H-indazol-3-yl]-N-({[2-(trimethylsilyl)ethyl]Joxy}methyl)-2- thiophenesulfonamide (for a preparation see Intermediate 8) (1.734 g, 3.66 mmol) was dissolved in DMF (2.4 mL) and an aliquot (0.1 mL, 0.15 mmol) added to 4- (bromomethyl)benzenesulfonamide (APAC Pharm) (0.15 mmol) and potassium carbonate (0.15 mmol) added last. The tubes were capped and shaken. Stood at room temperature for 18 h, more potassium carbonate (excess) added and reshaken the tubes. Filtered through alltech tube to remove inorganic solids, and washed tubes with MeOH (1 mL) and blown to dryness under a stream of nitrogen in a Radley's blow down unit. Redissolved in
DCM (0.5 mL) and applied to a 10 g silica cartridge, and purified by chromatography on
Flashmaster using a gradient of 0-100% DCM-(DCM with 20 % EtOAc) over 20 min. The appropriate fractions were combined and evaporated in vacuo using the Genevac. The residue was dissolved in TBAF (1M, 0.5 mL) and heated in a microwave oven (50 Watts, 10 min, at approx 110°C. The sample was purified by MDAP on Atlantis column using
Acetonitrile Water with a Formic acid modifier. The solvent was evaporated in vacuo using the Genevac to give the title compound (7.9 mg, 10%) LCMS (System A) RT=0.92 min, ES+ve m/z 513/515 (M+H)"
Example 63 2-(3-{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)-N-methylacetamide
0” (4°
Ao
N ame
N
’
NH
A mixture of 5-chloro-N-[4-(methyloxy)-1H-indazol-3-yl]-2-thiophenesulfonamide (for a preparation see Intermediate 26) (900 mg, 1.9 mmol), phenylmethyl [3- (bromomethyl)phenyllacetate (J. Med. Chem. 1992, 35, 2551-2562, compound 13) (1.23 g, 3.84 mmol) and potassium carbonate (525 mg, 3.80 mmol) in dry N,N-
Dimethylformamide (50 mL) was stirred and heated at reflux for 2 h. The reaction mixture was partitioned between water (50 mL) and ethyl acetate(50 mL). The aqueous was extracted with ethylacetate (x2). The combined organic solutions were washed with water and brine, dried (Na,SO,) and concentrated in vacuo to leave a dark yellow oil. The sample was loaded in dichloromethane and purified by chromatography on a silica 100 g cartridge on Flashmaster using a gradient of 0-50% ethyl acetate-cyclohexane over 40 min. The appropriate fractions were combined and evaporated in vacuo to give phenylmethyl (3-{[3-[[(5-chloro-2-thienyl)sulfonyl]({[2- (trimethylsilyl)ethylJoxy}methyl)amino]-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)acetate (1.038 g, 77%) as a yellow oil. LCMS RT=1.63 min, ES+ve m/z 729/731 (M+NH,)". To a portion of this (103 mg, 0.145 mmol) was added a solution of methylamine THF (2M, 2.1 mL, 4.20 mmol) (excess was added to aid transfer of ester to microwave vessel) and 1,3,4,6,7,8-hexahydro-2H-pyrimido[1,2-a]pyrimidine (TBD) (6 mg, 0.04 mmol). The microwave vessel was sealed and heated at 80°C in Biotage Initiator for 60 min. LCMS showed that the reaction was complete. The reaction mixture was concentrated in vacuo to leave a pale yellow oil. This was divided into 2 equal portions and each portion dissolved in 1:1 MeOH:DMSO (1 mL) and purified by MDAP (supelcosil
ABZ+Plus column) eluting with solvents A/B (A: Water + 0.1% Formic acid, B:
MeCN:Water 95:5 + 0.05% Formic acid). The solvent was evaporated in vacuo to give 2- (3-{[3-[[(5-chloro-2-thienyl)sulfonyl]({[2-(trimethylsilyl)ethyl]oxy}methyl)amino]-4- (methyloxy)-1H-indazol-1-yllmethyl}phenyl)-N-methylacetamide (39 mg, 42%) as a colourless oil. LCMS RT=1.43 min, ES+ve m/z 635/637 (M+H)". A mixture of this product and TBAF in THF (1M, 0.62 mL, 0.62 mmol) was sealed in a 0.2-2 mL miccrowave vessel.
Tetrahydrofuran (0.8 mL) was added to the mixture, and heated in Biotage Initiator microwave oven using normal to 100 °C for 10 min. This was repeated 2 more times.
The reaction mixture was then partitioned between water and dichloromethane. The phases were separated using a hydrophobic frit. The aqueous was extracted with DCM (x2) and the combined organic solutions were concentrated in vacuo to leave a white oil (46 mg). This was dissolved in 1:1 MeOH:DMSO (1 mL) and purified by MDAP (supelcosil ABZ+Plus column) eluting with solvents A/B (A: Water + 0.1% Formic acid, B:
MeCN:Water 95:5 + 0.05% Formic acid). The solvent was evaporated in vacuo to give the title compound (9 mg, 29%) as a white powder. LCMS (System A) RT=1.06 min,
ES+ve m/z 505/507 (M+H)".
Example 64 3-{[3-{[(5-Chloro-2-thienyl)sulfonyllJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}benzamide 0” ne s 1)
HN" ~O
To a solution of 5-chloro-N-[4-(methyloxy)-1H-indazol-3-yl]-N-({[2- (trimethylsilyl)ethylloxy}methyl)-2-thiophenesulfonamide ~~ (for a preparation see
Intermediate 8) (150 mg, 0.316 mmol) into DMF (2 mL) was added at ambient temperature potassium carbonate (87 mg, 0.63 mmol) and 3-(chloromethyl)benzamide (Maybridge)(64.4 mg, 0.380 mmol). The resulting mixture was stirred at 50 °C overnight, and then diluted with DCM (2 mL) and water (2 mL). The organic mixture was partitioned and the aqueous layer was further extracted with 2 mL of DCM. The organic solutions were combined together, dried over an hydrophobic frit and evaporated under a nitrogen stream in a blowdown unit. The crude product was judged by LCMS to be pure enough to be engaged in the next step without any further purification. LCMS (System A) RT=1.37 min, ES+ve m/z 607/609 (M+H)". In a 2 to 5 mL Biotage microwave vial were added the crude indazole product and TBAF solution in THF (1M, 3.16 mL, 3.16 mmol). The reaction vessel was sealed and heated in a Biotage Initiator at 110 °C for 10 min (very high absorption level). The crude mixture was then diluted with 2 mL of DCM and 2 mL of water. The organic layer was separated and the aqueous layer was further extracted with
2 mL of DCM. The combined organic solutions were dried over an hydrophobic frit, and evaporated under a nitrogen stream in a blowdown unit. The residue was dissolved in 1:1
MeOH:DMSO (1 mL) and purified by MDAP (supelcosil ABZ+Plus column) eluting with solvents A/B (A: Water + 0.1% Formic acid, B: MeCN:Water 95:5 + 0.05% Formic acid).
The solvent was removed under a stream of nitrogen in a Radleys blowdown apparatus to give the title compound (76 mg, 50%). LCMS (System A) RT=0.97 min, ES+ve m/z 477/479 (M+H)".
Example 65 3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1-ylJmethyl}-N- [2-(dimethylamino)ethyl]benzamide 6p o” wo
Co
Q
0 N\_/ \
To a solution of 5-chloro-N-[4-(methyloxy)-1H-indazol-3-yl]-N-({[2- (trimethylsilyl)ethylloxy}methyl)-2-thiophenesulfonamide ~~ (for a preparation see
Intermediate 8) (1 g, 2.1 mmol) in DMF (10 mL) was added at ambient temperature K,CO3 (0.583 g, 4.22 mmol) and methyl 3-(bromomethyl)benzoate (Alfa Aesar) (0.580 g, 2.53 mmol). The resulting mixture was stirred at 50 °C for 2 h by which time LCMS showed product as the major peak. The reaction mixture was diluted with 20 mL of DCM and 20 mL of water. The organic phase was separated and the aqueous layer was further extracted with 20 mL of DCM. The combined organic solutions were washed with brine, dried over an hydrophobic frit, and concentrated under reduced pressure. The residue was loaded on to a silica 100g cartridge in dichloromethane and purified by chromatography on Flashmaster using a 0-100% gradient EtOAc in DCM, over 40 min to give methyl 3-{[3-[[(5-chloro-2-thienyl)sulfonyl]({[2-(trimethylsilyl)ethylJoxy}methyl)amino]- 4-(methyloxy)-1H-indazol-1-yllmethyl}benzoate (571 mg, 43%). LCMS (System A)
RT=1.60 min, ES+ve m/z 622/624. A portion of the product (70 mg, 0.11 mmol) was placed in a 0.2 to 0.5 mL Biotage microwave vial, followed by N,N-dimethyl-1,2- ethanediamine (Aldrich) (246 ul, 2.25 mmol), 1,3,4,6,7,8-hexahydro-2H-pyrimido[1,2- alpyrimidine (TBD) (7.83 mg, 0.056 mmol). The reaction vessel was sealed and heated in a Biotage Initiator using initial very high absorption level to 80 °C for 75 min. After cooling the reaction, an LCMS showed the product as a single peak. The reaction mixture was diluted with DCM (2 mL) and water (3 mL). The organic phase was separated and the aqueous layer was further extracted with 2 mL of DCM. The combined organic solutions were dried through an hydrophobic frit and concentrated in a nitrogen blowdown unit.
LCMS (System A) RT=1.46 min, ES+ve m/z 678/680 (M+H)". The crude product was placed in a 0.5 to 2 mL Biotage microwave vial and a solution of TBAF in THF (1.125 mL, 1.125 mmol) was added. The reaction vessel was sealed and heated in a Biotage Initiator at 110 °C for 15 min (very high absorption level). The solvent was removed under a nitrogen stream in a blowdown unit at 35°C overnight. The residue was dissolved in 1:1
MeOH:DMSO (1 mL) and purified by MDAP on standard C18 column using Acetonitrile
Water with a TFA modifier. The solvent was removed under a stream of nitrogen in the
Radleys blowdown apparatus, and the residue was further purified on SCX-2 ion- exchange cartridge (pre-conditioned with MeOH, compound loaded in Methanol, eluted with Methanol (2 x column volumes), followed by 2M NH; in Methanol. The ammoniacal fractions were concentrated under reduced pressure to provide the title compound (55.3 mg, 90%). LCMS (System E) RT=2.15 min, ES+ve m/z 548/550 (M+H)".
Example 66 3-[(4-(Methyloxy)-3-{[(5-methyl-2-thienyl)sulfonyl]amino}-1 H-indazol-1- yl)methyllbenzamide o ~o -
Coy
N
N
5 NH, 3-{[3-Amino-4-(methyloxy)-1H-indazol-1-ylimethyl}benzamide (for a preparation see
Intermediate 12) 22 mg, 0.07 mmol) was dissolved in pyridine (1.6 mL) and added to 5- methyl-2-thiophenesulfonyl chloride (20 mg, 0.1 mmol). The reaction mixture was shaken at room temperature for 5 min and then stood overnight at room temperature. DMSO (0.2 mL) was added to the reaction mixture and purified by MDAP on Atlantis column using
Acetonitrile Water with a Formic acid modifier. The solvent was evaporated in vacuo using the Genevac to give the title compound (14.2 mg, 44%) LCMS (System A) RT=0.92 min, ES+ve m/z 457 (M+H)".
Example 67 3-{[3-{[(5-Bromo-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}benzamide ~o i LN
NX “s7 Br 0
N
: ]. 3-{[3-Amino-4-(methyloxy)-1H-indazol-1-ylimethyl}benzamide (for a preparation see
Intermediate 12) (22 mg, 0.07 mmol) was dissolved in pyridine (1.6 mL) and added to 5- bromo-2-thiophenesulfonyl chloride (27 mg, 0.1 mmol). The reaction mixture was shaken at room temperature for 5 min and then stood overnight at room temperature. DMSO (0.2 10 mL) was added to the reaction mixture and purified by MDAP on Atlantis column using
Acetonitrile Water with a Formic acid modifier. The solvent was evaporated in vacuo using the Genevac to give the title compound (4.6 mg, 12%) LCMS (System A) RT=1.04 min, ES+ve m/z 521/523 (M+H)". 15 Example 68 3-{[3-{[(5-Chloro-2-thienyl)sulfonyllJamino}-7-fluoro-4-(methyloxy)-1H-indazol-1- yllmethyl}benzamide cl oS
So 1 2 0 \
N
Cr
F I
NH,
To a solution of 3-{[3-amino-7-fluoro-4-(methyloxy)-1H-indazol-1-ylJmethyl}benzamide (for a preparation see Intermediate 14) (22 mg, 0.07 mmol) in anhydrous pyridine (1 mL) and anhydrous dichloromethane (3 mL) (gentle heating of the mixture for a few minutes with a heatgun was required in order for the starting material to go in solution) was added a solution of 5-chloro-2-thiophenesulfonyl chloride (16.71 mg, 0.077 mmol) in anhydrous dichloromethane (0.5 mL). The reaction was stirred at room temperature for 45 min, then at 45°C for 30 min. A solution of 5-chloro-2-thiophenesulfonyl chloride (16.7 mg) in anhydrous dichloromethane (0.2 mL) was added to the reaction mixture and stirred at 45°C for 25 h. The reaction mixture was cooled and then partitioned between water and dichloromethane. The organic layer was passed through an hydrophobic frit and evaporated in-vacuo to yield a pale yellow solid. The solid was dissolved in MeOH-DMSO (1 mL) and purified by MDAP on Sunfire C18 column, eluting with solvents A/B (A: 0.1% v/v solution of formic acid in water, B: 0.1% v/v solution of formic acid in acetonitrile).
Appropriate fraction was evaporated in-vacuo to yield the title compound as a white solid (15.7 mg, 45%). LCMS (5 min run) RT = 2.62 min, ES+ve m/z 495/497 (M+H)".
Example 69 3-[(3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-7-fluoro-4-hydroxy-1H-indazol-1- yl)methyllbenzamide
Cl
OH 20
Oo st
N o NH,
A suspension of 3-{[3-{[(5-chloro-2-thienyl)sulfonyllamino}-7-fluoro-4-(methyloxy)-1H- indazol-1-yllmethyl}benzamide (for a preparation see Example 68) (15.7 mg, 0.032 mmol) in anhydrous DCM (2 mL) under nitrogen atmosphere was treated with boron tribromide solution in DCM (1M, 0.032 mL) at room temperature. The reaction mixture was stirred at room temperature for 45 min and then saturated aqueous sodium bicarbonate solution was added dropwise to quench the reaction. The mixture was then partitioned between further saturated aqueous sodium bicarbonate solution and 10% methanol in ethyl acetate (white precipitate was present which was insoluble in both the organic and aqueous layer). The organic layer was separated, passed through an hydrophobic frit and evaporated in-vacuo to yield a yellow solid (13mg). This was dissolved in MeOH:DMSO (1:1) (0.5 mL) and purified by MDAP on Sunfire C18 column, eluting with solvents A/B (A: 0.1% v/v solution of formic acid in water, B: 0.1% v/v solution of formic acid in acetonitrile). Appropriate fraction was evaporated in-vacuo to yield the title compound as a yellow solid (8.5 mg, 56%). LCMS (System B) RT = 2.41 min, ES+ve m/z 481/483 (M+H)".
Example 70 3-[(3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-hydroxy-1H-indazol-1- yl)methyllbenzamide 1 re
HN" ~O
A suspension of 3-{[3-{[(5-chloro-2-thienyl)sulfonyllamino}-4-(methyloxy)-1H-indazol-1- yllmethyllbenzamide (for a preparation see Example 64) (50.0 mg, 0.105 mmol) in anhydrous DCM (1.5 mL) under nitrogen atmosphere was treated with boron tribromide solution in DCM (1M, 0.105 mL, 0.105 mmol) at room temperature, and the mixture was stirred at room temperature for 45 min. A further 0.2 ml portion of boron tribromide solution was added and the reaction mixture was stirred at room temperature for 90 min.
Saturated aqueous sodium bicarbonate solution was added dropwise to quench the reaction. The reaction was then partitioned between further saturated aqueous sodium bicarbonate solution and 10% methanol in ethyl acetate (off white precipitate was present, which was insoluble in both the organic and aqueous layer). The organic layer was separated, passed through a hydrophobic frit and evaporated in-vacuo to yield an off white solid (58 mg), which was dissolved in MeOH-DMSO (1:1) (1 mL) and purified by
MDAP on Sunfire C18 column eluting with solvents A/B (A: 0.1% v/v solution of formic acid in water, B: 0.1% v/v solution of formic acid in acetonitrile 25 min run). The appropriate fraction was evaporated in-vacuo to yield a white solid (17 mg, 35%). LCMS (System B) RT = 2.18 min, ES+ve m/z 463/465 (M+H)".
Example 71
N'-({3-[(3<{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-hydroxy-1H-indazol-1- yl)methyl]phenyl}methyl)-N*-methyl-D-alaninamide formic acid salt oN
OH aps
Crd Cl
N
Q 1 a OH
NH
To a solution of O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium- hexafluorophosphate (39.7 mg, 0.064 mmol) in anhydrous DMF (1 mL) was added at room temperature N-Boc-N-methyl-D-alanine (11.91 mg, 0.059 mmol), followed by N,N- diisopropylethylamine (0.0306 mL, 0.176 mmol) and finally a solution of N-(1-{[3- (aminomethyl)phenyl]methyl}-4-hydroxy-1H-indazol-3-yl)-5-chloro-2- thiophenesulfonamide formate salt (for a preparation see Intermediate 15) (29 mg, 0.059 mmol) in anhydrous DMF (1 mL). The reaction mixture was stirred at room temperature for 1 hour and then was partitioned between saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer was separated, washed with brine-water (1:1), passed through a hydrophobic frit, and evaporated in-vacuo to yield a colourless oil. LCMS (System B) RT = 3.01 min, ES+ve m/z 634/636 (M+H)+ for desired
BOC protected product. This product was suspended in a solution of hydrogen chloride in 1,4-dioxane (4M, 0.5 mL) and methanol was added until the reaction was in solution. The mixture was stirred at room temperature for 18 hours and then evaporated in-vacuo to yield a colourless oil. The residual oil was dissolved in MeOH-DMSO (0.5 mL) and purified by MDAP) on OA MDAP on Sunfire C18 column, eluting with solvents A/B (A: 0.1% v/v solution of formic acid in water, B: 0.1% v/v solution of formic acid in acetonitrile) (25 min run). The appropriate fractions were combined and evaporated in-vacuo to yield the title compound as a colourless oil (15 mg, 44%). LCMS (System B) RT = 1.63 min,
ES+ve m/z 534/536 (M+H)"
Example 72
N-({3-[(3-{[(5-Chloro-2-thienyl)sulfonyl]Jamino}-4-hydroxy-1H-indazol-1- yl)methyl]phenyl}methyl)acetamide
Cl
OH CT
0 ¢ or
To a solution of O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium- hexafluorophosphate (39.7 mg, 0.064 mmol) in anhydrous DMF (1 mL) was added at room temperature acetic acid (3.36 xL, 0.059 mmol), followed by N,N- diisopropylethylamine (0.031 mL, 0.18 mmol) and finally a solution of N-(1-{[3- (aminomethyl)phenyllmethyl}-4-hydroxy-1H-indazol-3-yl)-5-chloro-2- thiophenesulfonamide formate salt (for a preparation see Intermediate 15) (29 mg, 0.059 mmol) in anhydrous DMF (1 mL) and the reaction mixture was stirred at room temperature for 30 min. The mixture was partitioned between saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer was separated, washed with brine:water (1:1), passed through a hydrophobic frit and evaporated in-vacuo to yield a colourless oil (23 mg). This was dissolved in MeOH:DMSO (1 mL) and purified by MDAP
Sunfire C18 column eluting with solvents A/B (A: 0.1% v/v solution of formic acid in water,
B: 0.1% v/v solution of formic acid in acetonitrile) (25 min run). The appropriate fraction was evaporated in-vacuo to yield the title compound as a colourless oil (20 mg, 69%).
LCMS (System B) RT = 2.41 min, ES+ve m/z 491/493 (M+H)".
Example 73
N-({3-[(3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-hydroxy-1H-indazol-1- yl)methyllphenyl}methyl)-3-morpholinecarboxamide formate salt cl
OH HT
0
G
3 Ox OH
SL
To a solution of O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium- hexafluorophosphate (43.8 mg, 0.071 mmol) in anhydrous DMF (1 mL) was added at room temperature morpholine-3,4-dicarboxylic acid 4-fert-butyl ester (Fluorochem) (14.95 mg, 0.065 mmol) followed by N,N-diisopropylethylamine (0.034 ml, 0.19 mmol) and finally a solution of N-(1-{[3-(aminomethyl)phenyllmethyl}-4-hydroxy-1H-indazol-3-yl)-5-chloro-2- thiophenesulfonamide formate salt (for a preparation see Intermediate 15) (32 mg, 0.065 mmol) in anhydrous DMF (1 mL) and the reaction mixture was stirred at room temperature for 30 min. The reaction mixture was partitioned between saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer was separated, washed with brine-water (1:1), passed through a hydrophobic frit, and evaporated in-vacuo to yield a colourless oil. LCMS (System B) RT = 2.91 min, ES+ve m/z 662/664 (M+H)" for 1,1- dimethylethyl 3-{[({3-[(3-{[(5-chloro-2-thienyl)sulfonyllJamino}-4-hydroxy-1H-indazol-1- yl)methyl]phenyl}methyl)amino]carbonyl}-4-morpholinecarboxylate. This was suspended in anhydrous dichloromethane (2 mL) and treated with a solution of hydrogen chloride in 1,4-dioxane (4M, 0.162 mL, 0.646 mmol). The reaction mixture was still a suspension, therefore methanol was added dropwise until the reaction was in solution. The mixture was stirred at room temperature for 1 hour, and a further portion of hydrogen chloride solution (4M, 0.162 mL) was added to the reaction mixture and stirred for 90 min. Yet another portion of hydrogen chloride solution (4M, 0.162 mL) was added to the reaction mixture and stirred for 90 min. The reaction mixture was evaporated in-vacuo to yield a colourless oil. The residual oil was dissolved in MeOH:DMSO (1 mL) and purified by
MDAP Sunfire C18 column, eluting with solvents A/B (A: 0.1% v/v solution of formic acid in water, B: 0.1% v/v solution of formic acid in acetonitrile) (25 min run). Appropriate fractions were combined and evaporated in-vacuo to vield the title compound as a colourless oil (17 mg, 43%). LCMS (System B) RT = 1.62 min, ES+ve m/z 562/564 (M+H)".
Example 74 5-Chloro-N-[1-[(3-{[2-(dimethylamino)ethyl]oxy}phenyl)methyl]-4-(methyloxy)-1H- indazol-3-yl]-2-thiophenesulfonamide ~ Pa RP 0 N—S s
Cp O-
N
3 o—""N 5-Chloro-N-[(5-chloro-2-thienyl)sulfonyl]-N-[1-[(3-{[2- (dimethylamino)ethyl]oxy}phenyl)methyl]-4-(methyloxy)-1H-indazol-3-yl]-2- thiophenesulfonamide (for a preparation see Intermediate 18) (140 mg, 0.2 mmol) was suspended in methanol (25 mL) and treated with 2M NaOH aqueous solution (2 mL). The mixture was heated to 60°C for 4 h and then concentrated under reduced pressure. The residue was partitioned between 2M HCI (2 mL) and ethyl acetate. The aq. layer was back-extracted and the organic solution was washed with brine, dried (MgSQO,) and evaporated. The residue was dissolved in 1:1 MeOH:DMSO (1.5 mL) and purified by
MDAP on Xbridge column using Acetonitrile Water with an ammonium carbonate modifier.
Appropriate fractions were evaporated in vacuo to give the title product (40 mg, 39%).
LCMS (System C) RT=2.29 min, ES+ve m/z 521/523 (M+H)".
Example 75 5-Chloro-N-[1-[(4-{[2-(dimethylamino)ethyl]oxy}phenyl)methyl]-4-(methyloxy)-1H- indazol-3-yl]-2-thiophenesulfonamide ~o Pol
S
Crh O-
N
RP he
A solution of 5-chloro-N-[(5-chloro-2-thienyl)sulfonyl]-N-[1-[(4-{[2-
(dimethylamino)ethyl]oxy}phenyl)methyl]-4-(methyloxy)-1H-indazol-3-yl]-2- thiophenesulfonamide (for a preparation see Intermediate 18) (91 mg, 0.13 mmol) in
MeOH (5 mL) was treated with a 2M ag. NaOH solution (1 mL) and the mixture was heated to 70°C for 2 h, and then allowed to stand at RT over the weekend. The solvents evaporated by this time and the white solid residue was diluted with water and 2M HCI solution (1 mL) and extracted with ethyl acetate. The organic solution was washed with brine, dried (MgSO,) and evaporated to dryness (72 mg). The residue was dissolved in 1:1 MeOH:DMSO (1 mL) and purified by MDAP on Xbridge column using acetonitrile- water with an ammonium carbonate modifier. The solvent was evaporated in vacuo to give the title compound (43 mg, 64%) as a colourless gum. LCMS (System C) RT=2.20 min, ES+ve m/z 521/523 (M+H)".
Example 76 5-Chloro-N-[1-{[4-{[2-(dimethylamino)ethyl]oxy}-3-(methyloxy)phenyllmethyl}-4- (methyloxy)-1H-indazol-3-yl]-2-thiophenesulfonamide - Na
Oo (ad S
Crp Bs
N
4-{[2-(Dimethylamino)ethyl]oxy}-3-(methyloxy)phenyllmethanol (for a preparation see
Intermediate 20) (1.2 g, 5.3 mmol), triphenylphosphine (2.1 g, 8 mmol), di-tert-butyl azodicarboxylate (1.53 g, 6.7 mmol) and 5-chloro-N-[(5-chloro-2-thienyl)sulfonyl]-N-[4- (methyloxy)-1H-indazol-3-yl]-2-thiophenesulfonamide (for a preparation see Intermediate 10) (2.79 g, 5.3 mmol) in THF (60 mL) was heated under nitrogen to 80°C for 20 h. The mixture was concentrated under reduced pressure and then applied to two 50 g SCX-2 ion-exchange cartridges eluting with MeOH, followed by 10% aqueous ammonia in
MeOH. The ammoniacal solution was then concentrated to give a gum. The residue was dissolved in MeOH (100 mL) and THF (25 mL), and then treated with 2M NaOH aq solution (10 mL) and heated to 80°C for 2 h. LCMS indicated completion and formation of two products RT=0.95 min, 42% and 0.98 min, 25% ES+ve m/z 551/553 (M+H)+. The mixture was treated with 2M HCI (10 mL) and concentrated under reduced pressure. The residue was partitioned between ethyl acetate and NaHCO; solution (pH of solution after addition of HCI was 5-6 so NaHCO; was added to pH 8 before extractions). The organic solution was diluted with THF (20 mL) as a gum separated out of solution. The organic solution was washed with brine, dried (MgSQO,) and evaporated under reduced pressure to give a gum (1.92 g). This was dissolved in chloroform and purified by chromatography on two 100 g silica cartridges on Flashmaster using a 0-15% methanol (containing 1%Et;N)-dichloromethane over 40 min for one cartridge and 0-30% methanol (containing 1%Et;N)-dichloromethane over 40 min for the second cartridge. The earlier fractions of the first cartridge RT = 0.97 min, 95%, ES+ve m/z 551/553 (M+H)" were combined with the earlier fractions from the second cartridge and evaporated in vacuo to give a expected product but still impure (788 mg) as a yellow gum LCMS RT=2.15 min, 85%, ES+ve m/z 551/553. The compound was further purified by chromatography on Flashmaster on silica (100 g cartridge) using a 0-15% methanol(containing 1%Et;N)-dichloromethane over 60 min. The appropriate fractions (RT=35-48 min) were combined and evaporated in vacuo to give the crude product, (674 mg) as a white foam. LCMS RT=2.15 min, 89%, ES+ve m/z 551/553). This was dissolved in 1:1 MeOH-DMSO (7 x 1 mL) and purified by MDAP on Xbridge column using acetonitrile-water with an ammonium carbonate modifier. The solvent was evaporated in vacuo to give the title compound, (374 mg, 13%), as a white solid:
LCMS (System C) RT=2.14 min, 99%, ES+ve m/z 551/553 (M+H)"; NMR & (CDCl,) 7.42 (1H, d,J 4 Hz), 7.20 (1H, dd, J 8 Hz), 6.83 (1H, d, J 8 Hz), 6.81 (1H, d, J 2 Hz), 6.79 (1H, d, J 8 Hz), 6.74 (1H, d, J 4 Hz), 6.70 (1H, dd, J 8, 2 Hz), 6.35 (1H, d, J 8 Hz), 5.37 (2H, s), 4.08 (2H, t, J 6 Hz), 3.90 (3H, s), 3.78 (3H, s), 2.76 (2H, t, J 6 Hz), 2.33 (6H, s). NOE effect observed on irradiation of the benzylic protons at 5.39 ppm (spectrum run in DMSO- de) to the 7-H indazole proton, compatible with the expected product.
Example 77
N-[1-{[3-(aminosulfonyl)phenyl]methyl}-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide
N% ~o aos cr Cl
N
N
© 0
To a solution of 5-chloro-N-[(5-chloro-2-thienyl)sulfonyl]-N-[4-(methyloxy)-1H-indazol-3-yl]- 2-thiophenesulfonamide (for a preparation see Intermediate 10) (120 mg, 0.229 mmol), triphenylphosphine (120 mg, 0.458 mmol) and 3-(hydroxymethyl)benzenesulfonamide (85.8 mg, 0.458 mmol) in THF (3 mL) was added at rt diisopropyl azodicarboxylate (DIAD) (0.090 mL, 0.458 mmol). The resulting mixture was stirred at 65 °C for 7 hours. The mixture was partitioned between DCM (3 mL) and water (3 mL). The organic phase was separated and the aqueous layer was further extracted with 3 mL of DCM. The combined organic solutions were dried over an hydrophobic frit and evaporated under a nitrogen strean in a blowdown unit. The residue was loaded in dichloromethane on a silica cartridge (50 g) and purified by chromatography on Flashmaster using a 0-100% EtOAc in
DCM over 40 min. The appropriate fractions were combined and evaporated in vacuo, and the residue was dissolved in methanol (3 mL) and treated with sodium hydroxyde (2M,1.146 mL, 2.291 mmol). The resulting mixture was stirred at 60°C for 2 hours. The solvents were evaporated under reduced pressure. The residue was dissolved in DCM (2 mL) and 3 mL of water was added, followed by dilute HCI solution until the pH of the aqueous layer was around 1. The organic phase was separated and the aqueous layer was further extracted with 2 mL of DCM. The combined organic solutions were dried over an hydrophobic frit and concentrated under a stream of nitrogen in a blowdown unit. The residue was dissolved in 1:1 MeOH:DMSO (1 mL) and purified by MDAP (supelcosil
ABZ+Plus column) eluting with solvents A/B (A: Water + 0.1% Formic acid, B:
MeCN:Water 95:5 + 0.05% Formic acid). The solvent was removed under a stream of nitrogen in the Radleys blowdown apparatus to give the title compound, (51.6 mg, 22%).
LCMS (System A) RT=1.02 min, ES+ve m/z 513/515 (M+H)".
Examples 78 - 85 were prepared in array format according to the procedure described for
Example 44.
Example 78
N'-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-g-alaninamide trifluoroacetate o ~ WJ
AL oO
WN
WN
H Fo
N aad oO
NH,
LCMS (System A) RT=0.89 min, ES+ve m/z 534/536 (M+H)".
Example 79 N'(3-{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-L-glutamamide formate salt
Q
WJ
~o AO cb
N d 0
NH, as ~.
NH, oO
LCMS (System B) RT=1.76 min, ES+ve m/z 591/593 (M+H)".
Example 80
N*-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-L-asparagine trifluoroacetate
Q
~ WN
AL oO iy
N
{ / Fo
H " F OH ow ka OH
LCMS (System D) RT=1.76 min, ES+ve m/z 578/580 (M+H)".
Example 81 1,1-Dimethylethyl N*-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]Jamino}-4-(methyloxy)-1H- indazol-1-yllmethyl}phenyl)methyl]-L-asparaginate trifluoroacetate (
Q
WJ
~o AL oO
Co
N bp —£
N F © yg
N of
LCMS (System D) RT=0.99 min, ES+ve m/z 578/580 (M+H)".
Example 82 N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-D-prolinamide trifluoroacetate o \ S Cl oO os /
N
Fo © +4
H
N H
Jo N
J
LCMS (System D) RT=0.91 min, ES+ve m/z 560/562 (M+H)".
Example 83 1-Amino-N-[(3-{[3-{[(5-chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]cyclobutanecarboxamide trifluoroacetate
Q
~o AL o
N
Fo © an o
N o /
HN
LCMS (System B) RT=1.83 min, ES+ve m/z 560/562 (M+H)".
Example 84 1-Amino-N-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]lcyclopropanecarboxamide trifluoroacetate 0 ~ pl
NTH Cs a o or /
N
Fo
F—
F OH
H
N r=
NH,
LCMS (System B) RT=1.81 min, ES+ve m/z 546/548 (M+H)".
Example 85
N'-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-N?-methylglycinamide trifluoroacetate
Q
~ WZ \
AL o
Ny
NW
Fo
H FI
N a
N— LCMS (System A) RT=0.89 min, ES+ve m/z 534/536 (M+H)".
Examples 86 — 96 were prepared in array format according to the procedure described in
Example 30.
Example 86
N'-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-N? N>-dimethylglycinamide trifluoroacetate o
So dN
Ms Ta
O
Crd /
N
9 Fo
HT om 7
N— /
LCMS (System D) RT=0.90 min, ES+ve m/z 548/550 (M+H)".
Example 87
N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-3-(methyloxy)propanamide
Oo
So AN v Ss Cl
CL
N
H
N
2 0 \
LCMS (System D) RT=1.03 min, ES+ve m/z 549/551 (M+H)".
Example 88 N-[(3«{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-1H-pyrrole-3-carboxamide
Q
So AlN
W S Cl
Cr /
N
H
N xX © \ NH
LCMS (System B) RT=2.71 min, ES+ve m/z 556/558 (M+H)".
Example 89 N-(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]tetrahydro-2-furancarboxamide 0 ~o AL /
N d
Oo 7)
LCMS (System B) RT=2.81 min, ES+ve m/z 561/563(M+H)".
Example 90
N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]Jamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-1,3-oxazole-4-carboxamide 0
So H Wd a sa 0
N N
/
N
\ N
AN
7
LCMS (System B) RT=2.80 min, ES+ve m/z 558/560(M+H)".
Example 91
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-1H-pyrazole-3-carboxamide
Q
\\ Ss Cl
Oo
Cr /
N
H
\ N 7 NH
Oo —
LCMS (System B) RT=2.66 min, ES+ve m/z 557/559 (M+H)".
Example 92
N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-1H-pyrrole-2-carboxamide ( 0 ~ pb
NN Cs cl 0
N N
/
N
N H
0 0 o” \
LCMS (System B) RT=2.92 min, ES+ve m/z 556/558 (M+H)".
Example 93
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-1H-imidazole-2-carboxamide
0
No REY
Ws Cl - [ ©
AY
/
N
H g H ~ ay
N
LCMS (System B) RT=2.51 min, ES+ve m/z 557/559 (M+H)".
Example 94 N-[(3«{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-1H-imidazole-4-carboxamide 0
So dN i S Cl 0 oo /
N g \ N
XX
7),
LCMS (System B) RT=2.12 min, ES+ve m/z 557/559 (M+H)".
Example 95
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-furancarboxamide of ~
LUT cl
Crh /
N
0 o
N
Ho
LCMS (System D) RT=1.11 min, ES+ve m/z 557/559 (M+H)".
Example 96
N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-4-methyl-3-morpholinecarboxamide oN
No iN Th
Crh /
N
No “5 (Lo
LCMS (System C) RT=0.84 min, ES+ve m/z 590/592 (M+H)".
Example 97
N-[(4-{[3-{[(5-Chloro-2-thienyl)sulfonyl]Jamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]acetamide
Ni 0 ne |p¥ cl
NH
A
A solution of N-[1-{[4-(aminomethyl)phenyl]methyl}-4-(methyloxy)-1H-indazol-3-yl]-5- chloro-2-thiophenesulfonamide formate salt for a preparation see Intermediate 30)(15 mg, 0.03 mmol) and acetic acid (0.001 mL, 0.03 mmol) in acetonitrile (2 mL) and DIPEA (0.046 mL, 0.26 mmol) was treated with HATU (37.0 mg, 0.097 mmol) and the resulting mixture was stirred for 2 h and 15 min at ambient temperature. The reaction mixture was diluted with DCM (2 mL) and water (3 mL). The organic was separated and the aqueous layer was further extracted with DCM (2 mL). The combined organic solutions were dried through an hydrophobic frit and concentrated under reduced pressure. The residue was dissolved in 1:1 MeOH-DMSO (1 mL) and purified by Mass Directed AutoPrep on (supelcosil ABZ+Plus column) eluting with solvents A/B (A: Water + 0.1% Formic acid, B:
MeCN:Water 95:5 + 0.05% Formic acid). The solvent was removed under a stream of nitrogen in a Radleys blowdown apparatus to give the title compound (13 mg, 87%) as a gum. LCMS (System A) RT=1.11 min, ES+ve m/z 505/507 (M+H)".
Examples 98 and 99 were prepared in an array format as above from N-[1-{[4- (aminomethyl)phenyl]methyl}-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide formate salt (15 mg, 0.03 mmol), HATU (37 mg, 0.09 mmol),
DIPEA (0.046 mL, 0.26 mmol) in acetonitrile (2 mL), followed by cleavage of the BOC protecting group using hydrogen chloride in dioxane (4M, 0.074 ml):
Example 98
N-[(4-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-3-morpholinecarboxamide trifluoroacetate q Ni
LTT sila
Oo
NH
AN Fo
F
J I $
LCMS (System A) RT=0.91 min, ES+ve m/z 576/578 (M+H)".
Example 99 N'-[(4-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-N*-methyl-D-alaninamide trifluoroacetate ~ cry bom / oO,
NH
Fo
NH —4 ~ " F OH
LCMS (System A) RT=0.92 min, ES+ve m/z 548/550 (M+H)".
Example 100 3-{[3-{[(5-Chloro-2-thienyl)sulfonyllJamino}-4-(methyloxy)-1H-indazol-1-yllmethyl}-N- methylbenzamide o” wT) 0 NH
Methyl 3-{[3-[[(5-chloro-2-thienyl)sulfonyl]({[2-(trimethylsilyl)ethyl]oxy}methyl)amino]-4- (methyloxy)-1H-indazol-1-yllmethyl}benzoate (for a preparation see Intermediate 31) (70 mg, 0.112 mmol) in a Biotage microwave vial was added 1,3,4,6,7,8-hexahydro-2H- pyrimido[1,2-a]pyrimidine (Aldrich) (7.83 mg, 0.056 mmol) and methylamine solution in
THF (2M, 1.125 mL). The reaction vessel was sealed and heated in a Biotage Initiator microwave oven using initial very high absorption level to 80 °C for 75 min. The reaction mixture was diluted with DCM (2 mL) and water (3 mL). The organic phase was separated, and the aqueous layer was further extracted with DCM (2 mL). The combined organic solutions were dried through an hydrophobic frit and concentrated under a nitrogen stream in a blowdown unit. The residue was treated TBAF in THF (1M, 1.125 mL, 1.125 mmol). The reaction vessel was sealed and heated in a Biotage Initiator at 110 °C for 15 min (very high absorption level). The solvent was removed under a nitrogen stream in a blowdown unit (T=35°C overnight), dissolved in 1:1 MeOH-DMSO (2 mL) and purified by Mass Directed AutoPrep on standard C18 column using Acetonitrile Water with a TFA modifier (Method B). The solvent was removed under a stream of nitrogen in a
Radleys blowdown apparatus to give the title compound (41.7 mg, 75%) LCMS (System
A) RT=1.03 min, ES+ve m/z 491/493 (M+H)".
Example 101 3-{[3-{[(5-Chloro-2-thienyl)sulfonyllJamino}-4-(methyloxy)-1H-indazol-1-yllmethyl}-
N,N-dimethylbenzamide
0 0
W/ ~~ S S oO" uN TT)
N N
/
N
The title compound was prepared similarly to Example 100
LCMS (System A) RT=1.06 min, ES+ve m/z 505/507(M+H)".
Example 102
N'[(3-{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-L-serinamide
Q
WW s7 Ta oO
Cr /
N
H
N pa 0 x
NH,
The title compound was prepared in array format according to the procedure described in
Example 17. LCMS (System A) RT=0.78 min, ES+ve m/z 550/552 (M+H)".
Examples 103 — 105 were prepared according to the procedure described for Example 62.
Example 103 4-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}benzamide i . ow TT) ord /
N
CL.
NH,
LCMS (System A) RT=0.95 min, ES+ve m/z 477/479 (M+H)".
Example 104 5-Chloro-N-(4-(methyloxy)-1-{[4-(methyloxy)phenyl]methyl}-1H-indazol-3-yl)-2- thiophenesulfonamide 0 0 0” ap or /
N
~. \
LCMS (System B) RT=3.11 min, ES+ve m/z 464/466 (M+H)".
Example 105 5-Chloro-N-(4-(methyloxy)-1-{[2-(methyloxy)phenyl]methyl}-1H-indazol-3-yl)-2- thiophenesulfonamide 0. 0 0” ay cl
WY on / be 0 \
LCMS (System B) RT=3.23 min, ES+ve m/z 464/466 (M+H)".
Examples 106 and 107 were prepared according to procedure described for Example 53.
Example 106 5-Chloro-N-[1-({3-[(methylamino)sulfonyl]phenyl}methyl)-4-(methyloxy)-1H-indazol- 3-yl]-2-thiophenesulfonamide
Q gs —N 0°
A N_ s{ 4
N TT) o
LCMS (System B) RT=2.74 min, ES+ve m/z 527/529 (M+H)".
Example 107 5-Chloro-N-[1-({3-[(dimethylamino)sulfonyl]phenyl}methyl)-4-(methyloxy)-1H- indazol-3-yl]-2-thiophenesulfonamide 0
No 4
Ss / ~G ©
LCMS (System B) RT=2.94 min, ES+ve m/z 541/543 (M+H)".
Examples 108 and 109 were prepared by sulfonylation of Intermediate 12 and the appropriate sulfonyl chloride in a similar procedure to that of Example 66
Example 108 3-({4-(Methyloxy)-3-[(2-thienylsulfonyl)amino]-1 H-indazol-1-yl}methyl)benzamide
0 Ss
So LL) \\ oO
Ny /
N
“NH, oO
LCMS (System A) RT=0.93 min, ES+ve m/z 443 (M+H)".
Example 109 3-{[3-{[(4,5-Dichloro-2-thienyl)sulfonyl]Jamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}benzamide cl
LL
~ yo ? NH N Cl or
N N
/
N
{ 0
LCMS (System A) RT=0.99 min, ES+ve m/z 511/513 (M+H)".
Example 110 5-Chloro-N-[1-{[3-{[2-(dimethylamino)ethyl]oxy}-4-(methyloxy)phenyllmethyl}-4- (methyloxy)-1H-indazol-3-yl]-2-thiophenesulfonamide of 0
Crd
N
QL
5 “
The title compound was prepared according to Example 76 using Intermediate 10 and [3-
{[2-(dimethylamino)ethylJoxy}-4-(methyloxy)phenyllmethanol, which was prepared in a similar way to Intermediate 23.
LCMS (System A) RT=0.86 min, ES+ve m/z 551/553 (M+H)".
Example 111 (3R)-N-({3-[(3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-hydroxy-1H-indazol-1- yl)methyl]phenyl}methyl)-3-morpholinecarboxamide formate salt
EN 5
LT 0 /
N
©
NH
OH
AN
HN
The title compound was prepared according to the procedure described in Example 73 LCMS (System B) RT = 1.61 min, ES+ve m/z 562/564 (M+H)".
Example 112
N'-({3-[(3-{[(5-chloro-2-thienyl)sulfonyl]Jamino}-4-hydroxy-1H-indazol-1- yl)methyl]phenyl}methyl)-N*-methylglycinamide formate salt of
S
OH aN U-
Crd
N
NH T
AN OH
~
The title compound was prepared according to procedure described in Example 73.
LCMS (System B) RT = 1.74 min, ES+ve m/z 520/522 (M+H)".
Example 113 5-Chloro-N-[1-{[3-({[(ethylamino)carbonyl]amino}methyl)phenyl]methyl}-4-
(methyloxy)-1H-indazol-3-yl]-2-thiophenesulfonamide 0
NY
~~
LUD cl
Crh /
N
I i
H H
The title compound was prepared according to the procedure described in Example 61 using Intermediate 4 and ethyl isocyanate
LCMS (System A) RT=1.43 min, ES+ve m/z 534/536 (M+H)".
Example 114
N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-L-tryptophanamide of
No iN lpN oc /
N
NH
£2: : NH
NH,
The title compound was prepared by the generic array method described in Example 44
LCMS (System B) RT=2.06 min, ES+ve m/z 649/651 (M+H)".
Example 115 N'-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-D-allothreoninamide formate salt
<~ ed pn
N, cl /
N
: OH q
NH : Lo
AN
NH,
The title compound was prepared by the generic array method described in Example 44
LCMS (System B) RT=1.71 min, ES+ve m/z 564/566 (M+H)".
Example 116
N-{[3-({4-(Methyloxy)-3-[(2-thienylsulfonyl)amino]-1H-indazol-1- yl}methyl)phenyllmethyl}acetamide
So i [ey a s oO
NN
/
N g
N
P=
To a cooled (ice/water bath) solution of N-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyllamino}-4- (methyloxy)-1H-indazol-1-yllmethyl}phenyl)methyllacetamide (for a preparation see
Example 1)(30 mg, 0.06 mmol) in THF (1 mL) was added dropwise 2M lithium aluminium hydride in THF (0.074 mL, 0.149 mmol), and the suspension was stirred 10 min at 0 °C and then at room temperature for one hour. Reaction was quenched with 4 drops of water and then with aqueous solution of sodium hydroxide (2M, 0.5 mL). After stiring for 30 min, solid was removed and washed with THF (10 mL). The filtrate was concentrated under reduced pressure and the residue was dissolved in 1:1 MeOH-DMSO (1 mL) and purified by Mass Directed AutoPrep on Sunfire C18 column using Acetonitrile Water with a TFA modifier (Method B). The solvent from appropriate fractions was evaporated under a stream of nitrogen in a Radleys blowdown apparatus to give the title compound (18 mg, 64%). LCMS (System A) RT=0.89 min, ES+ve m/z 471 (M+H)".
Example 117 4-[(4-(Methyloxy)-3-{[(5-methyl-2-thienyl)sulfonyl]amino}-1H-indazol-1- yl)methyllbenzamide oe
SJ oO —S / \ 0
N N
/
N
=H 0
A solution of 4-{[3-amino-4-(methyloxy)-1H-indazol-1-ylimethyl}benzamide (32.4 mg, 0.2 mmol) in pyridine 3.6 mL) was added to 5-methyl-thiophenesulfonyl chloride (for a preparation see Intermediate 32) (0.30 mmol). The reaction mixture was shaken briefly and allowed to stand for 3 h at 21 °C prior to concentration by blowdown. The residue was dissolved in 1:1 MeOH-DMSO (0.6 mL) and purified by Mass Directed AutoPrep on Xbridge column using Acetonitrile Water with an ammonium carbonate modifier (Method
C). The solvent was evaporated in vacuo using the Genevac to give the title compound (12.5 mg, 14%). LCMS (System A) RT=0.86 min, ES+ve m/z 457 (M+H)".
Example 118 N-[1-{[3,4-Bis(methyloxy)phenyllmethyl}-4-(methyloxy)-1H-indazol-3-yl]-5-methyl-2- thiophenesulfonamide be, 7
Oo
N
0
Oo /
The title compound was prepared in array format according to the procedure described in
Example 117 using Intermediate 33.
LCMS (System A) RT=1.08 min, ES+ve m/z 474 (M+H)".
Example 119
N-({3-[(4-(Methyloxy)-3-{[(5-methyl-2-thienyl)sulfonylJamino}-1H-indazol-1- yl)methyl]phenyl}methyl)acetamide be ~~ H_t=0 1 7 oO
N N
/
HN
=o
The title compound was prepared in array format according to the procedure described in
Example 117 using Intermediate 34.
LCMS (System A) RT=0.96 min, ES+ve m/z 485 (M+H)".
Example 120 (3R)-N-({4-[(4-(methyloxy)-3-{[(5-methyl-2-thienyl)sulfonyl]amino}-1H-indazol-1- yl)methyl]phenyl}methyl)-3-morpholinecarboxamide trifluoroacetate jo ~ H_ _¢=0 7 MM
Cn © Fo
N —~<
N
FE OH
~~ 0
N
= "pe
The title compound was prepared in array format according to the procedure described in
Example 117 using Intermediate 35 followed by TFA cleavage of the BOC protecting group. LCMS (System A) RT=0.69 min, ES+ve m/z 556 (M+H)".
Example 121
N-({3-[(3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-fluoro-1H-indazol-1- yl)methyl]phenyl}methyl)acetamide
NV S\-cl rh /
N 0
H
To a solution of HATU (122 mg, 0.198 mmol) in anhydrous N,N-dimethylformamide (3 mL) was added at room temperature acetic acid (10.29 mL, 0.180 mmol) followed by N,N- diisopropylethylamine (0.094 mL, 0.539 mmol) and finally a solution of N-(1-{[3- (aminomethyl)phenyl]methyl}-4-fluoro-1H-indazol-3-yl)-5-chloro-2-thiophenesulfonamide (for a preparation see Intermediate 39)(81 mg, 0.18 mmol) in anhydrous N,N- dimethylformamide (2 mL). The reaction mixture was stirred at room temperature for 30 min, and then partitioned between saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer was separated, washed with brine-water (1:1), passed through a hydrophobic frit and evaporated in-vacuo to yield a colourless oil.
The residue was dissolved in MeOH-DMSO (1 mL) and purified by Mass Directed
AutoPreparative HPLC MDAP (Sunfire C18 column 150 mm x 30 mm i.d. 5 um packing diameter at ambient temperature) eluting with solvents A/B (A: 0.1% v/v solution of formic acid in water, B: 0.1% v/v solution of formic acid in acetonitrile) over 25 min. The appropriate fraction was evaporated in-vacuo to yield a colourless oil (5.9 mg, 6%).
LCMS (System B): RT = 2.53 min, ES+ve m/z 493/495 (M+H)".
Example 122
N-({3-[(4-Chloro-3-{[(5-chloro-2-thienyl)sulfonylJamino}-1H-indazol-1- yl)methyl]phenyl}methyl)acetamide
OQ 5 o wp
J oo /
N 0
OY
H
To an ice/water bath cooled solution of 5-chloro-N-{4-chloro-1-[(3-cyanophenyl)methyl]- 1H-indazol-3-yl}-2-thiophenesulfonamide (for a preparation see Intermediate 42) (95 mg, 0.20 mmol) in anhydrous tetrahydrofuran (4 mL) under nitrogen atmosphere was added dropwise over 1 min lithium aluminium hydride (1M solution in diethyl ether, 0.513 mL,
0.513 mmol). The reaction was stirred in the ice/water bath for 10 min, and then at room temperature for 30 min. Reaction re-cooled in the ice/water bath and a further portion of lithium aluminium hydride (1M solution in diethyl ether, 0.2 mL) was added dropwise over 1 min. Reaction stirred at room temperature for 1.5 h, then cooled (ice/water bath) and cautiously quenched with water (dropwise) until no more effervescence. The reaction mixture was then diluted with 1:1 methanol-dichloromethane in order to try to improve solubility and applied to a methanol pre-conditioned 20g SCX-2 cartridge. The cartridge was washed with methanol and then eluted using 2M ammonia in methanol solution. The 2M ammonia in methanol fractions were combined and evaporated in-vacuo to yield N-(1- {[3-(aminomethyl)phenyllmethyl}-4-chloro-1H-indazol-3-yl)-5-chloro-2- thiophenesulfonamide (68 mg, 0.15 mmol) as an off-white solid. This amine was dissolved in DMF (2 mL) and added to a mixture of HATU (99 mg, 0.16 mmol), acetic acid (8.3 pL, 0.14 mmol), N,N-diisopropylethylamine (0.076 mL, 0.44 mmol) in anhydrous DMF (1 mL). The reaction mixture was stirred at room temperature for 4 h, partitioned between saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer was separated, washed with brine-water (1:1), passed through a hydrophobic frit and evaporated in-vacuo to yield a yellow oil, which was dissolved in MeOH-DMSO (1:1) (1 mL) and purified by Mass Directed AutoPreparative HPLC (Sunfire C18 column 150 mm x 30 mm i.d. 5 um packing diameter at ambient temperature) eluting with solvents A/B (A: 0.1% v/v solution of formic acid in water, B: 0.1% v/v solution of formic acid in acetonitrile) over 25 min. Appropriate fraction was evaporated in-vacuo to yield the title compound as a yellow oil (6.7 mg, %). LCMS (System B) RT = 2.66 min, ES+ve m/z 509/511 (M+H)".
Example 123
N-[(3{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-4-methyl-3-morpholinecarboxamide « oO wn Th
AF 0 2
A solution of 4-methyl-3-morpholinecarboxylic acid hydrochloride (Chem-Impex
International) (60.0 mg, 0.33 mmol) in acetonitrile (2 mL) was treated with HATU (126 mg, 0.33 mmol) and DIPEA (0.157 ml, 0.901 mmol). The resulting mixture was stirred for 15 min at ambient temperature and then N-[1-{[3-(aminomethyl)phenyl]lmethyl}-4- (methyloxy)-1H-indazol-3-yl]-5-chloro-2-thiophenesulfonamide ~~ hydrochloride (for a preparation see Intermediate 4) (150 mg, 0.300 mmol) was added, and the resulting mixture was stirred at ambient temperature for 1 h. The reaction mixture was diluted with
DCM (3 mL) and water (3 mL). Organic phase was separated and the aqueous layer was further extracted with 3 mL of DCM. The combined organic solutions were washed with water (3 mL), dried through an hydrophobic frit and concentrated in a nitrogen blow-down apparatus. The residue was dissolved in 1:1 MeOH-DMSO 2 mL and purified by Mass
Directed AutoPrep (Method C) on Xbridge column using acetonitrile water with an ammonium carbonate modifier. The solvent was evaporated under reduced pressure to give the required product (53.1 mg, 30%). LCMS (System F) RT = 0.85 min, ES+ve m/z 590/592 (M+H)".
Examples 124 and 125
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-4-methyl-3-morpholinecarboxamide Enantiomer 1 (Example 124) and Enantiomer 2 (Example 125)
The racemic mixture above (22 mg) (for a preparation see Example 123) was resolved by chiral HPLC on Chiralpak AD (25 cm) eluting with 50% EtOH-heptane, 30 min isocratic run, flow rate 15 mL/min, detecting at 215 nm to give:
Enantiomer 1 (7.51 mg, 34%): Analytical chiral HPLC [on Chiralpak AD (25 cm) eluting with 50% EtOH-heptane flow rate 1 mL/min, detecting at 215 nm] RT = 13.2 min, 100%, [odo ® - 34 (c = 0.751 in chloroform) and
Enantiomer 2 (8.3 mg, 38%): Analytical chiral HPLC RT = 17.7 min, 98%, %, [a]p 0422 (c = 0.83 in chloroform).
Example 126 (2S)-N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-hydroxypropanamide (S-enantiomer of Example 37)
of] ~o ast
Cl 2
A
OH
A suspension of N-[1-{[3-(aminomethyl)phenyl]methyl}-4-(methyloxy)-1H-indazol-3-yl]-5- chloro-2-thiophenesulfonamide hydrochloride (for a preparation see Intermediate 4)(100 mg, 0.2 mmol) in DCM (5 mL) and triethylamine (0.28 mL, 2 mmol) was treated with the (S)-2-acetoxypropionyl chloride (0.065 mL). After 4 h, the solvent was removed by evaporation and the residue was dissolved in methanol (10 mL) and then treated with solid potassium carbonate (277 mg, 2 mmol) and the mixture was stood at RT for 3 days.
The mixture was concentrated under reduced pressure, and the residue was partitioned between 2M HCI and ethyl acetate. The organic solution was washed with more HCI, brine and dried (MgSQ,). The filtrate was evaporated under reduced pressure to give a white solid (113 mg). The sample was dissolved in 1:1 MeOH-DMSO 2 mL and purified by Mass Directed AutoPrep on Sunfire C18 column using Acetonitrile Water with a Formic acid modifier (Method A). The solvent was evaporated in vacuo to give the title compound (86 mg, 80%): LCMS (System A) RT=0.97 min, 100%, ES+ve m/z 535/537 (M+H)"; NMR 8 (CD;OD) 7.27-7.15 (5H, m), 7.05 (1H, br d, J 7 Hz), 6.97 (1H, d, J 8 Hz), 6.89 (1H, d, J 4 Hz), 6.42 (1H, d, J 8 Hz), 5.47 (2H, s), 4.33 (2H, s), 4.12 (1H, q, J 7 Hz), 3.76 (3H, s), 1.30 (3H, d, J 7 Hz).
Example 127 N'-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-methylalaninamide
Ns oO
N
2
A mixture of N-[1-{[3-(aminomethyl)phenyl]methyl}-4-(methyloxy)-1H-indazol-3-yl]-5- chloro-2-thiophenesulfonamide hydrochloride (for a preparation see intermediate 4)(529 mg, 1.06 mmol), N-BOC-alpha-methylalanine (Sigma) (248 mg, 1.22 mmol), HATU (503 mg, 1.32 mmol) was stirred in DMF (2 mL) and DIPEA (0.75 mL, 4.4 mmol) until the mixture dissolved and then stood overnight at room temperature. The mixture was then treated with TFA (1.5 mL, 19. 5 mmol) at room temperature and after 45 min more TFA (1.5 mL, 19. 5 mmol) added. After 1.5 h more TFA (1 mL) was added and the mixture was stirred for 18 h. The mixture was concentrated under reduced pressure and the residue was loaded in methanol and purified by SPE on ion exchange cardridge (SCX-2) 50g eluting with MeOH, followed by 10% aqueous ammonia in MeOH . The appropriate ammoniacal fractions were combined and evaporated in vacuo to give the crude product.
The sample was dissolved in 1:1 MeOH-DMSO 8 mL and purified by Mass Directed
AutoPrep on Xbridge column using Acetonitrile Water with an ammonium carbonate modifier (Method C) collecting the peak with RT~6.0 min. The solvent was evaporated in vacuo to give the title compound (242 mg, 42%): LCMS (System C) RT=2.01 min, ES+ve m/z 548/550 (M+H)"; NMR & (CD;OD) 7.26-7.13 (4H, m), 7.10 (1H, br d, J 7 Hz), 7.05 (1H, br s), 6.92 (1H, d, J 8 Hz), 6.86 (1H, d, J 4 Hz), 6.40 (1H, d, J 8 Hz), 5.45 (2H, s), 4.31 (2H, s), 3.77 (3H, s), 1.31 (6H, s).
Example 128
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-7-fluoro-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]lacetamide
} NY
S
> U 0 ; =
N-[1-{[3-(aminomethyl)phenyllmethyl}-7-fluoro-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide (for a preparation see Intermediate 46)(70 mg, 0.15 mmol) was dissolved in DCM (0.75 mL) and triethylamine (0.203 mL, 1.45 mmol) was added to the solution. The solution was stirred for 5 min and acetic anhydride (0.013 mL, 0.13 mmol) was added. The reaction was stirred for 1 h, and then concentrated under a stream of nitrogen. The residue was dissolved in MeOH-DMSO (1:1) (1 mL) and purified by Mass
Directed AutoPrep on Sunfire C18 column using Acetonitrile Water with a TFA modifier (Method B). The solvent was evaporated in vacuo to give the title compound (26 mg, 34%): LCMS (System A) RT = 1.04 min, ES+ve m/z 523/524 (M+H)".
Example 129
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-6-fluoro-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]lacetamide
Cl 0” wig!
Oo 3 )- N
N-[1-{[3-(Aminomethyl)phenyllmethyl}-6-fluoro-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide formate salt (for a preparation see Intermediate 54)(53 mg, 0.1 mmol) was dissolved in MeOH and applied to an SCX-2 cartridge (5g) eluting with MeOH, followed by 10% aqueous ammonia in MeOH. The ammoniacal fraction was evaporated under reduced pressure to give the free base (44 mg, 0.09 mmol) as a white crystalline solid. This was suspended in chloroform (2 mL) and triethylamine (1 mL) and then treated with acetic anhydride (0.024 mL). The mixture was shaken briefly until homogeneous and then it was stood at room temperature for 2 h. The mixture was treated with MeOH and allowed to stand to consume excess acetic anhydride and then was concentrated under reduced pressure. The residue was dissolved in 1:1 MeOH-DMSO 1 mL and purified by
Mass Directed AutoPrep on Xbridge column using Acetonitrile Water with an ammonium carbonate modifier (Method C). The solvent was evaporated in vacuo and the residue was dissolved in DCM and washed with 2M HCI solution, and evaporated under reduced pressure to give the title compound (25 mg, 52%) LCMS (System A) RT=1.02 min,
ES+ve m/z 523/525 (M+H)".
Example 130 3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-6-fluoro-4-(methyloxy)-1H-indazol-1- yllmethyl}benzamide cl
S
No 20 0 oo
F N
J.
A solution of 5-chloro-N-[(5-chloro-2-thienyl)sulfonyl]-N-[1-[(3-cyanophenyl)methyl]-6- fluoro-4-(methyloxy)-1H-indazol-3-yl]-2-thiophenesulfonamide (for a preparation see
Intermediate 53)(53 mg, 0.08 mmol) in methanol (10 mL) was treated with 2M NaOH solution (1 mL) was heated to 60 °C under nitrogen overnight. More 2M NaOH solution (0.5 mL) was added and the mixture was heated to 71°C over the weekend. The mixture was allowed to cool to RT and then treated with 2M HCI solution to pH 0. The mixture was extracted with ethyl acetate and the organic solution was washed with 2M HCI, brine, dried (MgSO,) and evaporated to a gum 54 mg. The residue was dissolved in 1:1 MeOHR-
DMSO 1 mL and purified by Mass Directed AutoPrep on Sunfire C18 column using
Acetonitrile Water with a Formic acid modifier (Method A) collecting fractions with
RT=7.77 min 19% and 8.73 min, 81%). The solvent was evaporated in vacuo from the major fraction (RT=8.73 min) to give 3-{[3-{[(5-chloro-2-thienyl)sulfonyllamino}-6-fluoro-4- (methyloxy)-1H-indazol-1-yllmethyl}benzoic acid (26 mg, 65%), as a white solid: LCMS (System A) RT=1.04 min, ES+ve m/z 496/498 (M+H)" for carboxylic acid product. The minor component (RT=7.77 min) was evaporated under reduced pressure to give the title compound (6.2 mg, 15%) as a white solid: LCMS (System A) RT=0.97 min, ES+ve m/z
495/497 (M+H)".
Example 131 (3R)-N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-6-fluoro-4-(methyloxy)-1H- indazol-1-yllmethyl}phenyl)methyl]-3-morpholinecarboxamide
Cl o 20 oO ¢ ~3 © AN)
N-[1-{[3-(Aminomethyl)phenyllmethyl}-6-fluoro-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide (for a preparation see Intermediate 54) (100 mg, 0.208 mmol) was suspended in dichloromethane (1 mL), (3R)-4-{[(1,1-dimethylethyl)oxy]carbonyl}-3- morpholinecarboxylic acid (52.9 mg, 0.229 mmol) and HATU (87 mg, 0.229 mmol) were added to the reaction mixture and stirred for 5 min. DIPEA (0.109 mL, 0.624 mmol) was added to the reaction mixture and stirred over the weekend. Trifluoroacetic acid (0.25 mL, 3.24 mmol) was added to the reaction mixture and stirred for 3.5 h. The mixture was concentrated under a stream of nitrogen leaving a brown residue. The residue was dissolved in 1:1 MeOH-DMSO (1 mL) and purified by Mass Directed AutoPrep on Sunfire
C18 column using Acetonitrile Water with a TFA modifier (Method B). The solvent was evaporated in vacuo to give the TFA salt of the required product as an off white residue.
The residue was dissolved in methanol and loaded onto a methanol pre-conditioned polymeric carbonate (SAX) cartridge. The sample was eluted with 1.25M HCI in methanol. The fractions were concentrated in vacuo, dissolved in methanol and loaded onto a methanol pre-conditioned SCX-2 ion exchange cartridge (2g). The cartridge was washed well with methanol, followed by 2M ammonia in methanol. Evaporation of the solvent from the ammoniacal fractions gave the title compound (30 mg, 24%): LCMS (System A) RT=0.88 min, ES+ve m/z 594/596 (M+H)".
Example 132
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-6-fluoro-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-hydroxy-2-methylpropanamide
Cl
S
So we
Oo ¢
N-[1-{[3-(Aminomethyl)phenyllmethyl}-6-fluoro-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide (for a preparation see Intermediate 54)(100 mg, 0.208 mmol) (intermediate ) was dissolved in dichloromethane (0.5 mL) and pyridine (0.5 mL), and then treated with 2-chloro-1,1-dimethyl-2-oxoethyl acetate (0.031 mL, 0.218 mmol). The mixture was stirred for 2 h. LCMS showed starting material remaining so more 2-chloro- 1,1-dimethyl-2-oxoethyl acetate (0.021 mL, 0.146 mmol) was added to the reaction mixture and stirred for 1.5 hr. LCMS showed starting material remaining so a further portion of 2-chloro-1,1-dimethyl-2-oxoethyl acetate (0.015 mL, 0.104 mmol) was added to the reaction and stirred for 1.25 h. The reaction mixture was concentrated under a stream of nitrogen to leave a yellow residue, which was dissolved in methanol (1 mL) and potassium carbonate (86 mg, 0.624 mmol) was added to the solution. The reaction mixture was heated to 40 °C for 1 hand then neutralised with 2M HCI and concetrated in vacuo. The residue was dissolved in ethyl acetate (50 mL), washed three times with water (50 mL) and once with brine (50 mL). The organic layer was dried over anhydrous magnesium sulfate before being evaporated in vacuo to leave a yellow residue. The sample was dissolved in 1:1 MeOH-DMSO (1 mL) and purified by Mass Directed
AutoPrep on Sunfire C18 column using Acetonitrile Water with a TFA modifier (Method B).
The solvent was evaporated in vacuo to give the title cimpound (60 mg, 51%). LCMS (System A) RT=1.04 min, ES+ve m/z 481/483 (M+H)".
Example 133
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-6-fluoro-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-4-methyl-3-morpholinecarboxamide
Cl 3
So A o or
F N
¢ \ <=
C
N-[1-{[3-(Aminomethyl)phenyllmethyl}-6-fluoro-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide (for a preparation see Intermediate 54)(250 mg, 0.520 mmol) was dissolved in dichloromethane (2.5 mL), 4-methyl-3-morpholinecarboxylic acid hydrochloride (104 mg, 0.572 mmol) and HATU (217 mg, 0.572 mmol) were added to the reaction mixture stirred for 5 min. DIPEA (0.272 mL, 1.559 mmol) was added to the mixture and stirred over the weekend. LCMS showed that the coupling was complete so the reaction was concentrated under a stream of nitrogen in ablow-down unit. The residue was dissolved in 1:1 MeOH:DMSO (1 mL) and purified by Mass Directed AutoPrep on Sunfire C18 column using Acetonitrile Water with a TFA modifier (Method B).
The solvent was evaporated in vacuo to give the TFA salt of required product as an orange oil. The compound was dissolved in methanol and passed down a polymeric carbonate (SAX) cartridge, the cartridge was eluted with methanol and solvent was evaporated in vacuo to give the free base of the required product as an orange oil (80 mg). The carbonate cartridge was further eluted with 1.25M HCI in methanol, the solution was evaporated in vacuo, the residue (150 mg) dissolved in methanol and loaded onto a methanol pre-conditioned SCX-2 ion-exchange cartridge (1 g). The cartridge was washed well with methanol, followed by 2M ammonia in methanol. Evaporation of the solvent from the ammoniacal fractions gave a further portion of the free-base of the required product, which was combined with the earlier batch.
The racemic mixture (140 mg) was then resolved by chiral HPLC separtion on Chiralpak
IA (20 mm x 250 mm, 10 mm packing), flow rate 15 mL/min, detecting at 300 nm, eluting with 25% ethanol-heptane (isocratically for 60 min) to give Enantiomer 1 of the title compound (67 mg, 20%): LCMS (System A) RT=0.86 min, ES+ve m/z 608/610 (M+H)",
Analytical Chiral HPLC Chiralcel 1A (4.6 mm x 250 mm, 10 um packing), flow rate 1 mL/min, detecting at 300 nm, eluting with 35% ethanol-heptane (isocratically for 22 min)
RT=13.5 min, >99.5% and Enantiomer 2 (67 mg, 20%) RT=17.0 min, >99.5%
Example 134
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-5-fluoro-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]lacetamide ( - 9 S cl
I
1
A solution of N-[1-{[3-(aminomethyl)phenyl]methyl}-5-fluoro-4-(methyloxy)-1H-indazol-3- yl]-5-chloro-2-thiophenesulfonamide (for a preparation see Intermediate 61)(49 mg, 0.10 mmol) in dry DMF (4 mL) was treated with HATU (38.7 mg, 0.10 mmol) and stirred under nitrogen for 3 min prior to the addition of DIPEA (0.018 mL, 0.10 mmol). The reaction mixture was stirred for a further 3 min prior to the addition of acetic acid (6.12 mg, 0.10 mmol) and stirring continued for a further 3 h. The reaction mixture was concentrated by nitrogen in a blowdown unit and the sample was loaded in dichloromethane onto aminopropy! ion-exchange cartridge (1 g) pre-equilibrated with DCM. The sample was eluted with methanol/dichloromethane and dried under a stream of nitrogen in the
Radleys blowdown apparatus to give the crude product. The sample was dissolved in 1:1
MeOH-DMSO (1 mL) and purified by Mass Directed AutoPrep on Xbridge column using
Acetonitrile Water with an ammonium carbonate modifier (Method C). The solvent was evaporated in vacuo using the Genevac to give the title compound (14.5 mg, 27%): LCMS (System A) RT=1.06 min, ES+ve m/z 523/525 (M+H)".
Example 135 (3S)-N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-5-fluoro-4-(methyloxy)-1H- indazol-1-yllmethyl}phenyl)methyl]-3-morpholinecarboxamide cl
S
No 20
F fo 2, , 0
N-[1-{[3-(Aminomethyl)phenyllmethyl}-5-fluoro-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide (for a preparation see Intermediate 61 ) (100 mg, 0.208 mmol) was suspended in DCM (1 mL), (3S)-4-{[(1,1-dimethylethyl)oxy]carbonyl}-3- morpholinecarboxylic acid (52.9 mg, 0.229 mmol) and HATU (87 mg, 0.229 mmol) were added to the reacion mixture and stirred for 5 min. DIPEA (0.109 mL, 0.624 mmol) was added to the reaction mixture and stirred over the weekend. LCMS showed the coupling had gone to completion. Trifluoroacetic acid (0.25 mL, 3.24 mmol) was added to the reaction and left to stir for 1 h and 50 min. LCMS showed the reaction had gone to completion so the mixture was concentrated under a stream of nitrogen. The sample was dissolved in 1:1 MeOH-DMSO (1 mL) and purified by Mass Directed AutoPrep on Sunfire
C18 column using Acetonitrile Water with a TFA modifier (Method B). The solvent was evaporated in vacuo to give the required product (as TFA salts ). The residue was dissolved in methanol and loaded onto a methanol pre-conditioned SCX-2 ion-exchange cartridge cartridge (10 g). The cartridge was washed well with methanol, followed by 2M ammonia in methanol. Evaporation of the solvent from the ammoniacal fractions gave the title compound as a colourless glassy solid (71 mg, 57%). LCMS (System A) RT=0.82 min, ES+ve m/z 594/596 (M+H)".
Example 136 (3R)-N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-5-fluoro-4-(methyloxy)-1H- indazol-1-yllmethyl}phenyl)methyl]-3-morpholinecarboxamide
Cl
S
2
F 0
To 3 ~3 © A
N-[1-{[3-(Aminomethyl)phenyllmethyl}-6-fluoro-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide (for a preparation see Intermediate 61) (100 mg, 0.208 mmol) was suspended in dichloromethane (1 mL), (3R)-4-{[(1,1-dimethylethyl)oxy]carbonyl}-3- morpholinecarboxylic acid (52.9 mg, 0.229 mmol) and HATU (87 mg, 0.229 mmol) were added to the reaction mixture and stirred for 5 min. DIPEA (0.109 mL, 0.624 mmol) was added to the reaction mixture and it was left to stir over the weekend. LCMS showed the coupling had gone to completion. Trifluoroacetic acid (0.25 mL, 3.24 mmol) was added to the reaction and left to stir for 1 h and 50 min. LCMS showed the reaction had gone to completion so the mixture was concentrated under a stream of nitrogen to afford a brown residue. The residue was dissolved in 1:1 MeOH-DMSO (1 mL) and purified by Mass
Directed AutoPrep on Sunfire C18 column using Acetonitrile Water with a TFA modifier (Method B). The solvent was evaporated in vacuo to give the required product as an off white residue (as TFA salt). The residue was dissolved in methanol and loaded onto a methanol pre-conditioned SCX-2 ion-exchange cartridge (10 g). The cartridge was washed well with methanol, followed by 2M ammonia in methanol. Evaporation of the solvent from the ammoniacal fractions gave the title compound (76 mg, 61% yield).
LCMS (System A) RT=0.83 min, ES+ve m/z 594/596 (M+H)".
Example 137
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-5-fluoro-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-hydroxy-2-methylpropanamide
Cl o S
So A
F 0
N
H
N
1
OH
A suspension of N-[1-{[3-(aminomethyl)phenyl]methyl}-5-fluoro-4-(methyloxy)-1H-indazol- 3-yl]-5-chloro-2-thiophenesulfonamide (for a preparation see Intermediate 61)(100 mg, 0.208 mmol) in dichloromethane (0.5 mL),pyridine (0.5 mL) and potassium hydroxide (11.67 mg, 0.208 mmol) was treated with 2-chloro-1,1-dimethyl-2-oxoethyl acetate (0.054 mL, 0.37 mmol) and the mixture was stirred for 2.5 h. The reaction mixture was concentrated in vacuo and the orange residue was dissolved in 1:1 MeOH-DMSO (1 mL) and purified by Mass Directed AutoPrep on Sunfire C18 column using Acetonitrile Water with a TFA modifier (Method B). The solvent was evaporated in vacuo to give the title compound (58 mg, 49%). LCMS (System A) RT=1.04 min, ES+ve m/z 567/569 (M+H)".
Example 138 4-{[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]amino}-4-oxobutanoic acid >So Po .
Cr De
N
]
N
H
J
OH
4-(Methyloxy)-4-oxobutanoic acid (0.013 g, 0.1 mmol) was treated with a solution of 2- (1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.076 g, 0.2 mmol) in anhydrous DMF (0.2 ml) and N,N-diisopropylethylamine (0.052 ml, 0.3 mmol) and then the solution was stirred for 10 min. N-[1-{[3-(Aminomethyl)phenyl]methyl}-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide (for a preparation see Intermediate 4) (0.046 g, 0.1 mmol) was added to the solution and the resulting solution stirred for 18 h at room temperature. The solvent was removed by genevac, the residue was dissolved in DMSO (0.5 ml) and purified by mass directed auto-preparative HPLC to give methyl 4-{[(3-{[3-{[(5-chloro-2- thienyl)sulfonyllamino}-4-(methyloxy)-1H-indazol-1-yllmethyl}phenyl)methyllamino}-4- oxobutanoate. This was dissolved in methanol (0.2 ml), sodium hydroxide (2M, 0.15 ml) and water (0.09 ml) were added, and the reaction mixture was stirred at 30°C for 1 h. The solution was neutralised and concentrated in a blow-down unit, and the residue was purified by mass directed auto-preparative HPLC (Method E) to give the title compound.
LCMS (System A) RT= 0.99 min, ES+ve m/z 563/565 (M+H)*
Examples 139 - 145 were similarly prepared to Example 138 using N-[1-{[3- (Aminomethyl)phenyllmethyl}-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide and the appropriate carboxylic acid
Example 139
Example 5-{[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]amino}-5-oxopentanoic acid 0 ~~ oN 0 N~S . “N / al
N
RK
H
HO
LCMS (System A) RT= 0.97 min, ES+ve m/z 577/579 (M+H)"
Example 140 6-{[(3{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]amino}-6-oxohexanoic acid
O he AY .
Cr Ce
N
]
N
H
O
LCMS (System A) RT= 0.99 min, ES+ve m/z 591/593 (M+H)*
Exanple 141 3-({[(3{[3-{[(5-Chloro-2-thienyl)sulfonyl]Jamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methylJamino}carbonyl)benzoic acid oO
So {ad .
Cr Di
N
}
HO N
H
LCMS (System A) RT= 1.05 min, ES+ve m/z 611/613 (M+H)"
Example 142 4-({[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]Jamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]amino}carbonyl)benzoic acid >So 0 .
Cry O-
N
]
N
HO
Oo LCMS (System A) RT= 1.04 min, ES+ve m/z 611/613 (M+H)"*
Example 143 trans-4-({[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]Jamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]amino}carbonyl)cyclohexanecarboxylic acid
I
Cr De
N
] 3
H
Ho
Oo
LCMS (System A) RT= 1.01 min, ES+ve m/z 617/619 (M+H)"
Example 144 8-{[(3{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]amino}-8-oxooctanoic acid
O
So {ad .
Cr |p
N
]
N
H
~ Bie oO
LCMS (System A) RT= 1.04 min, ES+ve m/z 619/621 (M+H)"
Example 145 9-{[(3{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]amino}-9-oxononanoic acid)
So PL . rb Bs
N
] as
H
O
HO
LCMS (System A) RT= 1.07 min, ES+ve m/z 633/635 (M+H)"
Example 146 2-({[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]Jamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyllJamino}carbonyl)benzoic acid 0 ~o Pd
S
Cry
N
N
N go
OH
To a solution of N-[1-{[3-(aminomethyl)phenylmethyl}-4-(methyloxy)-1H-indazol-3-yl]-5- chloro-2-thiophenesulfonamide (for a preparation see Intermediate 4)(0.046 g, 0.1 mmol) in THF (0.5 ml) was added N,N-diisopropylethylamine (0.035 ml, 0.2 mmol), followed by phthalic anhydride (0.014 g, 0.1 mmol). The solution was stirred for 18 hours at room temperature, concentrated in a blow-down unit and the residue was dissolved in DMSO (0.5 ml) and purified by mass directed auto-preparative HPLC (Method E) to give the title compound (35 mg, 51%).
LCMS (System A) RT= 1.03 min, ES+ve m/z 611/613 (M+H)"*
Example 147
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(difluoromethyl)-1H-indazol-1- yllmethyl}phenyl)methyl]acetamide
Cl ¢ —
F Fo LO
NT oY
N-[1-{[3-(Aminomethyl)phenyl]methyl}-4-(difluoromethyl)-1H-indazol-3-yl]-5-chloro-N-[(5- chloro-2-thienyl)sulfonyl]-2-thiophenesulfonamide (for a preparation see Intermediate 70) (26 mg, 0.039 mmol) was suspended in dichloromethane (0.5 mL) and triethylamine (0.055 mL, 0.39 mmol) and then acetic anhydride (0.004 mL, 0.043 mmol) was added to the suspension. The mixture was stirred for 1 h, and concentrated under a stream of nitrogen to give N-[(3-{[3-{Bis[(5-chloro-2-thienyl)sulfonyllJamino}-4-(difluoromethyl)-1H- indazol-1-yllmethyl}phenyl)methyllacetamide, which was used without further purification.
The residue was dissolved in methanol (2 mL) and treated with NaOH (0.553 mL, 1.105 mmol) and the reaction mixture was stirred at 60 °C for 3 h. LCMS showed the reaction had gone to completion so the mixture was concentrated in vacuo and acidified with 5% citric acid. The solution was extracted with ethyl acetate and the organic layer was washed twice with water (25 mL) and once with brine (25 mL). The organic layer was dried over anhydrous magnesium sulfate before being evaporated in vacuo to give a yellow residue which was dissolved in 1:1 MeOH-DMSO (1 mL) and purified by Mass
Directed AutoPrep on Sunfire C18 column using Acetonitrile Water with a Formic acid modifier (Method A). The solvent was evaporated in vacuo to give the title compound (7 mg, 36%). LCMS (System A) RT=1.02 min, ES+ve m/z 525/527 (M+H)".
Example 148
N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]Jamino}-4-(hydroxymethyl)-1H-indazol-1- yllmethyl}phenyl)methyl]acetamide
Cl =
HO [_o
Ns
ORS
N-[1-{[3-(Aminomethyl)phenyllmethyl}-4-(hydroxymethyl)-1 H-indazol-3-yl]-5-chloro-N-[(5- chloro-2-thienyl)sulfonyl]-2-thiophenesulfonamide (for a preparation see Intermediate 72)(53 mg, 0.082 mmol) was suspended in dichloromethane (0.5 mL) and triethylamine (0.115 mL, 0.823 mmol). Acetic anhydride (0.008 mL, 0.09 mmol) was added to the suspension and it stired for 1 h. LCMS showed starting material remaining so dichloromethane (0.3 mL) and acetic anhydride (3.88 uL, 0.041 mmol) were added to the solution and stirred for 2 h. LCMS showed only a small amount of starting material remaining so the reaction mixture was concentrated in vacuo to leave an off-white residue, which was dissolved in methanol (3 mL) and treated with NaOH (1.546 mL, 3.09 mmol). The reaction was stirred at room temperature for 1 h and then was concentrated in vacuo, and acidified with 5% citric acid. The solution was extracted with ethyl acetate and the organic layer was washed twice with water (25 mL) and once with brine (25 mL).
The organic layer was dried over anhydrous magnesium sulfate before being evaporated in vacuo. The yellow residue was dissolved in 1:1 MeOH-DMSO (1 mL) and purified by
Mass Directed AutoPrep on Sunfire C18 column using Acetonitrile Water with a Formic acid modifier (Method A). The solvent was evaporated in vacuo to give the title compound (17 mg, 43%) as a colourless glassy solid. LCMS (System A) RT = 0.91 min,
ES+ve m/z 505/507 (M+H)".
Example 149
N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]Jamino}-4-(1-hydroxyethyl)-1H-indazol-1- yllmethyl}phenyl)methyl]acetamide cl ~~ —
HO 0 ; R—s< 0
Ny /
N 0
H
Sodium borohydride (3.09 mg, 0.082 mmol) was added to a stirring solution of N-({3-[(4- acetyl-3-{[(5-chloro-2-thienyl)sulfonyllamino}-1H-indazol-1- yhmethyl]phenyl}methyl)acetamide (for a preparation see Intermediate 75) (40 mg, 0.068 mmol) in MeOH (2 mL) at 25 °C under nitrogen. The reaction mixture was stirred at room temp. for 2 hours, and then 1N HCI (5 mL) was slowly added and the methanol was evaporated in vacuo. The product was extracted with EtOAc (2 x 20 mL) and the combined organic layers were dried by pasing through a hydrophobic frit and concentrated. The residue was dissolved in DMSO (1 mL) and purified by Mass Directed AutoPrep on Sunfire C18 column using Acetonitrile Water with a Formic acid modifier (Method A). The solvent was evaporated in vacuo to give the title compound (18 mg, 48%). LCMS (System A) RT= 0.97 min, ES+ve m/z 519/521 (M+H)".
Example 150
N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(1-hydroxy-1-methylethyl)-1H- indazol-1-yllmethyl}phenyl)methyl] cl =
S
—
LF
0
Ny /
N 0 oY
H
Methylmagnesium bromide (3M solution in diethyl ether) (0.256 mL, 0.768 mmol) was added slowly to a stirring solution of N-({3-[(3-{[(5-chloro-2-thienyl)sulfonyllamino}-4- cyano-1H-indazol-1-ymethyllphenylimethyl)acetamide (for a preparation see
Intermediate 73)(64 mg, 0.128 mmol) in THF (1 mL) at room temp. The reaction was stirred for 2 h. LCMS showed starting material still remaining. Therefore, added more methylmagnesium bromide (3M solution in diethyl ether) (0.128 mL, 0.384 mmol) was added and stirred the reaction at room temp overnight. 0.5N HCI (4 mL) was added and the product was extracted with EtOAc (10 mL x 3). The combined organic layers were dried by passing through a hydrophobic frit and concentrated in vacuo. The resulting yellow oil was dissolved in THF (1 mL) and methylmagnesium bromide (3M solution in diethyl ether) (0.256 mL, 0.768 mmol) was slowly added at 0°C under nitrogen. The reaction was warmed to room temp over ~20 min and was stirred for 2 h. LCMS showed starting material co-elutes with the product - molecular ion at 533 [M+H] corresponding to the desired alcohol product. 1N HCI (4 mL) was slowly added and the product was extracted with EtOAc (15 mL x 3). The combined organic layers were dried by passing through a hydrophobic frit and concentrated in vacuo to give a yellow oil, which was dissolved in DMSO (1 mL) and purified by Mass Directed AutoPrep on Sunfire C18 column using Acetonitrile Water with a Formic acid modifier (Method A). The solvent was evaporated in vacuo to give the title compound ( 23.2 mg, 30%) as a yellow solid. LCMS (System A) RT=1.03 min, ES+ve m/z 533/535 (M+H)".
Example 151
N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]Jamino}-4-(1-hydroxyethyl)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-hydroxy-2-methylpropanamide
OH 0 J
A
Ny Cl
N
H on
Triethylamine (0.021 mL, 0.151 mmol) was added to N-[1-{[3- (aminomethyl)phenyllmethyl}-4-(1-hydroxyethyl)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide (for a preparation see Intermediate 77)(24 mg, 0.050 mmol) in dichloromethane (1 mL). 2-Chloro-1,1-dimethyl-2-oxoethyl acetate (7.92 uL, 0.055 mmol) was added and the reaction mixture was stirred at room temp for 2 h. The reaction mixture was concentrated on the blowdown unit, potassium carbonate (69.5 mg, 0.503 mmol) and methanol (2 mL) was added and the mixture was stirred at room temp for 1h.
The mixture was concentrated, acidified with 2N HCI and extracted with EtOAc (2 x15 mL). The combined organic layers were dried by passing through a hydrophobic frit and concentrated to afford the crude product. The residue was dissolved in DMSO (1 mL) and purified by Mass Directed AutoPrep on Sunfire C18 column using Acetonitrile Water with a Formic acid modifier (Method A). The solvent was removed under a stream of nitrogen in the Radleys blowdown apparatus to give the title compound (10.5 mg, 37%). LCMS (System A) RT=0.99 min, ES+ve m/z 563/565 (M+H)".
Example 152 (3R)-N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]Jamino}-4-(1-hydroxyethyl)-1H-indazol-1- yllmethyl}phenyl)methyl]-3-morpholinecarboxamide formate salt
Cl £
HO. 1°
Oo
S&L
SL
DIPEA (0.059 mL, 0.336 mmol) was added to a stirring solution of (3R)-4-{[(1,1- dimethylethyl)oxy]carbonyl}-3-morpholinecarboxylic acid (19.41 mg, 0.084 mmol) in DCM (1 mL). HATU (35.1 mg, 0.092 mmol) was then added followed by N-[1-{[3- (aminomethyl)phenyllmethyl}-4-(1-hydroxyethyl)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide (for a preparation see Intermediate 77)(44 mg, 0.084 mmol) and stirred for an hour at room temp. The mixture was treated with 4M hydrogen chloride in dioxane (0.5 mL, 2 mmol) and the reaction stirred at room temperature for 0.5 h. The reaction mixture was passed through an SCX-2 cartridge, washed with methanol and then eluted using 2M ammonia in methanol. The appropriate ammoniacal fractions were concentrated under reduced pressure and the residue was dissolved in DMSO-Methanol (1:1) (1 mL) and purified by MDAP (Method A) to give the title compound (31.2 mg, 58%).
LCMS (System C) RT=2.04 min, ES+ve m/z 590/592 (M+H)".
Example 153 (3S)-N-[(3<{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(1-hydroxyethyl)-1H-indazol-1- yllmethyl}phenyl)methyl]-3-morpholinecarboxamide formate salt
Cl -
S
—
HO He) : N—sZ
Oo
AY
/
N Oo
H
N jeaaciie
Oo
The title compound was similarly prepared to Example 152.
LCMS (System C) RT=2.04 min, ES+ve m/z 590/592 (M+H)".
Example 154
N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(1-hydroxy-1-methylethyl)-1H- indazol-1-yllmethyl}phenyl)methyl]-2-hydroxy-2-methylpropanamide on, WP = -
Ny Cl
N d
Cor
Oo
Triethylamine (0.034 mL, 0.244 mmol) was added to N-[1-{[3- (aminomethyl)phenyllmethyl}-4-(1-hydroxy-1-methylethyl)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide (for a preparation see Intermediate 78)(40 mg, 0.081 mmol) in dichloromethane (1 mL). 2-Chloro-1,1-dimethyl-2-oxoethyl acetate (0.013 mL, 0.090 mmol) was added and the reaction mixture was stirred at room temp for 2 h. The reaction mixture was concentrated on the blowdown, potassium carbonate (113 mg, 0.815 mmol) and methanol (2 mL) was added and the reaction was stirred at room temp for 1h. LCMS showed the acetate group was removed. The reaction mixture was concentrated, acidified with 2N HCI and extracted with EtOAc (2 x 15 mL). The combined organic layers were dried by passing through a hydrophobic frit and concentrated to afford the crude product as a yellow oil. The residue was dissolved in DMSO (1 mL) and purified by Mass
Directed AutoPrep on Sunfire C18 column using Acetonitrile Water with a Formic acid modifier (Method A). The solvent was removed under a stream of nitrogen in the Radleys blowdown apparatus to give the title compound (11.5 mg, 24%). LCMS (System A)
RT=1.05 min, ES+ve m/z 577/579 (M+H)".
Example 155 (3R)-N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]Jamino}-4-(1-hydroxy-1-methylethyl)-1H- indazol-1-yllmethyl}phenyl)methyl]-3-morpholinecarboxamide formate salt
Cl £
HO. 42°
Oo
N ” oro tL,
DIPEA (0.057 mL, 0.326 mmol) was added to a stirring solution of (3R)-4-{[(1,1- dimethylethyl)oxy]carbonyl}-3-morpholinecarboxylic acid (18.84 mg, 0.081 mmol) in DCM (1 mL). HATU (31.0 mg, 0.081 mmol) was then added, followed by N-[1-{3- (aminomethyl)phenyllmethyl}-4-(1-hydroxy-1-methylethyl)-1H-indazol-3-yl]-5-chloro-2- thiophenesulfonamide (for a preparation see Intermediate 78)(40 mg, 0.081 mmol) and the reaction was stirred for an hour at room temp. The reaction mixture was concentrated and 4N Hydrogen chloride in dioxane (0.020 mL, 0.081 mmol) was then added and the reaction stirred at room temperature for 0.5h. The reaction mixture was passed through a pre-conditioned (MeOH) SCX-2 cartridge, washed with methanol and then eluted using 2M ammonia in methanol. The appropiate ammoniacal fractions were concentrated, and the residue was dissolved in DMSO (0.5 mL) and purified by Mass Directed AutoPrep on
Sunfire C18 column using Acetonitrile Water with a Formic acid modifier (Method A). The solvent was removed under a stream of nitrogen in the Radleys blowdown apparatus to give the title compound (2.7 mg, 5%). LCMS (System F) RT=0.84 min, ES+ve m/z 604/606 (M+H)".
Example 156 (3S)-N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(1-hydroxy-1-methylethyl)-1 H- indazol-1-yllmethyl}phenyl)methyl]-3-morpholinecarboxamide
Cl
HO 42°
Oo
MW
N Oo
H
N
N
NORA )
Oo
The title compound was similarly prepared to Example 155
LCMS (System F) RT=0.84 min, ES+ve m/z 604/606 (M+H)".
Example 157- 160 were prepared in array format from Intermediate 4 and the appropriate acid using HATU and cleavage of the BOC protecting group with TFA according to
Example 44
Example 157 N'-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-D-serinamide trifluoroacetate
Q
4 ~o AYE oO
N
Fo y
OH
7
NH,
LCMS (System D) RT=0.80 min, ES+ve m/z 550/552 (M+H)".
Example 158
N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-L-prolinamide trifluoroacetate o \\ Ss Cl o
Cr /
N
H
N H
~
Fo o ~<.
LCMS (System A) RT=0.82 min, ES+ve m/z 560/562 (M+H)".
Example 159 (2S)-N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]Jamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-azetidinecarboxamide trifluoroacetate oO ~ WN ? AL
Oo
Cr
N
9 F 0 d F
H
N FE OH
~~
LCMS (System B) RT=1.82 min, ES+ve m/z 546/548 (M+H)".
Example 160 (3R)-N-({3-[(4-(Methyloxy)-3-{[(5-methyl-2-thienyl)sulfonylJamino}-1H-indazol-1- yl)methyl]phenyl}methyl)-3- bo 7
Oo
Cr /
G0
HN
C
LCMS (System A) RT=0.68 min, ES+ve m/z 556 (M+H)".
Examples 161 and 162 were prepared from N-[1-{[3-(aminomethyl)phenyl]methyl}-5- fluoro-4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2-thiophenesulfonamide (for a preparation see Intermediate 61) following HATU coupling with 4-methyl-3-morpholinecarboxylic acid hydrochloride and then resolution of the resulting racemic mixture by chiral HPLC:
Example 161
N-[(3-{[3{[(5-Chloro-2-thienyl)sulfonyl]amino}-5-fluoro-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-4-methyl-3-morpholinecarboxamide Enantiomer 1 of
IU
E rd cl
N
Neo
X oe
LCMS (System A) RT=0.96 min, ES+ve m/z 608/610 (M+H)".
Example 162
N-[(3{[3-{[(5-Chloro-2-thienyl)sulfonylJamino}-5-fluoro-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-4-methyl-3-morpholinecarboxamide Enantiomer 2 oF ~o aN Ip¥
E rd cl
N
! 0 “5 (Ls
LCMS (System A) RT=0.96 min, ES+ve m/z 608/610 (M+H)".
Example 163 4-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1-ylmethyl}-
N,N-diethylbenzamide
0” nV S
Cl cr
J
0 ™
To a solution of 4-{[3-[[(5-chloro-2-thienyl)sulfonyl]({[2- (trimethylsilyl)ethyl]loxy}methyl)amino]-4-(methyloxy)-1H-indazol-1-ylimethyl}-N,N- diethylbenzamide (for a preparation see Intermediate 79)(125.5 mg, 0.189 mmol) in dichloromethane (DCM) (1 ml) was added dropwise TFA (0.292 ml, 3.78 mmol) at ambient temperature. The resulting mixture was stirred at ambient temperature for 30 h.
Reaction mixture was concentrated under a stream of nitrogen in a blowdown unit. The residue was purified using the high pH-MDAP and further purified by MDAP to give the title compound (3 mg, 3%) LCMS (System A) RT=1.19 min, ES+ve m/z 533/535 (M+H)".
Example 164 5-Chloro-N-(4-(methyloxy)-1-{[3-(methyloxy)phenyl]methyl}-1H-indazol-3-yl)-2- thiophenesulfonamide o
Sd 4
N
N
0
Was prepared by alkylation of 5-chloro-N-[4-(methyloxy)-1H-indazol-3-yl]-N-({[2- (trimethylsilyl)ethylloxy}methyl)-2-thiophenesulfonamide (for a prepararation see
Intermediate 8) with 3-methoxybenzyl bromide and potassium carbonate in DMF as above. LCMS (System A) RT=1.25 min, ES+ve m/z 464/466 (M+H)".
Example 165
N-[1-{[3-Fluoro-4-(methyloxy)phenyl]lmethyl}-4-(methyloxy)-1H-indazol-3-yl]-5- methyl-2-thiophenesulfonamide oO
A solution of 1-{[3-fluoro-4-(methyloxy)phenyllmethyl}-4-(methyloxy)-1H-indazol-3-amine (for a preparation see Intermediate 80)(130 mg, 0.8 mmol) in pyridine (2 mL) was added to 5-methyl-2-thiophenesulfonyl chloride (0.24 mmol). The reaction mixture was shaken 5 briefly and allowed to stand for 3 h at 21 °C prior to concentration by blowdown. The residue was dissolved in 1:1 MeOH-DMSO (1 mL) and purified by Mass Directed
AutoPrep on Xbridge column using Acetonitrile Water with an ammonium carbonate modifier (Method C). The solvent was evaporated in vacuo to give the title compound (76 mg) LCMS (System A) RT=1.11 min, ES+ve m/z 462 (M+H)".
Example 166 (3S)-N-({3-[(3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-hydroxy-1H-indazol-1- yl)methyl]phenyl}methyl)-3-morpholinecarboxamide formate salt of oH Te
Crd Pe 2 o 3
To a solution of O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium- hexafluorophosphate (77 mg, 0.124 mmol) in anhydrous N,N-dimethylformamide (1 mL) was added at room temperature (S)-4-Boc-morpholine-3-carboxylic acid (26.2 mg, 0.113 mmol), followed by N,N-diisopropylethylamine 0.059 mL, 0.339 mmol) and finally a solution of N-(1-{[3-(aminomethyl)phenyllmethyl}-4-hydroxy-1H-indazol-3-yl)-5-chloro-2- thiophenesulfonamide (formate salt) (for a preparation see intermediate 15)( (56 mg, 0.113 mmol) in anhydrous N,N-dimethylformamide (2 mL) and the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was partitioned between saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer was separated, washed with brine:water (1:1), passed through a hydrophobic frit and evaporated in-vacuo. The was treated with hydrogen chloride (4M solution in 1,4- dioxane) (1 mL) and then added methanol (~4 mL) until the reaction was in solution.
Reaction stirred at room temperature for 2 hours. The reaction mixture was evaporated in-vacuo and the residue was dissolved in MeOH/DMSO (1 mL) and purified by Mass
Directed AutoPreparative HPLC (MDAP) on (Sunfire C18 column Method A) eluting with solvents A/B (A: 0.1% v/v solution of formic acid in water, B: 0.1% v/v solution of formic acid in acetonitrile) using a method B over 25 min. Appropriate fractions were combined and evaporated in-vacuo to yield the title compound as a colourless oil (13 mg, 19%).
LCMS (System B) RT = 1.63 min, ES+ve m/z 562/564 (M+H)".
Biological Test Methods [35S8]- GTPyS SPA Binding Assays for CCR4 Antagonist Activity
Antagonist potency was determined by a radioligand [35S]-GTPyS competition assay.
Briefly, CCR4 expressing CHO membranes were homogenised by passing through a 23G needle. These membranes were then adhered to WGA-coated Leadseeker SPA beads in assay buffer (20mM HEPES, 10mM MgCl,, 100mM NaCl, 0.05% BSA, 40ug/ml Saponin and pH adjusted to 7.4 using KOH 5M) to generate a 3ug/well final assay concentration (FAC) membrane and 250ug/well FAC bead, solution.
After 60 minutes pre-coupling on ice, GDP was added to give a 4.4uM FAC. [35S]-GTPyS made in assay buffer was then added to the bead/membrane solution to give a 0.33nM
FAC. Human MDC was added to the bead/membrane/[35S]-GTPyS suspension to give an FAC that exhibits 80% of the maximal agonist response (EC80). The bead/membrane/[35S]-GTPyS/Agonist suspension was dispensed into white Greiner polypropylene 384-well plates (45ul/well), containing 0.5ul of compound. The final assay solution (45.5ul) was then sealed, spun using a centrifuge and then incubated at room temp for 3 - 6 hours. Plates were then read on a Viewlux instrument and luminescence was then plotted as a percentage of the maximum inhibitional response elicited by an [C100 of a standard antagonist.
Examples 1- 77, 80, 82, 85, 88-90, 95, 100-103, 114-157, 160, 164 and 165 were tested in the above assay.
All tested compounds were found to have pIC50 = 7.0 and < 8.4 with the exception of
Examples 101, 116, 120 and 156 which had a pIC50 = 6.4 and < 7.0.
Examples 2-4, 6-8, 10, 12, 16-18, 21, 26-28, 33, 35, 37, 43, 44, 48, 51, 52, 55, 57, 70, 71- 73, 80, 85, 102, 114, 124, 125, 127, 133, 134, 138-140, 142-144, 148, 149 and 151-153 were found to have plC50 27.8 and < 8.4.
Chemokine Stimulated Increases in Cellular F-actin Content
Blood was taken from normal volunteers who had taken no medication within the previous ten days and mixed with 1/9 of the volume of 3.8% tri-sodium citrate solution. Chemokine- induced increases in the F-actin content of CD4+ CCR4+ T cells were measured by a modification of the method of Pilette et al. (Eur. Respir. J; 23: 876 — 884, 2004).
Peripheral blood mononuclear cells (PBMC) were isolated by dextran sedimentation followed by Percoll density gradient centrifugation. The PBMCs were incubated with FITC- conjugated anti-human CD4 and PE-conjugated anti-CCR4 antibodies or appropriate isotype controls for 15 min. The cell suspensions were then centrifuged at 400 g for 10 min and the pellets resuspended in assay buffer (phenol red-free RPMI 1640 medium containing 10 mM HEPES and 0.1% bovine serum albumin) at 10’/mL. The resulting cell suspension was incubated with antagonist or vehicle (0.1% DMSO) for 30 min at 37°C before stimulation with the agonist for 15 sec. The assay was terminated by addition of 3% formaldehyde. The fixed cells were washed twice with PBS (centrifuging at 1000 g for 5 min to recover the cells) and incubated at room temperature with Alexa fluor-647 phalloidin (0.075 U/mL) in the presence of lyso-phosphatidylcholine (93.75 pg/ml) for 20 min to stain F-actin. The cells were washed once more with PBS and the relative F-actin content of the cells was measured flow cytometrically. The mean fluorescence intensity of 1000 CD4" CCR4" cells per sample was determined and expressed as a fraction of the mean intensity of the CD4" CCR4" cells in that sample.
Examples 1-81, 83-86, 89, 90, 95, 96, 102, 103, 113, 110-113, 116-122, 124, 125, 128, 129, 157-160, 163, 164 and 166 were tested in the above assay.
All tested compounds were found to have a pA2 = 6.0 with the exception of Example 163.
Examples 1- 79, 83-86, 89, 96, 110-113, 118, 124, 125, 129, 158-160 and 166 were found to have a pA2 = 6.9.
All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
Claims (21)
1. A compound of formula (1) or a salt thereof R5 0 R? is re \\ O s ord N me , (RY), R1 (1 wherein R'is selected from the group consisting of (1), (2), (3) (4) and (5) (1) a group of formula (a) . 0 Ha (a) in which A is selected from the group consisting of (i), (ii), (iii), (iv), (v), (vi), (vii) and (viii) (i) hydrogen; (ii) C1.salkyl optionally substituted by one or more -NR?R®, -OR°, -C(O)NR®R®, -C(O)OR?, heterocyclyl, phenyl or heteroaryl groups; (iii) Cs.soycloalkyl optionally substituted by a -C(O)OR® or -NR?R" group; (iv) heterocyclyl optionally substituted by one or more C,salkyl; (Vv) heteroaryl optionally substituted by one or more halogen or C4. salkyl; (vi) -NR°R" (vii) phenyl substituted by a —(CH,),C(O)OH group in which pis 0, 1, 2 or 3; or (viii) —(CH2);C(O)OH
(2) a group of formula (b) TN 7 ns 0 (b) in which B is Cqsalkyl; (3) —C(O)NR®R® or -CH,C(O)NR®R”; (4) —S(O)NRR’; (5) Cysalkoxy optionally substituted by NR*R®; R? R® and Rare independently hydrogen or Cgalkyl; R? is halogen, Cqsalkyl, CFs, hydroxy or Cqsalkoxy; R? is halogen, CF, hydroxy, Ci.galkoxy, CR‘R°OH or CHF; in which R® and R® are independently hydrogen or methyl; R*is hydrogen, halogen, Cyalkyl or CF; R®and R® are independently hydrogen, halogen or Cysalkyl; and nis 0 or 1.
2. A compound according to claim 1 or a salt thereof wherein R'is selected from the group consisting of (1), (2), (3) (4) and (5) (1) a group of formula (a) . 0 Ha (a) in which A is selected from the group consisting of (i), (ii), (iii), (iv), (v) and (vi): (i) hydrogen; (ii) C1salkyl optionally substituted by one or more -NR?R®, -OR°, -C(O)NR®R®, -C(O)OR?, heterocyclyl, phenyl or heteroaryl groups; (iii) Cacycloalkyl optionally substituted by a —-NR®R® group; (iv) heterocyclyl optionally substituted by one or more C,salkyl;
(Vv) heteroaryl optionally substituted by one or more halogen or Cqsalkyl (vi) -NR°R" (2) a group of formula (b) \ 0 NL Hj 8 0 (b) in which B is Cqsalkyl; (3) —C(ONR®R”; (4) -S(O),NR°R” (5) Cysalkoxy optionally substituted by NR*R®; R? R® and R®are independently hydrogen or Cgalkyl; R? is halogen, Cqsalkyl, CFs, hydroxy or Cqsalkoxy; R® is halogen, CF3, hydroxyl, C;¢alkoxy, CH,OH or CHF»; R*is hydrogen, halogen, Cysalkyl or CFs; R®and R® are independently hydrogen, halogen or Cysalkyl; and nisOor1.
3. A compound according to claim 1 or claim 2 which is a compound of formula (la) or a salt thereof oO > 0 NT Ss cl oO N N / R1 (la) in which R' and R® are defined in claim 1 or claim 2.
4. A compound according to any one of claims 1 -3 or a salt thereof in which R is a group of formula (a) . 0 Ha (a)
5 A compound according to claim 4 or a salt thereof in which A is Cgalkyl.
6. A compound according to claim 4 or a salt thereof in which A is Cigalkyl substituted by one or more -NR°R®, -OR°, -C(O)NR®R" , -C(O)OR?, pyrrolidinyl, phenyl or imidazolyl.
7. A compound according to claim 4 or a salt thereof in which A is a heterocyclyl selected from the group consiting of pyrrolidinyl, piperidinyl and morpholinyl.
8. A compound according to claim 4 or a salt thereof in which A is a heteroaryl selected from the group consisting of furyl, imidazolyl, pyrazolyl and oxazolyl.
9. A compound according to any one of claims 1 — 8 or a salt thereof in which R® is methoxy.
10. A compound which is any of one of Examples 1 — 166 or a salt thereof.
11. A compound which is N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyllacetamide, N-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]Jamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-3-morpholinecarboxamide, N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-hydroxy-2-methylpropanamide N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyllamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-hydroxypropanamide; (2S5)-N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyllamino}-4-(methyloxy)-1H-indazol-1- yllmethyl}phenyl)methyl]-2-hydroxypropanamide or a salt thereof.
12. A compound which is N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyllamino}-4-(methyloxy)- 1H-indazol-1-ylImethyl}phenyl)methyl]-2-hydroxy-2-methylpropanamide 0 ~ Rea O N H y © ho
13. A pharmaceutical composition which comprises a compound according to any one of claims 1 — 12 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents and excipients.
14. A combination pharmaceutical product comprising a compound of formula (1) or a pharmaceutically acceptable salt thereof according to any one of claims 1 — 12 together with one or more other therapeutically active agents.
15. A compound according to any of claims 1 - 12 or a pharmaceutically acceptable salt thereof for use in therapy.
16. A compound according to any one of claims 1 — 12 or a pharmaceutically acceptable salt thereof for use in the treatment of a disease or condition for which a CCR4 receptor antagonist is indicated.
17. The use of a compound according to any of claims 1 - 12 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease or condition for which a CCR4 receptor antagonist is indicated.
18. A method of treating a disease or condition for which a CCR4 receptor antagonist is indicated in a subject in need thereof which comprises administering a therapeutically effective amount of compound according to any of claims 1 — 12 or a pharmaceutically acceptable salt thereof.
19. A process for the preparation of a compound of formula (I) or a salt thereof which comprises a process selected from (a), (b), (¢) or (d) in which: (a) involves reacting a compound of formula (ll) or a salt thereof R5 R R3 H —S R8 ! \ Oo 8 \ N N mr \ (R2), HN (I) in which R? — R® and n are as defined in claim 1 with a compound of formula (Illa), (llIb), (llc) or (llld) or a protected derivative thereof 7 7 7 LG ~—~g__ O=—C=N—-A HO LG" Il A A A 0 IE) (Ib) (llc) (Id) in which A is as hereinbefore defined; e and optionally thereafter de-protecting the resulting product; (b) involves reacting a compound of formula (IV) or a protected derivative thereof R5 2 R3 H —S R8 / \ oO 8S N N / N R4 H (IV) in which R® — R® are as hereinbefore defined with a compound of formula (Va) or (Vb)
Hal HO 2 \ , (RY), \ FO R? R! (Va) (Vb) in which R', R? and n are as defined in claim 1 and Hal is halogen; e and optionally thereafter de-protecting the resulting product; (c) involves reacting a compound of formula (VI) R3 NH, Cr N mr \ , (RY), R1 (VI) in which R' — R* and n are as defined in claim 1 with a compound of formula (VI) R5 Oo \ Hal —S R® \! Oo S (VII) in which R® and R® are as defined in claim 1 and Hal is halogen; (d) involves converting a compound of formula (I) or a salt thereof into a further compound of formula (I) or a salt thereof.
20. A compound of formula (I) or a salt thereof
R5 2 R3 H —S R8 ! \ Oo 8 N N N nr (R?), HN (I) in which R? — R® and n are as defined in claim 1.
21. A compound according to claim 20 which is N-[1-{[3-(Aminomethyl)phenyllmethyl}- 4-(methyloxy)-1H-indazol-3-yl]-5-chloro-2-thiophenesulfonamide or a salt thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15570209P | 2009-02-26 | 2009-02-26 | |
PCT/EP2010/052307 WO2010097395A1 (en) | 2009-02-26 | 2010-02-24 | Pyrazole derivatives used as ccr4 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
SG173768A1 true SG173768A1 (en) | 2011-09-29 |
Family
ID=42110309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2011059813A SG173768A1 (en) | 2009-02-26 | 2010-02-24 | Pyrazole derivatives used as ccr4 receptor antagonists |
Country Status (31)
Country | Link |
---|---|
US (3) | US8357716B2 (en) |
EP (1) | EP2401270B1 (en) |
JP (1) | JP5520969B2 (en) |
KR (1) | KR20110128896A (en) |
CN (1) | CN102388039B (en) |
AR (1) | AR075594A1 (en) |
AU (2) | AU2010217629A1 (en) |
BR (1) | BRPI1013396A2 (en) |
CA (1) | CA2753337A1 (en) |
CL (1) | CL2011002103A1 (en) |
CO (1) | CO6420342A2 (en) |
DK (1) | DK2401270T3 (en) |
DO (1) | DOP2011000272A (en) |
EA (1) | EA021740B1 (en) |
ES (1) | ES2439773T3 (en) |
HK (1) | HK1159621A1 (en) |
HR (1) | HRP20131174T1 (en) |
IL (1) | IL214655A0 (en) |
MA (1) | MA33132B1 (en) |
MX (1) | MX2011008972A (en) |
NZ (1) | NZ594641A (en) |
PE (1) | PE20120307A1 (en) |
PL (1) | PL2401270T3 (en) |
PT (1) | PT2401270E (en) |
RS (1) | RS53133B (en) |
SG (1) | SG173768A1 (en) |
SI (1) | SI2401270T1 (en) |
SM (1) | SMT201400001B (en) |
TW (1) | TW201041879A (en) |
UY (1) | UY32464A (en) |
WO (1) | WO2010097395A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0815773A2 (en) | 2007-08-31 | 2019-09-24 | Eisai R&D Man Co Ltd | compound and medicine. |
JP5580816B2 (en) | 2009-02-26 | 2014-08-27 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Tetrahydrotriazolopyridine derivative salts and crystals |
TW201035101A (en) | 2009-02-26 | 2010-10-01 | Eisai R&D Man Co Ltd | Nitrogen-containing fused heterocyclic compound |
US8729260B2 (en) * | 2010-05-19 | 2014-05-20 | Savior Lifetec Corporation | Process for the preparation of carbapenem using cabapenem intermediates and recovery of cabapenem |
WO2012025473A1 (en) * | 2010-08-24 | 2012-03-01 | Glaxo Group Limited | Cc.chemokine receptor 4 antagonists |
DK3107902T3 (en) * | 2014-02-20 | 2021-05-03 | Cornell Univ Cornell Center For Technology Enterprise & Commercialization Cctec | CONNECTIONS AND METHODS OF INHIBITING FASCIN |
WO2018022992A1 (en) * | 2016-07-29 | 2018-02-01 | Flx Bio, Inc. | Chemokine receptor modulators and uses thereof |
WO2018049271A1 (en) | 2016-09-09 | 2018-03-15 | Flx Bio, Inc. | Chemokine receptor modulators and uses thereof |
JOP20190192A1 (en) * | 2017-03-01 | 2019-08-08 | Glaxosmithkline Ip No 2 Ltd | Pyrazole derivatives as bromodomain inhibitors |
WO2018187509A1 (en) | 2017-04-04 | 2018-10-11 | Flx Bio, Inc. | Heterocyclic compounds as chemokine receptor modulators |
CN108727340B (en) * | 2017-04-11 | 2020-12-29 | 广东东阳光药业有限公司 | Fluorine substituted indazoles and use thereof |
RU2020118594A (en) | 2017-11-06 | 2021-12-09 | Рапт Терапьютикс, Инк. | ANTI-CANCER AGENTS |
CN110028501B (en) * | 2018-01-12 | 2022-02-22 | 迈德欣国际有限公司 | Compound and preparation method and application thereof |
SG11202007072RA (en) | 2018-01-26 | 2020-08-28 | Rapt Therapeutics Inc | Chemokine receptor modulators and uses thereof |
CN113893220A (en) * | 2020-07-07 | 2022-01-07 | 迈德欣国际有限公司 | Nasal mucosal dosage form and uses thereof |
WO2023196432A1 (en) | 2022-04-06 | 2023-10-12 | Rapt Therapeutics, Inc. | Chemokine receptor modulators and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2848554A1 (en) * | 2002-12-12 | 2004-06-18 | Aventis Pharma Sa | New aminoindazole derivatives are kinase inhibitors, useful in the treatment of neurodegenerative diseases, obesity, metabolic disorders, diabetes, hypertension, polycystic ovarian syndrome, cancers and other disorders |
MXPA05005554A (en) | 2002-12-12 | 2005-07-26 | Aventis Pharma Sa | Aminoindazole derivatives and use thereof as kinase inhibitors. |
SE0301650D0 (en) * | 2003-06-04 | 2003-06-04 | Astrazeneca Ab | Novel compounds |
WO2008089307A2 (en) | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer |
-
2010
- 2010-02-24 DK DK10705594.9T patent/DK2401270T3/en active
- 2010-02-24 EA EA201190142A patent/EA021740B1/en not_active IP Right Cessation
- 2010-02-24 US US13/202,139 patent/US8357716B2/en not_active Expired - Fee Related
- 2010-02-24 PL PL10705594T patent/PL2401270T3/en unknown
- 2010-02-24 CA CA2753337A patent/CA2753337A1/en not_active Abandoned
- 2010-02-24 ES ES10705594.9T patent/ES2439773T3/en active Active
- 2010-02-24 SI SI201030466T patent/SI2401270T1/en unknown
- 2010-02-24 AU AU2010217629A patent/AU2010217629A1/en not_active Abandoned
- 2010-02-24 EP EP10705594.9A patent/EP2401270B1/en active Active
- 2010-02-24 AR ARP100100532A patent/AR075594A1/en not_active Application Discontinuation
- 2010-02-24 BR BRPI1013396A patent/BRPI1013396A2/en not_active IP Right Cessation
- 2010-02-24 RS RS20130585A patent/RS53133B/en unknown
- 2010-02-24 JP JP2011551485A patent/JP5520969B2/en not_active Expired - Fee Related
- 2010-02-24 UY UY0001032464A patent/UY32464A/en not_active Application Discontinuation
- 2010-02-24 CN CN201080016319.3A patent/CN102388039B/en not_active Expired - Fee Related
- 2010-02-24 MA MA34179A patent/MA33132B1/en unknown
- 2010-02-24 NZ NZ594641A patent/NZ594641A/en not_active IP Right Cessation
- 2010-02-24 MX MX2011008972A patent/MX2011008972A/en active IP Right Grant
- 2010-02-24 TW TW099105340A patent/TW201041879A/en unknown
- 2010-02-24 PT PT107055949T patent/PT2401270E/en unknown
- 2010-02-24 US US12/711,283 patent/US8304446B2/en not_active Expired - Fee Related
- 2010-02-24 PE PE2011001557A patent/PE20120307A1/en not_active Application Discontinuation
- 2010-02-24 WO PCT/EP2010/052307 patent/WO2010097395A1/en active Application Filing
- 2010-02-24 KR KR1020117022518A patent/KR20110128896A/en not_active Application Discontinuation
- 2010-02-24 SG SG2011059813A patent/SG173768A1/en unknown
-
2011
- 2011-08-15 IL IL214655A patent/IL214655A0/en unknown
- 2011-08-25 DO DO2011000272A patent/DOP2011000272A/en unknown
- 2011-08-26 CL CL2011002103A patent/CL2011002103A1/en unknown
- 2011-08-26 CO CO11109505A patent/CO6420342A2/en active IP Right Grant
-
2012
- 2012-01-04 HK HK12100042.4A patent/HK1159621A1/en not_active IP Right Cessation
- 2012-10-02 US US13/633,382 patent/US8507543B2/en not_active Expired - Fee Related
-
2013
- 2013-12-10 HR HRP20131174AT patent/HRP20131174T1/en unknown
-
2014
- 2014-01-03 SM SM201400001T patent/SMT201400001B/en unknown
-
2016
- 2016-06-02 AU AU2016203684A patent/AU2016203684A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2401270B1 (en) | Pyrazole derivatives used as ccr4 receptor antagonists | |
US7265120B2 (en) | Pyrazine derivatives and pharmaceutical use thereof | |
DE602004012260T2 (en) | CHINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | |
US8470835B2 (en) | Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase | |
JP2022512201A (en) | Functionalized amine derivative as IL-17 modulators | |
JP6412102B2 (en) | Cycloalkylnitrile pyrazolopyridones as Janus kinase inhibitors | |
WO2007009681A1 (en) | 1 , 1-DIOXID0-2 , 3-DIHYDRO-l , 2-BENZISOTHIAZ0L-6-YL-1H-INDAZOL-4-YL-2 , 4-PYRIMIDINEDI AMINE DERIVATIVES | |
MXPA06013414A (en) | Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors. | |
JP5807058B2 (en) | Bifunctional quinoline derivative | |
JP2005520791A (en) | N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives | |
US20110281909A1 (en) | Substituted quinoline derivatives as h1 receptor antagonists | |
US20160272632A1 (en) | Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors | |
US8754101B2 (en) | N-cyclobutyl-imidazopyridine-methylamine as TRPV1 antagonists | |
US20080280911A1 (en) | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | |
WO2012025474A1 (en) | Indazole compounds | |
WO2012025473A1 (en) | Cc.chemokine receptor 4 antagonists |